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Abstract 
Clostridium difficile infection (CDI) is one of the most common causes of infective 
hospital-acquired diarrhoea and one of the leading causes of healthcare-associated 
infection (HCAI) worldwide. The emergence of hypervirulent strains has caused 
outbreaks in several countries, and the disease has been a challenge to healthcare 
workers, settings and systems mainly related to the disease heterogeneity, high rates 
of recurrence, antibiotic resistance and high disease-associated healthcare costs. 
In this thesis, a CDI cohort recruited over different time periods (2008-2012 and 2013-
2015) was used. More patients were recruited by a clinical audit (2008-2012 and 
2012-2016) to increase sample size for some of my analyses, and to assess the 
representativeness of the cohort group. In general, the cohort and audit groups were 
similar, but did have some notable differences: audit patients were older [79 vs 75 
years (IQR: 61-81), p<0.001 for phase I and 77 vs 66 years (IQR: 56-79), p=0.007 for 
phase II], and more debilitated as mortality rates were higher, considering both short-
term mortality (32% vs 7%, p<0.001, for phase I and 25% vs 4%, p<0.001, for phase 
II) and long-term mortality (62% vs 32%, p<0.001, for phase I and 59% vs 41%, 
p=0.010, for phase II). 
Taking all patients from 2012 to 2016 into consideration, carrier patients (GDH+/TOX-
/PCR+) and CDI cases were more likely to have had longer hospitalisation [(HR=0.73, 
95% CI: 0.59-0.90) and (HR=0.76, 95% CI: 0.61-0.95)], to have died within 1 year 
[(OR=2.34, 95% CI: 1.30-4.24) and (OR=3.02, 95% CI: 1.71-5.41)], and have incurred 
higher costs [(OR=1.18, 95% CI: 1.07-1.31) and (OR=1.25, 95% CI: 1.13-1.38)] 
compared to diarrhoea control patients. Considering only patients infected by 
toxigenic strains, a toxin positive test was a predictor of only CDI severity (OR=3.18, 
95% CI: 1.05-9.60). The addition of a third and confirmatory diagnostic test was cost-
saving when considering the use of a high cost antibiotic. 
When procalcitonin (PCT) was measured within 72 hours after the C. difficile test in 
cohort patients, high levels of PCT were associated with CDI diagnosis (OR=1.76, 
95% CI: 1.04-2.58), CDI severity (OR=1.56, 95% CI: 1.18-2.07), long-term mortality 
(OR=1.43, 95% CI: 1.15-1.77) and with increased risk of delayed discharge 
(HR=0.87, 95% CI: 0.80-0.95). A toxin positive result was only predictive of time to 
discharge when PCT was one of the covariates of the models. 
Cost-effective interventional measures identified by the systematic review undertaken 
in this thesis were screening all patients during admission, vaccination in a simulation 
model, treatment with fidaxomicin (FDX) and faecal microbiota transplantation (FMT) 
via colonoscopy. 
Multivariable analysis showed that costs of hospitalisation were higher for CDI cases 
than diarrhoea control patients in phase I (£5,761 vs £4,924 for cohort group and 
£6,272 vs £5,151 for audit and cohort groups). During phase II, CDI cases treated 
with FDX (£6,355 and £5,694) and GDH+/TOX- patients treated with FDX (£5,746 
and £5,448) were more expensive than diarrhoea control patients (£4,227 and 
£4,251).  
In conclusion, this thesis has presented clinical and economic perspectives of CDI in 
epidemic and endemic phases in a secondary healthcare setting. CDI is associated 
with a number of adverse clinical outcomes, such as higher mortality rates, longer 
time to discharge and hospitalisation costs, which have been highlighted in this thesis. 
Tackling CDI requires a multifunctional approach, including prevention and control 
measures, and better treatment strategies to decrease the incidence rates and 
improve outcomes in infected patients in a cost-effective manner.  
1 
 
 
 
Chapter 1 
Introduction 
  
 
 
2 
 
1.1 Aetiology 
Clostridium difficile infection (CDI) is one of the most common causes of 
healthcare-associated infection (HCAI) worldwide. The organism is anaerobic, 
Gram-positive, spore-forming bacillus and producer of exotoxins (Kelly et al., 
1994). A disruption to the normal bowel flora usually caused by broad-
spectrum antibiotics, plus the production of toxins when spores are converted 
to vegetative forms, cause an inflammatory condition that can reach the colon 
and develop a pseudomembranous colitis (Kelly et al., 1994, Spencer, 1998). 
 
1.2 Risk factors 
Antibiotic exposure has been considered one of the major risk factors for the 
development of CDI and cephalosporins (CF), clindamycin (CLI) and 
fluoroquinolones (FQ) the most frequent antibiotics associated with the 
disease (Bartlett, 2010, Spencer, 1998). Besides, long-term hospitalisation 
and exposure to the bacteria, male gender, advanced age (more than 65 
years), age less than 1 year with co-morbidity, prolonged duration of diarrhoea, 
serious underlying illness, weakened immune system and surgery on the 
digestive system are also risk factors for the disease (NHS, 2012, Goudarzi et 
al., 2014). Moreover, gastric acid suppressants have been related to increased 
risk of CDI as can decrease the protective effect of gastric acid and altering 
the microbiota but this is still unclear and controversial, as some studies have 
not shown association (Surawicz et al, 2013, Tariq et al, 2017). The findings 
of Novack et al study (Novack et al, 2014) have suggested a potential bias 
when recruiting control patients as a reason for the discordant results. 
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1.3 Pathogenesis 
The spread of Clostridium difficile is via the oral-faecal route after oral 
ingestion of spores or vegetative forms of the pathogen. In the lower 
gastrointestinal tract (Figure 1.1), the bile acids and other substances induce 
spore germination and vegetative growth (Abt et al., 2016). Due to the 
disruption of gut microbiota, vegetative cells invade the large intestine, 
interacting and adhering to epithelial cells (Abt et al., 2016, Usacheva et al., 
2016, Goudarzi et al., 2014). The consequent multiplication of the micro-
organism and the production of toxins cause injuries to the cells and induce 
an inflammatory process in the mucosa by neutrophil infiltration (Usacheva et 
al., 2016, Abt et al., 2016). 
 
Figure 1.1 Pathogenesis of CDI (Source: Association 
for Professionals in Infection Control & Epidemiology, 
2008)  
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The major toxins produced by C. difficile are the enterotoxic toxin A (tcdA) and 
the cytotoxic toxin B (tcdB). Studies have diverged about the role of the tcdA 
in the virulence process (Usacheva et al., 2016), as some authors suggested 
a synergistic effect between tcdA and tcdB (Kuehne et al., 2010, Kuehne et 
al., 2011) whilst other authors suggested that it has no relevance as only toxin 
B is cytotoxic (Carter et al., 2012). A binary toxin called C. difficile transferase 
(CDT) has also been identified in CDI case strains. Although the role of CDT 
is still not completely known, higher mortality rates and severe disease were 
associated with strains that express this toxin, such as the hypervirulent strain 
NAP1/BI1/027 (RT027) (Gerding et al., 2014, Depestel and Aronoff, 2013, 
Berry et al, 2017). 
 
1.4 Epidemiology  
CDI epidemiology has been changing during the years. According to a meta-
analysis conducted in the United States (US) (Zimlichman et al., 2013), C. 
difficile was the healthcare-associated infection with the second highest 
number of cases per year (133,657) after surgical site infection (SSI) with 
158,369 cases per year. In some US areas it is already considered the most 
common cause of HCAI (Depestel and Aronoff, 2013). Data from 2011 
suggested more than 450,000 cases (147 cases/100,000 population) of those 
65% were HCAI and led to 29,000 deaths in a year in the US (Lessa et al., 
2015). In the same period, 19,000 cases (36 cases/100,000 population) were 
reported in the United Kingdom (UK) (PHE, 2017). 
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1.4.1 Outbreak 
Last decade witnessed a significant upsurge in the incidence and severity of 
CDI in North America and Europe (Loo et al., 2005, Kuijper et al., 2006) with 
the spread of the new epidemic strain RT027. This epidemic strain type is 
widely acknowledged to be more virulent and associated with severe illness 
and increased mortality and recurrence rates (Deneve et al., 2009). Since 
2003 outbreaks have been reported in the US, Canada and Europe. In the UK, 
the number of cases started rising in 2006-2007 when notification of all CDI 
cases from National Health Service (NHS) Trusts to Public Health England 
(PHE) became mandatory. For this reason, this outbreak put healthcare 
systems under severe strain, triggering major reviews in antimicrobial policies 
and introduction of stringent hygiene and cleanliness measures, often not 
practically sustainable, to try to control the number of infected patients and to 
avoid spending money unnecessarily (Department of Health & Health 
Protection Agency, 2008, Simor, 2010).  
In England, surveillance of C. difficile started in 1990 as voluntary monitoring, 
becoming mandatory in people aged 65 years and over in 2004 and including 
people aged from 2 years and over in 2007. Figures with number of cases per 
financial year since 1990 and deaths related to CDI since 2001 in England 
from National Statistics (Office for National Statistics, 2013) and PHE (PHE, 
2017) databases are presented in Figures 1.2 and 1.3.  
The epidemic period started with the increasing in the number of CDI cases 
around 2002, reaching a peak with the emergence of the hypervirulent strain 
when 55,000 cases and 11,000 deaths whose certificates mentioned C. 
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difficile as a cause or underlying cause of death were reported in England 
(PHE, 2017, Office for National Statistics, 2013). The incidence of CDI 
decreased year by year falling by 70% in 2010 as a result of interventional 
measures implemented by the healthcare settings. In 2012 the number of 
cases have remained relatively stable consistent with an endemic period. 
  
 
Figure 1.2 Number of HCAI and CAI CDI cases in England between 1990 
and 2016 (Source: Public Health England, 2017) 
 
PHE reports after 2007 presented both total CDI cases and cases by mode of 
acquisition the bacteria, whether if it is a HCAI or a community-acquired 
infection (CAI). A HCAI case is usually defined as an infection detected within 
48h after the patient admission in a healthcare setting if the patient received 
healthcare treatment inside or outside the hospital 30 days before the 
infection, or was hospitalised for at least 2 days within 90 days before the 
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infection, or lived in a nursing home (Friedman et al, 2002; Cardoso et al, 
2014). Figure 1.2 shows that the number of CDI cases considered HCAI has 
decrease during the years and in 2010 cases not related to healthcare 
interventions have become higher than HCAI cases in England. However, 
these data may not be accurate as the PHE reports all cases and Trust 
apportioned cases, which is considered when specimen was taken at an Acute 
Trust and after the fourth day of the hospital admission and patient was 
hospitalised, a day-patient or an emergency assessment patient (PHE, 2017). 
Also, a systematic review published in 2014 suggested that 2 or more days of 
hospitalisation in the previous year and treatment with broad spectrum 
antibiotics in the last month should also be considered to define a HCAI case 
(Cardoso et al, 2014). 
Data were also reported by England regions (Figure 1.4, 1.5 and 1.6). Heat 
maps represent case rates/100,000 population (Figure 1.7) and death 
rates/1,000,000 population (Figure 1.8) between 2009 and 2016 and between 
1999 and 2002 per England region. A higher incidence occurred in the North 
West and there was a higher rate of CDI cases in Northern regions whilst the 
London region showed the lowest rate during the whole period. Death related 
to C. difficile had a higher rate in the South West region before the outbreak, 
the Midlands regions during the outbreak and Northern regions after the 
outbreak.  
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Figure 1.3 Number of deaths related to C. difficile in England between 
2001 and 2012 (Source: Office for National Statistics, 2013) 
 
 
Figure 1.4 Number of CDI cases and CDI deaths between 1999 and 2016 
by England regions (Source: Office for National Statistics, 2013 & Public 
Health England, 2017) 
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Figure 1.5 Number of CDI cases between 2009 and 2016 by England 
regions (Source: Public Health England, 2017) 
 
 
 
Figure 1.6 Number of deaths related to C. difficile between 1999 and 2012 
by England regions (Source: Office for National Statistics, 2013) 
 
 
 
10 
 
 
Figure 1.7 CDI cases rate in England between 2009 and 2016 (Source: Public 
Health England, 2017) 
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Figure 1.8 CDI death rate in England between 1999 and 2016 (Source: Office for 
National Statistics, 2013) 
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1.5 Transmission  
Spores, the inactive state of the bacteria, are resistant to cleaning and 
disinfection measures and can survive in the environment for a long period of 
time (Fekety et al., 1981). Thereby, infected humans (symptomatic or 
asymptomatic) and inanimate objects are two major reservoirs of C. difficile 
and the transmission can occur from the healthcare environment or via patient 
care activities (APIC, 2008). The faecal-oral route can allow spores to 
contaminate bedclothes, bathroom fixtures, medical equipment and clothing, 
and then spread when healthcare staff or other people touch contaminated 
areas or infected patients. Studies have also reported potential airborne 
transmission, as bacteria could be isolated from the air of patients’ rooms 
(Roberts et al., 2008, Best et al., 2010), however clinical relevance is limited 
(Donskey, 2010) as the number of spores recovered was low. Spores were 
also recovered from the air of a pig farm (Keessen et al., 2011) and toilet area, 
including floor, cistern and toilet seat (Best et al., 2012). 
Recent advances in the molecular profiling of CDI using next generation 
sequencing are likely to improve the understanding of C. difficile epidemiology, 
as well as its emergence, spread and transmission in both hospitals 
(microevolution) and worldwide (global evolution) (He et al., 2012). 
 
1.6 Signs and symptoms  
Clinical presentation varies from asymptomatic carriage to death, including a 
wide spectrum of manifestations such as diarrhoea, antibiotic-associated 
colitis without pseudomembrane formation and fulminant colitis. These 
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manifestations are easily confounded with other intestinal diseases making the 
diagnosis more difficult. The most common symptom presented in around 90% 
of the patients is brown or clear watery diarrhoea (Knoop et al., 1993). 
Asymptomatic carriers are not frequent among healthy adults ranging from 0 
to 15%, in contrast with healthy neonates and infants whose rate varies from 
18 to 90% (Furuya-Kanamori et al., 2015).  
PHE published a guideline assessing the severity of CDI considering clinical 
manifestation as Bristol Stool Chart, levels of white cell count (WCC), levels of 
serum creatinine, temperature, blood pressure, evidence of colitis and ileus or 
toxic megacolon (PHE, 2013), as showed in Table 1.1. Thus, CDI can be 
categorised as mild, moderate, severe or life-threatening. 
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Table 1.1 CDI severity grading 
Severity Bristol stool chart/day WCC Serum creatinine Other manifestation 
Mild <3 type 5-7 . . . 
Moderate 3-5 <15 x109/L . . 
Severe variable >15 x109/L >50% increase above baseline 
Temperature >38.5°C 
Evidence of severe colitis 
Life-
threatening 
variable >15 x109/L >50% increase above baseline 
Temperature >38.5°C 
Evidence of severe colitis 
Hypotension 
Partial or complete ileus or toxic megacolon 
CT evidence 
WCC: white cell count; CT: computed tomography. 
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1.7 Diagnosis  
Diagnosis is based on clinical manifestations and on identification of the 
toxigenic organisms or detection of toxins. It is strongly recommended that 
only symptomatic patients should be tested for C. difficile, unless for 
epidemiological purposes (Cohen et al., 2010, Surawicz et al., 2013). The best 
diagnostic test has not been established yet but the recommendation is a 
combination of tests as this can produce reliable results. According to the 
Public Health England UK (PHE, 2012), the NHS has three main options of 
tests to detect CDI: toxin (TOX) enzyme immunoassays (EIAs), nucleic acid 
amplification test (NAAT) and glutamate dehydrogenase (GDH) EIA, but the 
first option should be NAAT or GDH EIA and the other a TOX EIA test 
(Department of Health, 2012a). In US healthcare settings, the use of a 2-step 
or 3-step method consisting of GDH EIA as initial screening followed by TOX 
EIA or NAAT or NAAT to confirm discordant EIA result is recommended. 
However toxin assays have been switched to NAAT for detection of toxigenic  
C. difficile and it has been performed as a stand-alone test (Cohen et al., 
2010b, Surawicz et al., 2013, Fang et al., 2017). Sensitivity, specificity and 
costs of the different tests must be checked when choosing the best test to 
diagnose CDI (Table 1.2). 
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Table 1.2 Comparison of diagnostic tests for C. difficile  
 Diagnostic Test Sensitivity Specificity Turnaround time Costs Availability 
Toxin 
detection 
Cytotoxin assay +++ +++ 48 hours $15-25 Limited 
Enzyme Immunoassay (EIA) + +++ < 24 hours $5-15 Widely 
NAAT +++ +++ < 1 hour $20-50 Widely 
Organism 
detection 
Common antigen testing (GDH antigen) +++ + 15-45 minutes $5-15 Widely 
Stool culture +++ + 72 hours $5-10 Limited 
(Source: Surawicz, 2013)
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Toxin assay can detect both toxins A and B but its sensitivity is low and 
specificity is high. The production of the enzyme GDH by C. difficile can be 
detected by an EIA assay with high sensitivity but low specificity as all strains, 
both toxigenic and non-toxigenic, produce the enzyme at high levels. A 
combined test that detects GDH and toxin in one assay was developed and 
became available on the market. NAAT which uses the polymerase chain 
reaction (PCR) technology has a high negative predictive value (NPV) and its 
sensitivity was reported to be 88-100% (Burnham and Carroll, 2013). NAAT 
does not detect the C. difficile toxin but the gene of organisms that can produce 
toxins and has higher costs compared to others. However it is a rapid test and 
overcomes one of the main limitations of GDH screening, which lacks 
specificity for toxigenic strains (Burnham and Carroll, 2013, Polage et al., 
2015). Stool culture is important for epidemiological studies but it is not 
clinically useful, as its sensitivity is low and results take three days to be ready 
(Cohen et al., 2010). 
 
1.8 Treatment  
The current standard treatment for CDI (Table 1.3) is metronidazole (MTZ) or 
vancomycin (VAN). In 2011/2012 oral fidaxomicin (FDX) was also approved 
for this purpose in the US and Europe. VAN was considered superior to MTZ 
for the treatment of severe cases in a clinical trial (Johnson, 2014) but it was 
inferior to FDX in recurrent cases when using whole-genome sequencing 
(Eyre, 2014). Therefore, the choice of treatment is usually clinical-based and 
according to the severity of the disease. PHE (PHE, 2012), Society for 
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Healthcare Epidemiology of America (SHEA) and the Infectious Diseases 
Society of America (IDSA) (Cohen et al., 2010) and American College of 
Gastroenterology (Surawicz et al., 2013) recommend oral MTZ 400 to 500 mg 
three times a day (tds) for 10 to 14 days for mild and moderate CDI. The 
treatment of severe CDI should be oral VAN 125 mg four times a day (qds) for 
10 to 14 days and in cases of high risk of recurrence and in the elderly with 
multiple comorbidities and in treatment with antibiotics, FDX 200 mg twice 
daily (bd) should be considered. Oral VAN up to 500mg qds for 10 to 14 days 
and MTZ 500mg tds is recommended for life-threatening CDI. Oral FDX 
200mg bd is also indicated for recurrent cases. Intravenous treatment or via 
enema are also options to be considered when there are restrictions or 
complicated CDI. The most updated algorithm recommended in the UK is 
presented in the Figure 1.9. 
 
Table 1.3 Treatment for CDI  
Antibiotic therapy Regimen Cost/10 days ($) Cost/10 days (£) 
Metronidazole  500 mg tds $22.00 £2.53 
 Vancomycin  125 mg qds $680.00 £188.27 
Fidaxomicin 200 mg bd $2,800.00 £1,350.00 
(Source: Surawicz et al, 2013, NICE, 2012) 
 
Faecal microbiota transplant (FMT) has become more popular as evidences 
have suggested potential benefits for treatment of recurrent, severe and 
complicated cases (Kassam et al., 2013, Dodin and Katz, 2014). The number 
of published studies has showed a three-fold increase in the last 3 years. The 
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procedure aims to replace good bacteria by transplanting faecal matter from a 
healthy donor via colonoscopy, endoscopy, sigmoidoscopy or enema. 
National Institute for Health and Care Excellence (NICE) recommends the use 
of FMT only for recurrent cases when there is failure to respond to standard 
treatment, according to evidence of efficacy and safety of published studies 
(NICE, 2014). In the guidelines of the American College of Gastroenterology 
FMT is recommended in the third recurrence (Surawicz et al., 2013). A recent 
systematic review with 37 (Quraishi et al., 2017), 23 (van Beurden et al., 2017) 
and 35 (Drekonja et al., 2015) studies showed efficacy of FMT treatment for 
recurrent, severe and complicated cases and insufficient evidence for initial or 
refractory cases, respectively. 
Moreover, clinical trials have been conducted to study the potential efficacy 
and safety of novel treatment for CDI such as cadazolid, ridinilazole and 
bezlotoxumab. In the phase 2 study, cadazolid demonstrated efficacy and 
safety (Louie et al., 2015); ridinilazole showed a clinical cure rate in 10 days 
higher than VAN and no recurrence after 30 days of treatment (Vickers et al., 
2017); bezlotoxumab IV, when administered with standard therapy, showed 
lower recurrence rate compared to a placebo in a phase 3 trial (Wilcox et al., 
2017). 
There are other alternative options for CDI treatment or prevention, such as 
probiotics, anion exchange resin, non-toxigenic C. difficile (NTCD), fusidic 
acid, rifampicin and rifaximin, but they are not commonly used nowadays. 
There is no significant evidence to support the use of probiotics (Cohen et al., 
2010), anion exchange resin is not recommended for this purpose (PHE, 
2012), NTCD is not licensed but could be used as a supplement to the 
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standard therapy preventing relapses (Musher and Koo, 2016; Gerding et at, 
2015), fusidic acid role is unclear but the resistance rate is high (PHE, 2012), 
rifampicin had no clinical trial reported (PHE, 2012) and rifaximin has been 
used for refractory cases but it is not approved for the treatment of CDI (Al-
Jashaami and DuPont, 2016). 
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Figure 1.9 Algorithm for management of first episode of CDI (Source: Public 
Health England, 2013). 
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1.8.1 Recurrence 
Recurrent episodes can affect 15 to 30% of patients after the first infection and 
this number is higher in subsequent recurrences (Eyre et al., 2012, Johnson, 
2009). Recurrence can be due to either relapse when there is an infection with 
the same strain or reinfection when the new infection is caused by a different 
strain within the period of 90 days after the first infection. Inadequate antitoxin 
antibody response, severity of initial infection, persistent disruption of the 
colonic flora, advanced age, continuation of non-C. difficile antimicrobial 
therapy following a first episode of CDI, long hospital stays and concomitant 
receipt of antacid medication are some of the risk factors that can contribute 
to the development of recurrent episodes (Johnson, 2009). A recent meta-
analysis published (Tariq et al., 2017) suggests an association between the 
use of gastric acid suppressant and the risk of recurrences after revision of 16 
studies. This condition is a challenge for the treatment and can persist for 
months or years (Johnson, 2009, Eyre et al., 2012). Thus, it is recommended 
and important to identify the risk factors and treat the patient correctly (Figure 
1.10) to try to avoid potential recurrences. 
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Figure 1.10 Algorithm for recurrence of CDI (Source: Public 
Health England, 2013). 
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1.8.2 Resistance 
C. difficile can also resist the majority of routine antimicrobials, such as 
ampicillin, amoxicillin, CF and CLI (APIC, 2008). Some antibiotics are also 
known to promote CDI and this has changed during the years; CLI showed a 
high risk in the 70s, CFs around the 80s and 90s and fluoroquinolones in the 
2000s (Spigaglia, 2016). Resistance is multifactorial and influenced mainly by 
local and national policies and prescribers, thus resistance rates are variable 
between countries, cities and hospitals. Considering 30 studies between 2012 
and 2015, ciprofloxacin (CIP), a second-generation FQ, showed resistance in 
around 99% of strain tested and cefotetan (CTT) and cefoxitin (FOX), second-
generation CFs, in 79%. Resistance rates of CLI, CFs, erythromycin (ERY) 
and FQs were on average 55%, 51%, 47% and 47%, respectively (Spigaglia, 
2016). 
Some strains also showed resistance to the antibiotics for treatment of CDI, 
but resistance rates are usually low. In a review, MTZ showed in general 0-
0.11% resistance and VAN 0-1.2%. However, the rates in Iran and Israel were 
higher with 5.3% and 18% for MTZ and 8% and 47% for VAN (Spigaglia, 
2016). In Israel, this reduced susceptibility to antibiotics in 2014 was related to 
the dissemination of R027 as 65 patients presented on average 87.7% and 
44.6% resistance rate for MTZ and VAN (Adler et al., 2015). The indiscriminate 
use of MTZ in Iran could be the cause of increased resistance in the study 
conducted in 2010/2011 (Goudarzi et al., 2013). Reduced susceptibility of FDX 
was rarely reported (Spigaglia, 2016) and no evidence was found in a study 
(Freeman et al., 2015) and a review published in 2016 (Tang et al., 2016).  
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1.9 Prevention and control 
Prevention and control measures were implemented to avoid direct and 
indirect contamination and to reduce the number of infected patients in the 
healthcare sites. The Health Protection Agency (HPA) has published a 3 grade 
system (Table 1.4) with recommendations to manage CDI: a mnemonic 
protocol called SIGHT (Table 1.5) should be used by doctors and healthcare 
staff in suspected cases. The Association for Professionals in Infection Control 
& Epidemiology (APIC) (Table 1.6) also suggests contact precautions, hand 
hygiene and environmental control as the three main approaches to deal with 
the bacteria (APIC, 2008).  
The components of contact precautions are: (a) patient placement (private 
room and bathroom and when it is not possible, a dedicated C. difficile ward 
for isolation); (b) personal protective equipment (PPE, such as gloves and 
gowns); (c) patient transport (infected patient transportation should be limited 
and hand hygiene should be performed by patients and PPE should be used 
and discarded by healthcare professionals); (e) patient care equipment, 
instruments, devices and the environment (as C. difficile can contaminate all 
of the environment and equipment and can persist for months, all healthcare 
sites should have cleaning and disinfection plans); (e) discontinuing contact 
precautions (after the end of the symptoms, contact precautions may be 
discontinued); and (f) assessment of adherence to isolation precautions 
(Department of Health & Health Protection Agency, 2008, APIC, 2008). 
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Table 1.4 Grade system for CDI management  
Grade Strength of evidence 
A Strongly recommended and supported by systematic review of randomised controlled trials (RCTs) or individual RCTs. 
B Strongly recommended and supported by non-RCT studies and/or by clinical governance reports and/or the Code. 
C Recommended and supported by group consensus and/or strong theoretical rationale. 
(Source: Health Protection Agency, 2013) 
 
Table 1.5 SIGHT protocol for CDI management  
S Suspect that a case may be infective where there is no clear alternative cause for diarrhoea  B 
I Isolate the patient and consult with the infection control team (ICT) while determining the diarrhoea  B 
G Gloves and aprons must be used for all contacts with the patient and their environment  B 
H Hand washing with soap and water should be carried out before and after each contact with the patient and the patient’s 
environment  
A 
T Test the stool for toxin, by sending a specimen immediately. B 
(Source: Health Protection Agency, 2013)
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Besides gloves, hand washing with a non-antimicrobial or an antimicrobial 
soap and water is also very important to control the spread of the bacteria. Not 
only must healthcare professionals clean their hands properly, but also 
patients and their family must do it. For this purpose, it is recommended to 
teach hand hygiene and bathing to all patients and their families and promote 
understanding of the infection, spread of bacteria, how to reduce the spread 
of the disease, the risks of acquiring it and how to clean their homes (APIC, 
2008, Department of Health & Health Protection Agency, 2008). Hand washing 
is known to be one of the most important measures in control and prevention 
of infections. 
 
Table 1.6 Control measures and grade of recommendation  
 
(Source: Cohen, 2010) 
 
The entire environment, including surfaces and objects, must be cleaned daily 
using specific environmental disinfectants that are also able to kill the 
vegetative form and spores. The HPA recommends chlorine-containing 
cleaning agents (at least 1,000 ppm of available chlorine) (Department of 
Health & Health Protection Agency, 2008). Vaporised hydrogen peroxide can 
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also be used to clean and disinfect the environment in private rooms and 
isolation wards. Healthcare sites should provide a checklist to help staff to 
confirm that all areas and objects were cleaned and disinfected and also 
provide a team to monitor the cleaning process routinely. Besides, meetings 
with the infection control team, cleaning staff and healthcare professionals 
should be held to discuss this subject (Department of Health & Health 
Protection Agency, 2008, APIC, 2008).  
Antibiotic stewardship is considered the most useful measure to control the 
bacteria and this has been widely implemented to reduce the inappropriate 
use of antibiotics. Between 1997 and 2013, CFs and FQs were the classes of 
antibiotics with more restrictions according to a meta-analysis that included 16 
studies (Feazel et al., 2014). This study also concluded that control of these 
classes was effective in decreasing the incidence of CDI. A genomic study has 
shown a decrease in FQ-resistant isolates after restriction of use of 
fluoroquinolones (Dingle et al., 2017). In a hospital in the UK, interventions 
have been implemented since 2003 aiming to decrease the number of HCAI 
and included: antibiotic stewardship, surveillance and feedback, infection 
control standards and practice, education and training, governance 
framework/programmes and leadership and a national policy and campaign 
(Marufu et al., 2015). Restriction of quinolones and CFs use between 2007 
and 2011 was associated with reduction of CDI incidence in accordance with 
other studies (Marufu et al., 2015). An American hospital showed a decrease 
in the number of cases, total expenditure and resistance rate after the 
implementation of CLI restriction. Resistance rate dropped from 91% to 39% 
in 26 months (Climo et al., 1998). 
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However, one decade after the outbreak, HCAI CDI has been decreasing over 
the years and asymptomatic and untested symptomatic patients have been 
suggested to be a source of C. difficile and that isolation of confirmed patients 
may not be sufficient to reduce the transmission of disease. Moreover, C. 
difficile was recovered from environmental sources such as piglets, cattle, 
horses and poultry, water, soil and household environs (Martin et al., 2016). 
 
1.10 Policy 
1.10.1 Costs and Health economics 
CDI causes a substantial economic burden for the healthcare systems and 
adds an extra layer of complexity to the patient’s management due to its easy 
spread and resilience to environmental control measures. It is estimated that 
CDI extends hospital stays by 1 to 3 weeks (Chang et al., 2007, Forster et al., 
2012) and that in-patients are over twice as likely to die of CDI than methicillin-
resistant Staphylococcus aureus (MRSA) in England and Wales (Department 
of Health & Health Protection Agency, 2008).  
A systematic review of CDI in some European countries showed that the 
median length of stay (LoS) ranged from 7.8 to 48.8 days (Wiegand et al., 
2012), while in the US from 6.6 to 18 days (Ghantoji et al., 2010). The 
attributable length of stay in the US was between 2.8 and 5.5 days (Dubberke 
and Olsen, 2012). The HPA reported that approximately 1 in 4 patients has 
recurrent episodes and that the majority are subsequently re-admitted to 
hospital, vastly increasing direct and indirect costs (Department of Health & 
Health Protection Agency, 2008). Hospital stay is considered not only a risk 
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factor to the development of CDI, but also is directly related to increasing 
costs, comprising about 85-94% of total costs (Kyne et al., 2002, Wiegand et 
al., 2012). An extra length of stay can amount on average to €14,000 per 
patient with a bed day in an intensive care unit being set at €1,200, almost 
twice as high as in a regular ward (Magalini et al., 2012). 
A review by Ghantoji (Ghantoji et al., 2010) estimated that total costs for CDI 
patients was between $9,822-13,854, over 40% more when compared to the 
matched control group ($6,950-9,008). It has been suggested that the cost per 
episode is in the range of €5,000-15,000 (Kuijper et al., 2006). In addition, 
estimates from three health-economic studies in the US suggest that the 
overall management costs associated with C. difficile range from $436 million 
to more than $3 billion (Kuijper et al., 2006, Simor, 2010, Deneve et al., 2009). 
Recent reviews suggested that the direct and indirect burden to the healthcare 
systems are projected to be between $1.0-4.8 billion for the US (Dubberke and 
Olsen, 2012) and around €3 billion for the European Union (Kuijper et al., 
2006, Wiegand et al., 2012).  
Traditional economic studies on C. difficile usually rely on the collection of 
batches of data and are based on basic parameters such as hospitalisation 
times, costs of laboratory tests and associated antimicrobial therapies. In most 
studies indirect costs, the costs from days lost due to absence or productivity 
losses, are usually not calculated and these studies did not take into account 
outpatient costs, thus the overall costs could be underestimated (Ghantoji et 
al., 2010). Therefore, while cost analysis is useful for assessing direct costs, it 
poses difficulties for accurate ascertainment of indirect costs and cost-
effectiveness of interventional measures, which require a robust framework for 
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the integration of information, often linked to individual patients’ episodes, as 
well as a deep understanding of the disease epidemiology and dynamics. One 
of the main challenges for economic studies is the accurate measurement of 
disease recurrence since it is an inconstant clinical feature and difficult to 
predict and investigate. 
 
1.10.2 Guidelines 
Several guidelines have been published over the years in the US, Europe and 
the UK, mainly focused on prevention, treatment and diagnosis to help 
healthcare sites and professionals deal with CDI patients and CDI outbreaks. 
Some of them are listed below: 
 Clostridium difficile infection: how to deal with the problem (Public 
Health England, 2008); 
 Guide to the elimination of Clostridium difficile in healthcare settings 
(Association for Professionals in Infection Control & Epidemiology, 
2008); 
 Clostridium difficile: what it is, how to prevent, how to treat (Public 
Health England, 2009); 
 Clostridium difficile infection (CDI): management in care homes (Public 
Health England, 2010); 
 Clinical practice guidelines for Clostridium difficile infection in adults 
(Society for Healthcare Epidemiology of America and the Infectious 
Diseases Society of America, 2010); 
 
 
32 
 
 Treating Clostridium difficile infection with faecal microbiota 
transplantation (American Gastroenterological Association, 2011); 
 Clostridium difficile: updated guidance on diagnosis and reporting 
(Public Health England, 2012); 
 Clostridium difficile infection: fidaxomicin (National Institute for Health 
and Care Excellence, 2012); 
 Clostridium difficile infection: guidance on management and treatment 
(Public Health England, 2013); 
 Guidelines for Diagnosis, Treatment, and Prevention of Clostridium 
difficile Infections (American College of Gastroenterology, 2013); 
 Faecal microbiota transplant for recurrent Clostridium difficile infection 
(National Institute for Health and Care Excellence, 2014); 
 Update of the treatment guidance document for Clostridium difficile 
infection (European Society of Clinical Microbiology and Infectious 
Diseases, 2014); 
 Infection prevention and control (National Institute for Health and Care 
Excellence, 2014); 
 Guidance on Prevention and Control of Clostridium difficile Infection 
(CDI) in Care Settings in Scotland (Health Protection Network, 2014); 
 WSES guidelines for management of Clostridium difficile infection in 
surgical patients (World Society of Emergency Surgery, 2015); 
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1.11 Aims  
Clinical, epidemiological and molecular advances have showed the 
importance of trying to avoid new cases and recurrences. These advances 
have not been followed by systematic economic studies evaluating the recent 
impact of the disease on healthcare systems and the cost-effectiveness of 
major interventional measures. Moreover, the actual economic impact caused 
by several epidemic seasons of C. difficile on the NHS and healthcare systems 
has yet to be determined in more details. The situation clearly denotes a need 
for further economic and prevention studies. 
Thus, we propose an investigation to: 
1. Describe characteristics of CDI patients and diarrhoea control patients 
recruited in two epidemiological seasons and assess representativeness 
of those patients compared to patients who have not met the inclusion 
criteria; 
2. Investigate the contribution of patients with discordant assay results as a 
reservoir of Clostridium difficile and potential cost-saving with the 
implementation of a confirmatory test;  
3. Assess the use of procalcitonin (PCT) as a potential prognosis test for 
hospitalised patients infected by Clostridium difficile; 
4. Conduct a systematic review on the economics of interventional measures 
for CDI; 
5. Estimate the costs associated with CDI during the epidemic and endemic 
seasons in a large hospital setting.  
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Chapter 2 
Clostridium difficile infection in Liverpool 
from 2008 to 2016 
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2.1 Introduction 
CDI is one of the most common causes of hospital-acquired diarrhoea 
worldwide but there is patient and microbiological heterogeneity. Clostridium 
difficile ribotyping network report (PHE, 2014) has shown that England is 
becoming more heterogeneous with respect to C. difficile strains. Therefore, 
recruitment and characterisation of patients are important to understand this 
variability.  
Biobanks have been developed as a health resource to help and improve 
diagnosis, prevention and treatment of different diseases (UK Biobank, 2017). 
Databases and biobanks can recruit a large number of individuals, being able 
to be representative of the general population. Also, they have been set up in 
many countries and are available in every continent. In the UK, the UK Biobank 
has recruited around 500,000 patients between 2006 and 2010 (UK Biobank, 
2017) and The Infectious Diseases Biobank (IDB) has collected samples from 
patients infected with human immunodeficiency virus (HIV), hepatitis B and C 
and MRSA (IDB, 2017).  
For CDI, some studies with databases and biobanks have been published in 
the literature. 45,341 patients from OptumInsight Clinformatics Database 
developed CDI and were recruited between 2001 and 2012 in the US (Ma et 
al., 2017), it contains information on insured patients from different regions of 
the country. In 2010/2011, 1,026 CDI cases were recruited from 47 facilities in 
Japan (Takahashi et al., 2014). A French study used the French national 
health insurance database which have more than 600,000 registered 
individuals to select 482 patients with a CDI diagnosis between 2007 and 2014 
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(Barbut et al., 2017a). In the UK, the Clostridium difficile Ribotyping Network 
for England and Northern Ireland has developed a tool to help hospitals to 
investigate and manage the disease with a molecular epidemiological service 
(PHE, 2016). 
To understand clinical, economic and molecular aspects of this disease, 
patients infected with C. difficile were recruited at the Royal Liverpool and 
Broadgreen University Hospitals Trust (RLBUHT) in epidemic (2008-2012) 
and endemic (2012-2016) phases. Thus, the aim of this chapter was to present 
the cohort groups recruited and assess the representativeness of the cohorts 
compared to all patients tested for C. difficile in the setting during the same 
period. 
 
2.2 Methods 
2.2.1 Patient recruitment 
2.2.1.1 Phase I  
Recruitment occurred from July 2008 to March 2012. The cohort was 
composed of inpatients aged>18 years, who had developed antibiotic-
associated diarrhoea and had a sample tested for C. difficile. A stool positive 
for TOX, a positive clinical diagnosis and a positive bacterial culture were the 
inclusion criteria for CDI cases. Control patients were included in this study 
when they had antibiotic-associated diarrhoea but had negative tests for both 
stool TOX and bacterial culture. Thus, phase I patients were categorised as 
TOX+ or TOX-. This study was approved by the Liverpool Research Ethics 
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Committee (reference number 08/H1005/32). Informed consent form for both 
phases is presented in the appendix 1. 
 
2.2.1.2 Phase II 
Recruitment of phase II was similar to phase I, again, patients who had been 
tested for C. difficile and aged>18 years were recruited from February 2013 to 
July 2015. In May 2012, a two-stage diagnostic algorithm for CDI – consisting 
of a glutamate dehydrogenase (GDH) enzyme immunoassay (EIA) and an EIA 
detecting C. difficile toxins A and B (TOX) – was implemented at the RLBUHT, 
the main recruiting site. Thus, the inclusion criteria for CDI cases were a stool 
specimen that was positive for TOX and GDH, a positive clinical diagnosis and 
a positive bacterial culture. Control patients were included when they had 
antibiotic-associated diarrhoea plus both negative test for stool TOX 
regardless of the GDH result and negative bacterial culture. In addition, a 
random sample of patients with inflammatory bowel disease (IBD) and healthy 
patients who were not tested for C. difficile were recruited. Based on these two 
diagnostic tests, three groups of patients were recruited during phase II: 
 Patients categorised as cases (GDH+/TOX+), 
 Potential C. difficile carriers (GDH+/TOX-),  
 Patients categorised as controls (GDH-/TOX-). 
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2.2.1.3 Clinical audit 
To fill the gap between the recruitment of the two cohorts and to increase the 
number of observations, a clinical audit titled “An effectiveness assessment of 
the on-going Clostridium difficile infection programme, overseen by Infectious 
Diseases, to audit/reaudit different strands facilitating quality improvement” 
was submitted in August 2015. Thus, it was possible to obtain information on 
patients tested between July 2008 and January 2016. The first phase (July 
2008 to April 2012) included all patients tested before the introduction of the 
GDH detection and the second phase (May 2012 to January 2016) included 
patients tested for both TOX and GDH. 
A list with all faecal samples sent to Liverpool Clinical Laboratories (LCL) was 
used to select the patients. Sample selection was according to test results and 
followed the priority: GDH+/TOX+, GDH+/TOX- and GDH-/TOX-. All 
GDH+/TOX+ samples were selected as the index episode and all samples 
from these patients retested within 90 days were excluded regardless of the 
result. The process was repeated for GDH+/TOX- samples and lastly for GDH-
/TOX- samples. Duplicate samples were also excluded. Samples already 
included in both cohorts were excluded from the audit, however, the same 
patient could be included in more than one group (cohort or audit, phase I or 
phase II) when retested after 90 days.  
Demographic and hospitalisation data were obtained without patients’ consent 
from the finance department when data were available. For samples tested 
after the implementation of GDH, clinical data on GDH+/TOX+ patients, 
GDH+/TOX- patients and a random sample of GDH-/TOX- patients were 
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collected using the databases described in the session 2.2.3. This audit was 
approved by Effectiveness Team at the RLBUHT (reference number 
AC03389). 
 
2.2.2 Microbiological assessment 
During phase I, a TOX A/B ELISA kit was used to test faecal samples for C. 
difficile toxin (Techlab, Blacksburg, USA). Culture was performed using 
Brazier’s cefoxitin-cycloserine egg yolk agar (Lab M Ltd, Bury, UK) and 
incubated in an anaerobic chamber at 37ºC for 48 hours. Potential isolates 
were identified based on the characteristic smell, colonial morphology and 
fluorescence under long wave UV light. A latex agglutination test for C. difficile 
somatic antigen (Oxoid, Basingstoke, UK) was used to confirm the 
identification and purity of isolates that were stored on PROTECT beads at -
70ºC (Technical Services Consultants Ltd, Heywood, UK). Standards methods 
were used to perform PCR ribotyping (Fawley et al., 2011) after isolates were 
sub-cultured in a fastidious anaerobe agar (Bioconnections, Wetherby, UK) 
and then compared to a panel of the commonest ribotypes circulating in the 
UK. 
In May 2012, the algorithm to diagnose CDI was changed and faecal samples 
were tested using a combined test for detection of GDH antigen and toxin A/B 
test in one cartridge (Techlab C. diff Quik Chek Complete). In 2015, a nucleic 
acid amplification test (NAAT) (Cepheid Xpert® C. difficile) was also 
implemented in this setting as a confirmatory test for those patients who had 
a negative result for TOX but positive result for GDH. The PCR assay was 
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used for detection of the toxin gene targeting a species-specific internal 
fragment of the triose phosphate isomerase (tpi) housekeeping gene, as well 
as internal core sequences of both tcdA and B tcdB genes to verify their 
individual toxigenicity (Lemee et al., 2004). 
 
2.2.3 Data collection 
All cohort patient data were collected using a Case Report Form (CRF; 
presented in the appendix 2) and accessing hospital information systems such 
as Patient Manager (iPM), Integrated Clinical Environment (ICE) and End-to-
End E-Prescribing & Medicines Administration (EPMA). Data collected include 
demographic, clinical and hospitalisation information, laboratory results and 
medicines. For audit patients, only demographic and hospitalisation data were 
available.  
Demographic information included age at recruitment, gender and index of 
multiple deprivation 2015 (IMD). Clinical information included the Charlson 
comorbidity index 2011 (CCI), CDI severity, CDI recurrence and mode of 
acquisition, and whether the infection was a healthcare-associated infection 
(HCAI) or community-acquired infection (CAI). Hospitalisation information 
include length of stay (LoS), disease and pre-test periods, number of 
hospitalised days within 6 months prior (LoS before) and 6 months post (LoS 
after) the index hospitalisation, costs of index hospitalisation, costs of 
hospitalisations within 6 months prior (costs before) and 6 months post (costs 
after) the index hospitalisation. Laboratory results included the white cell count 
(WCC), neutrophils, albumin, estimated glomerular filtration rate (eGFR) and 
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C-reactive protein (CRP). Medicines information included the antibiotics used 
for CDI treatment and information about proton-pump inhibitors (PPI), a 
medication for chronic use and potential risk factor for development of CDI.  
IMD is a measurement that relates deprivation of hospitalisation, employment, 
health and disability, education skills and training, barriers to housing and 
services, living environment and crime by Lower layer Super Output Area 
(LSOA) (Department For Communities And Local Government, 2011). 
England is divided into 32,844 LSOA and each LSOA has a minimum of 1,000 
residents (average of 1,600) and 400 households (average of 650). IMD was 
derived using the patients’ post codes and Department for Communities and 
Local Government datasets updated in 2015 (Department For Communities 
And Local Government, 2015).  
CCI is a measurement tool developed to classify and weight comorbid 
conditions. It predicts ten-year mortality for each patient (Charlson et al., 1987) 
and takes into account comorbidities such as cardiovascular disease, renal 
disease, liver disease, cancer and acquired immune deficiency syndrome 
(AIDS). CCI was derived from CRF notes of comorbidities and history of past 
diseases and classified according to the recommendations by Quan et al 
(Quan et al., 2011), which is an updated version of Charlson (Charlson et al., 
1987).  
HCAI was defined as an infection acquired and developed in healthcare 
settings as a result of medical interventions or contact with the environment 
(PHE, 2012). An infection was assumed to be HCAI if the TOX test was 
performed at least 48 hours after admission to the hospital (Friedman et al, 
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2002, Gupta and Khanna, 2014). Tests performed before 48h of the hospital 
admission were considered CAI. Medical history of past hospitalisation and 
healthcare interventions was not considered and for this reason the definition 
of cases is not accurate. 
All continuous variables were presented as median and interquartile range 
(IQR) while categorical variables were presented as frequency (F) and 
percentage (P). T-test or ANOVA were employed to compare normally 
distributed continuous variables, Mann-Whitney U test or Kruskal Wallis were 
employed to compare non-normally distributed and chi-square test to compare 
categorical variables. 
  
2.2.4 Definitions of outcomes 
LoS or time to discharge was defined as the total period between the patient’s 
admission until the discharge from hospital. This period was divided in two 
different periods: the disease period comprising the time between the C. 
difficile test (positive for cases and negative for controls) to discharge from 
hospital, and the pre-test period which was the time between admission to the 
C. difficile test. 
All cause-mortality of patients was assessed at different time-points: short-
term mortality (within 4 weeks after TOX), long-term mortality (within 1 year 
after TOX) and during hospitalisation. Time to death within 1 year was 
considered the time after the C. difficile test until date of death. 
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The severity of CDI was categorised as either severe or not-severe and 
assessed only in the cohort of patients who tested GDH+/TOX+ and 
GDH+/TOX-/PCR+. Severe disease was considered when one of the following 
clinical signs was present: WCC>20x109/L, temperature>38.5ºC, 
eGFR<30ml/min/1.73m2, severe colitis, hypotension, partial or complete ileus, 
colectomy and toxic mega colon, according to PHE guideline (PHE, 2013) with 
inclusion of a more strict cut-off for WCC and eGFR levels in substitution of 
serum creatinine, as defined previously (Swale, 2014). Levels of WCC higher 
than 20x109/L have been identified as predictor of complicated CDI in 
systematic reviews (Chakra et al, 2012, Chakra et al, 2014) and basal serum 
creatinine was not always available and not always possible to calculate the 
increase in creatinine levels, for this reason eGFR levels were used instead.  
Hospitalisation costs were calculated according to Healthcare Resource 
Group (HRG) codes and based on the national tariff. After hospital discharge, 
each hospitalisation received codes by the hospital’s clinical coders for 
diseases and interventions performed during the period. These codes were 
submitted to Secondary Uses Service that assigns an HRG code based on 
clinical codes and other patient information. Each HRG code was priced by 
Department of Health according to the national tariff which is based on 
average clinical and non-clinical costs of a particular procedure from all NHS 
hospitals in England. Every year, hospitals should collect costs by type of 
treatment and submit it to the Department of Health (Department of Health, 
2012b). These costs include only direct medical and non-medical costs, such 
as staff, consumables, overheads, capital charges and diagnostic tests 
charges. Thus, hospitalisation dates of all patients were submitted to the 
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information centre and finance department in the RLBUHT to obtain the HRG 
codes and costs of each patient, however not all patients had these 
information available The total cost of hospitalisation was based on the 
2016/2017 national tariff (NHS England, 2016) and adjusted for LoS when the 
time point was lower than the total hospitalisation period. In addition, for phase 
II patients who had been treated with FDX – a high cost antibiotic comparing 
to standard therapy (£1,350 for 10 days treatment) – the treatment cost was 
added to the hospitalisation costs.  
CDI recurrence, including relapse and reinfection, was considered when a 
patient had a positive result for TOX within 90 days after the index CDI episode 
(Swale et al., 2014a). A second positive test within 30 days was excluded 
following recommendation (Surawicz et al., 2013) as tests could remain 
positive within this period.  
Clinical outcomes were presented in the same format as other variables: 
continuous variables were presented as median and IQR and categorical 
variables were presented as F and P. To compare variables, the same testes 
described in section 2.2.3 were employed. 
 
2.3 Responsibility breakdown 
The development of the study “Clostridium difficile-associated toxin disease: 
development of a tool to predict individual susceptibility based on 
environmental and genetic factors” design was carried out by the Principal 
Investigator (Professor Sir Munir Pirmohamed), the Study Lead (Dr Fabio 
Miyajima), the Study Administrator (Ms Anita Hanson), the Microbiology 
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Consultant (Dr Christopher Parry) and the leading Infectious Disease 
Consultants (Dr Nicholas Beeching and Dr Mike Beadsworth). The clinical 
audit was submitted by Dr Mike Beadsworth. 
The recruitment of patients and collection of information for CRF were 
conducted by Pharmacology Research Nurses (Mrs Margaret Little and Ms 
Rachel Hornby). The electronic version of CRFs was developed by Dr Fabio 
Miyajima, Dr Andrew Swale, Mr James McKenna and Mr Jon Creswell. Further 
appropriate data of recruited patients were collected by Mrs Margaret Little, 
Ms Rachel Hornby, Dr Andrew Swale, Dr Fabio Miyajima and myself. Clinical 
and hospitalisation information of audit patients were collected by Ms Kathryn 
Mcgregor, Ms Hannah Richards, Ms Anne Wiltshire and myself.  
Blood samples were processed by Dr Andrew Swale and Ms Alejandra Doce 
Carracedo. Faecal samples were processed by Mr Paul Roberts and Ms 
Valerie Price at LCL who also performed the microbiological profile. Additional 
microbiological tests were performed by Ms Zolal Hekmat, Mr Leandro 
Carneiro and Ms Qing Zhang. Procalcitonin measurement was performed by 
Dr Suzannah Phillips and Ms Jean Devine at LCL. 
Hospitalisation codes were obtained by Mr Paul Currie from The Corporate 
Information Department and hospitalisation costs were obtained by Colin 
Duckworth from Finance Department at RLBUHT. 
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2.4 Results 
2.4.1 Overview of main patients’ characteristics 
Figure 2.1 shows when (phase I or II) and how (cohort or audit) patients were 
recruited between 2008 and 2016 and Table 2.1 shows the number of patients 
recruited by diagnostic tests performed and phase of recruitment. In the 
cohort, 257 CDI cases and 139 diarrhoea control patients were recruited 
during phase I, while 70 CDI cases, 47 potential carrier patients and 84 
diarrhoea control patients were included during phase II. Clinical audit 
included 416 CDI case patients in the phase I and 171 CDI case patients, 428 
potential carrier patients and 3,658 diarrhoea control patients in phase II.  
 
 
Figure 2.1 Recruitment of patients between 2008 and 2016 
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Table 2.1 Patients recruited by phase, diagnosis tests and recruitment status 
Period Phase Diagnosis tests Patients recruited 
2008-2012 I TOX 
 cohort audit 
TOX-b 139 . 
TOX+c 257 416 
2013-2015a 
2012-2016 
II 
GDH 
TOX 
GDH-/TOX-d 164 3,658 
GDH+/TOX-e 57 428 
GDH+/TOX+f 78 171 
TOX: toxin test, GDH: glutamate dehydrogenase 
a Cohort patients were recruited between 2013 and 2015 and audit patients were recruited 
between 2012 and 2016 b diarrhoea control patients c CDI case patients d diarrhoea control 
patients e potential carrier patients f CDI case patients. 
 
2.4.2 Patient Cohorts  
2.4.1.1 Phase I recruitment 
Patients’ characteristics are shown in Table 2.2. Both groups were on average 
older than 65 years, a potential risk factor for the disease. CDI patients stayed 
hospitalised longer [24 days (IQR: 12-46), p=0.001], and the costs of their 
hospitalisation was higher [£4,563 (IQR: £3,394-8,789), p=0.001] than 
controls. Mortality rates were also higher during hospitalisation [9% (n=24), 
p=0.047] and within 1 year [32% (n=81), p=0.002]. 42% (n=107) of CDI 
patients presented severe disease (as described in section 2.2.4) and 18% 
(n=47) had recurrence within 90 days. Patients categorised as CDI cases 
typically presented with leucocytosis (WCC>11x109/L), neutrophilia 
(neutrophils>7.5x109/L) and hypoalbuminemia (albumin<35g/L) and both 
groups presented with elevated CRP levels (CRP>5mg/L). In terms of drug 
intake, 68% (n=173) of CDI cases were treated with any PPI compared to 58% 
(n=80) of diarrhoea controls. Additionally, 94% (n=241) of CDI patients were 
treated with MTZ and/or VAN after a positive test for TOX. 
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 Table 2.2 Patients characteristics of cohort phase I 
 
TOX-a (n=139) TOX+b (n=257)  
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
p 
Demographics      
Age (years), median (IQR) 139 67 (57-78) 257 75 (61-81) 0.011 
gender (female, %) 139 78 (56) 257 149 (58) 0.721 
IMD (score),  
median (IQR) 
135 
37.9 
(20.4-58.0) 
229 
34.2 
(17.3-56.3) 
0.438 
Clinical  
CCI (score), median (IQR) 139 1 (0-2) 256 1 (0-2) 0.270 
mode of acquisition  
(HCAI, %) 
139 87 (62.6) 257 161 (62.6) 0.991 
CDI severity (%) 0 
 
257 107 (41.6) . 
CDI recurrence (%) 0 
 
257 47 (18.3) . 
Clinical outcomes  
LoS (days), median (IQR) 139 14 (7-28) 257 24 (12-46) 0.001 
disease (days), median (IQR) 139 7 (4-15) 257 14 (8-27) 0.002 
pre-test (days), median (IQR) 139 4 (1-10) 257 7 (1-17) 0.018 
Time to death (days),  
median (IQR) 
24 
141.5 
(44-199.5) 
81 
79 
(31-159) 
0.146 
Mortality hospitalisation (%) 139 5 (3.6) 257 24 (9.3) 0.047 
4 weeks (%) 139 5 (3.6) 257 18 (7.0) 0.167 
1 year (%) 139 24 (17.3) 257 81 (31.5) 0.002 
Hospitalisation costs (£),  
median (IQR) 
132 
3,221 
(2,116-5,000) 
217 
4,563 
(3,394-8,789) 
0.001 
Laboratory results, median (IQR)  
albumin baseline (g/L) 88 34 (29-39) 212 30 (25-35) <0.001 
WCC baseline (109/L) 129 8.6 (6.6-12.3) 252 11.6 (8.5-18.0) 0.001 
Neutrophils baseline (109/L) 126 6.0 (4.2-9.7) 247 9.0 (6.0-15.0) <0.001 
eGFR baseline  
(mL/min/1.73m2) 
129 
71.0 
(33.0-95.0) 
251 
74.0 
(46.0-106.0) 
0.104 
CRP baseline (mg/L) 129 25 (8-85) 240 70.5 (30.5-137.5) 0.002 
Medicines (%)  
PPI 139 80 (57.6) 255 173 (67.8) 0.042 
CDI treatmentc 139 14 (10.1) 257 241 (93.8) <0.001 
Fidaxomicin 139 0 257 0 . 
Vancomycin 139 6 (4.3) 257 228 (88.7) <0.001 
Metronidazole 139 10 (7.2) 257 111 (43.2) 0.062 
TOX: toxin test, IMD: Index of multiple deprivation, CCI: Charlson Comorbidity Index, HCAI: 
healthcare-associated infection, CDI: Clostridium difficile Infection, LoS: length of stay, WCC: 
white cell count, eGFR: estimated glomerular filtration rate, CRP: C-reactive protein, PCT: 
procalcitonin, PPI: Proton-pump inhibitor.  
a diarrhoea control patients, b CDI case patients, c treatment with any antibiotic (standard 
treatment or fidaxomicin) 
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2.4.1.2 Phase II recruitment 
Table 2.3 shows characteristics of patients recruited during phase II. The 
median age of CDI cases in phase II was higher than 65 years. A higher 
median score of comorbidities was observed in CDI cases (2), followed by 
GDH+/TOX- (1) and GDH-/TOX- patients (0, p<0.001). Similar clinical 
outcomes were found in CDI cases and GDH+/TOX- groups when considering 
the average time to discharge and costs of hospitalisation [16 (IQR: 7-32) vs 
18 (IQR: 7-37) days and £5,192 (IQR: £3,842-7,379) vs £5,192 (IQR: £3,144-
1,6827], however, the LoS of both groups was higher than diarrhoea control 
patients (Los 7 days, IQR: 2-10, p>0.001) and costs were similar [£2,971, 
(IQR: 1,894-3,842), p=0.095]. CDI cases were more likely to die during 
hospitalisation [8% (n=6), p=0.032] and within 1 year after diagnosis [41% 
(n=32), p<0.001] compared to the other groups. Hypoalbuminemia 
(albumin<35g/L) and neutrophilia (neutrophils>7.5x109/L) were present in CDI 
cases and GDH+/TOX- patients. Serum levels of CRP were elevated 
(CRP>5mg/L) in all groups but levels were higher in the case group [61.5mg/L 
(IQR: 36.5-195.5), p=0.008]. On average, 72% (n=56) of the CDI group, 63% 
(n=36) of the GDH+/TOX- group and 47% (n=76) of the control group were 
treated with a PPI (p=0.001). 92% (n=72) of the CDI patients were treated with 
standard treatment or FDX whilst 65% (n=37) of GDH+/TOX- patients received 
antibiotics commonly used for CDI treatment. 
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Table 2.3 Patients characteristics of cohort phase II 
 
GDH-/TOX-a (n=164) GDH+/TOX-b (n=57) GDH+/TOX+c (n=78)  
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
p 
Demographics  
Age (years), median (IQR) 164 65 (55.5-72.0) 57 61 (50-72) 78 66.5 (56-79) 0.101 
gender (female, %) 164 85 (51.8) 57 30 (52.6) 78 35 (44.9) 0.550 
IMD (score), median (IQR) 146 30.5 (16-54) 50 26.2 (11.4-54.8) 75 29.9 (17.3-49.2) 0.870 
Clinical  
CCI (score), median (IQR) 164 0 (0-1) 57 1 (0-2) 78 2 (0-3) <0.001 
mode of acquisition (HCAI, %) 164 106 (64.6) 57 33 (57.9) 78 39 (50.0) 0.092 
CDI severity (%) 0 
 
29 7 (24.1) 78 34 (43.6) 0.066 
CDI recurrence (%) 0 
   
 78 7 (9.0) . 
Clinical outcomes  
LoS (days), median (IQR) 109 7 (2-10) 55 18 (7-37) 77 16 (7-32) <0.001 
disease (days), median (IQR) 85 6 (4-9) 55 13 (5-23) 77 10 (5-20) <0.001 
pre-test (days), median (IQR) 85 1 (1-3) 55 4 (1-12) 77 2 (1-12) 0.005 
Time to death (days), median (IQR) 6 129 (24-170) 16 127 (88-192) 32 113.5 (46-201) 0.777 
Mortality hospitalisation (%) 164 2 (1.2) 57 2 (3.5) 78 6 (7.7) 0.032 
4 weeks (%) 164 2 (1.2) 57 1 (1.8) 78 3 (3.8) 0.391 
1 year (%) 164 6 (3.7) 57 16 (28.1) 78 32 (41.0) <0.001 
Hospitalisation costs (£),  
median (IQR) 
84 
2,971 
(1,894-3,842) 
47 
5,192 
(3,144-16,827) 
69 
5,192 
(3,842-7,379) 
0.095 
Laboratory results  
albumin baseline (g/L) 82 38 (34-41) 51 34 (28-37) 71 31 (27-36) <0.001 
WCC baseline (109/L) 88 10 (7.4-13.2) 56 7.8 (5.4-11.0) 77 10.8 (7.1-13.9) 0.711 
Neutrophils baseline (109/L) 88 7.3 (4.9-10.4) 55 7.8 (4.6-13.0) 74 7.8 (4.6-13.0) <0.001 
eGFR baseline (mL/min/1.73m2) 87 81.0 (60.0-90.0) 56 77.0 (50.0-90.0) 77 59.0 (39.0-84.0) 0.001 
CRP baseline (mg/L) 84 23.5 (8.5-64.5) 44 49 (19.5-97.0) 64 61.5 (36.5-195.5) 0.008 
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Table 2.3 (continued) Patients characteristics of cohort phase II 
 
GDH-/TOX-a (n=164) GDH+/TOX-b (n=57) GDH+/TOX+c (n=78)  
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
p 
Medicines (%)  
PPI 161 76 (47.2) 57 36 (63.2) 78 56 (71.8) 0.001 
CDI treatmentd 164 5 (3.1) 57 37 (64.9) 78 72 (92.3) <0.001 
Fidaxomicin 164 0 57 26 (45.6) 78 51 (65.4) <0.001 
Vancomycin 164 0 57 8 (14.0) 78 24 (30.8) <0.001 
Metronidazole 164 5 (3.1) 57 12 (21.1) 78 22 (28.2) <0.001 
GDH: glutamate dehydrogenase, TOX: toxin test, IMD: Index of multiple deprivation, CCI: Charlson Comorbidity Index, HCAI: 
healthcare-associated infection, CDI: Clostridium difficile Infection, LoS: length of stay, WCC: white cell count, eGFR: estimated 
glomerular filtration rate, CRP: C-reactive protein, PCT: procalcitonin, PPI: Proton-pump inhibitor.  
a diarrhoea control patients, b potential carrier patients, c CDI case patients, d treatment with any antibiotic (standard treatment or 
fidaxomicin)
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2.4.2 Audit patients 
2.4.2.1 Phase I time-period 
CDI case patients included in the clinical audit (Table 2.4) had a median age 
above 65 years, were hospitalised for an average of 29 days (IQR: 3-56.5), 
and incurred costs of £4,387 (IQR: £3,507-9,367) as a result of hospitalisation. 
In terms of mortality, 32% (n=135) of the patients died within 4 weeks after the 
diagnosis, 62% (n=256) within 1 year and 38% (n=157) during hospitalisation. 
 
Table 2.4 Patients characteristics of audit phase I 
TOX+a (n=416)  
n Median (IQR)/F(P) 
Demographics 
Age (years), median (IQR) 416 79 (70-87) 
gender (female, %) 416 240 (57.7) 
IMD (score), median (IQR) 412 40.67 (25.6-59.4) 
Clinical 
mode of acquisition (HCAI, %) 416 297 (71.4) 
CDI recurrence (%) 416 56 (13.5) 
Clinical outcomes 
LoS (days), median (IQR) 416 29 (13-56) 
disease (days), median (IQR) 416 14 (6-31) 
pre-test (days), median (IQR) 416 9 (2-22) 
Time to death (days), median (IQR) 256 27 (676) 
Mortality hospitalisation (%) 416 157 (37.7) 
4 weeks (%) 416 135 (32.5) 
1 year (%) 416 256 (61.5) 
Hospitalisation costs (£), median (IQR) 416 4,387 (3,507-9,367) 
TOX: toxin test, IMD: Index of Multiple Deprivation, HCAI: healthcare-associated 
infection, LoS: length of stay 
a CDI case patients 
 
  
 
 
53 
 
2.4.2.2 Phase II time-period 
All three groups of audit patients (Table 2.5) were on average older than 65 
years of age, but CDI group was older than the others [77 years (IQR: 63-84), 
p<0.001]. The median LoS of the CDI case group was higher than that of the 
GDH+/TOX- group [18.5 (IQR: 8-36) vs 17 (IQR: 9-34) days, p<0.001] but the 
costs of hospitalisation were similar [£5,192 (IQR: £3,408-7,406) vs £4,243 
(IQR: £3,190-7,325) vs £3,630 (IQR: £2,241-5,205), p=0.179]. The mortality 
rates were also higher for CDI cases: 25% (n=43) during hospitalisation, 25% 
(n=43) within 4 weeks, 58% (n=100) within 1 year after diagnosis, p-value for 
all outcomes were lower than 0.001 comparing the three groups. Laboratory 
results and use of medicines were collected for only a random sample of 
control patients. All groups presented with hypoalbuminemia (albumin<35g/L), 
an elevated level of serum CRP (CRP>5mg/L) and CDI cases with 
leucocytosis (WCC>11x109/L) and neutrophilia (neutrophils>7.5x109/L). The 
use of any PPI was similar in all groups and use of CDI treatments were higher 
in CDI cases 87% (n=148) compared to potential carrier group 40% (n=172, 
p<0.001). 
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Table 2.5 Patients characteristics of audit phase II 
  GDH-/TOX-a (n=3,658) GDH+/TOX-b (n=428) GDH+/TOX+c (n=171)  
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
p 
Demographics  
Age (years), median (IQR) 3,658 68 (53-79) 428 70 (53-81) 171 77 (63-84) <0.001 
gender (female, %) 3,658 1,866 (51.0) 428 237 (55.4) 171 102 (59.6) 0.026 
IMD (score), median (IQR) 3,545 38.9 (21.4-58.6) 397 42.2 (21.7-58.6) 149 45.7 (25.9-63.7) 0.134 
Clinical  
mode of acquisition (HCAI, %) 3,658 1,733 (47.4) 428 231 (54.0) 171 100 (58.5) 0.001 
CDI recurrence (%) 0  0  171 16 (9.4) . 
Clinical outcomes  
LoS (days), median (IQR) 3,646 11 (5-24) 399 17 (9-34) 162 22 (10-44) <0.001 
disease (days), median (IQR) 3,646 6 (3-14) 399 10 (5-23) 162 12 (5-25) <0.001 
pre-test (days), median (IQR) 3,646 2 (1-8) 399 3 (1-12) 162 6 (1-17) <0.001 
Time to death (days), median (IQR) 1,043 55 (14-149) 176 52 (18-123) 100 38 (10-111) 0.358 
Mortality hospitalisation (%) 3,658 60 (1.6) 428 60 (14.0) 171 43 (25.2) <0.001 
4 weeks (%) 3,658 403 (11.0) 428 67 (15.6) 171 43 (25.2) <0.001 
1 year (%) 3,658 1,043 (28.5) 428 176 (41.1) 171 100 (58.5) <0.001 
Hospitalisation costs (£),  
median (IQR) 
3,618 
3,630 
(2,241-5,205) 
335 
4,243 
(3,190-7,325) 
133 
5,192 
(3,842-7,406) 
0.179 
Laboratory results, mean (IQR)        
albumin baseline (g/L) 150 33.0 (26.0-38.0) 351 32.0 (26.0-38.0) 139 28.0 (24.0-32.0) <0.001 
WCC baseline (109/L) 186 9.1 (6.5-13.1) 417 9.6 (6.6-13.2) 170 11.3 (7.9-19.0) <0.001 
Neutrophils baseline (109/L) 185 6.8 (4.4-10.0) 410 7.3 (4.6-10.4) 162 9.0 (6.0-16.3) <0.001 
eGFR baseline (mL/min/1.73m2) 164 69.0 (46.0-90.0) 380 67.0 (36.0-90.0) 152 63.5 (34.0-90.0) 0.102 
CRP baseline (mg/L) 103 42.0 (11.0-91.0) 249 57.0 (18.0-127.0) 97 84.0 (36.0-170.0) <0.001 
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Table 2.5 (continued) Patients characteristics of audit phase II 
  GDH-/TOX-a (n=3,658) GDH+/TOX-b (n=428) GDH+/TOX+c (n=171)  
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
p 
Medicines (%)        
PPI 189 104 (55.0) 428 226 (52.8) 171 87 (50.9) 0.731 
CDI treatmentd 189 0 428 172 (40.2) 171 148 (86.6) <0.001 
Fidaxomicin 189 0 428 120 (28.0) 171 101 (59.1) <0.001 
Vancomycin 189 0 428 40 (9.4) 171 43 (25.2) <0.001 
Metronidazole 189 0 428 29 (6.8) 171  32 (18.7) <0.001 
TOX: toxin test, IMD: Index of Multiple Deprivation, HCAI: healthcare-associated infection, LoS: length of stay, WCC: white cell count, eGFR: 
estimated glomerular filtration rate, CRP: C-reactive protein, PPI: Proton-pump inhibitor, CDI: Clostridium difficile infection. 
a diarrhoea control patients, b potential carrier patients, c CDI case patients, d treatment with any antibiotic (standard treatment or 
fidaxomicin)
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2.4.3 Comparison of CDI patients between cohorts and audits  
2.4.3.1 Cohort phase I vs Cohort phase II 
Comparison between patients recruited during phase I and II is shown in Table 
2.6. Phase I were older [75 years (IQR: 61-81) vs 66 years (IQR: 56-79), 
p=0.037), with a lower CCI score [1 (IQR: 0-2) vs 2 (IQR: 0-3), p=0.037] and 
with a higher proportion of female [58% (n=149) vs 45% (n=35), p=0.042] and 
HCAI [63% (n=161) vs 50% (n=39), p=0.046] than patients recruited during 
phase II. Although mortality rates were similar, time to death within 1 year after 
diagnosis was lower for the phase I cohort [81 days (IQR: 31-159) vs 114 days 
(IQR: 46-201), p=0.038]. Serum levels of WCC, neutrophils and eGFR were 
also higher in the phase I cohort and the pattern of antibiotic use changed in 
2011 when FDX was approved to be used as a CDI treatment. 
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Table 2.6 Comparison between CDI case patients of cohort phase I and cohort phase II 
 
Cohort I Cohort II  
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
p 
Demographics      
Age (years), median (IQR) 257 75 (61-81) 78 66.5 (56-79) 0.037 
gender (female, %) 257 149 (58) 78 35 (44.9) 0.042 
IMD (score),  
median (IQR) 
229 
34.2 
(17.3-56.3) 
75 
29.9 
(17.3-49.2) 
0.093 
Clinical  
CCI (score), median (IQR) 256 1 (0-2) 78 2 (0-3) 0.037 
mode of acquisition  
(HCAI, %) 
257 161 (62.6) 78 39 (50.0) 
0.046 
CDI severity (%) 257 107 (41.6) 78 34 (43.6) 0.760 
CDI recurrence (%) 257 47 (18.3) 78 7 (9.0) 0.050 
Clinical outcomes  
LoS (days), median (IQR) 257 24 (12-46) 77 16 (7-32) 0.210 
disease (days), median (IQR) 257 14 (8-27) 77 10 (5-20) 0.102 
pre-test (days), median (IQR) 257 7 (1-17) 77 2 (1-12) 0.930 
Time to death (days),  
median (IQR) 
81 79 
(31-159) 
32 114 
(46-201) 
0.038 
Mortality hospitalisation (%) 257 24 (9.3) 78 6 (7.7) 0.729 
4 weeks (%) 257 18 (7.0) 78 3 (3.8) 0.314 
1 year (%) 257 81 (31.5) 78 32 (41.0) 0.120 
Hospitalisation costs (£), 
median (IQR) 
217 
4,563 
(3,394-8,789) 
69 
5,192 
(3,842-7,379) 
0.487 
Laboratory results, median (IQR)  
albumin baseline (g/L) 212 30 (25-35) 71 31 (27-36) 0.160 
WCC baseline (109/L) 252 11.6 (8.5-18.0) 77 10.8 (7.1-13.9) 0.026 
Neutrophils baseline (109/L) 247 9.0 (6.0-15.0) 74 7.8 (4.6-13.0) 0.023 
eGFR baseline 
(mL/min/1.73m2) 
251 
74.0 
(46.0-106.0) 
77 
59.0 
(39.0-84.0) 
<0.001 
CRP baseline (mg/L) 240 
70.5 
(30.5-137.5) 
64 
61.5 
(36.5-195.5) 
0.286 
Medicines (%)  
PPI 255 173 (67.8) 78 56 (71.8) 0.552 
CDI treatmentc 257 241 (93.8) 78 72 (92.3) 0.168 
Fidaxomicin 257 0 78 51 (65.4) <0.001 
Vancomycin 257 228 (88.7) 78 24 (30.8) 0.050 
Metronidazole 257 111 (43.2) 78 22 (28.2) <0.001 
IMD: Index of Multiple Deprivation, CCI: Charlson comorbidity index, HCAI: healthcare-associated 
infection, CDI: Clostridium difficile infection, LoS: length of stay, WCC: white cell count, eGFR: 
estimated glomerular filtration rate, CRP: C-reactive protein, PPI: Proton-pump inhibitor. 
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2.4.3.2 Audit phase I vs audit phase II 
Comparing audit patients (Table 2.7), as cohort groups, phase I audit had 
median age (79 years, IQR: 70-87) higher than phase II audit [77 years, (IQR: 
63-84), p<0.001) and higher proportion of HCAI [71% (n=297) vs 58% (n=100), 
p<0.001]. Mean Los [29 days (IQR: 13-56) vs 22 days (IQR: 10-44), p=0.001] 
and long-term mortality [62% (n=256) vs 59% (n=100), p=0.040] were higher 
during phase I, but costs of hospitalisation [£4,387 (IQR: 3,507-9,367) vs 
£5,192 (IQR: 3,842-7,406), p=0.047] were lower compared to phase II. 
 
Table 2.7 Comparison between CDI case patients of audit phase I and audit phase II 
 
Audit I    Audit II  
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
p 
Demographics      
Age (years), median (IQR) 416 79 (70-87) 171 77 (63-84) <0.001 
gender (female, %) 416 240 (57.7) 171 102 (59.6) 0.728 
IMD (score),  
median (IQR) 
412 
40.7 
(25.6-59.4) 
149 
45.7 
(25.9-63.7) 
0.838 
Clinical  
CCI (score), median (IQR) . . . . . 
mode of acquisition  
(HCAI, %) 
416 297 (71.4) 171 100 (58.5) <0.001 
CDI severity (%) . . . . . 
CDI recurrence (%) 416 56 (13.5) 171 16 (9.4) 0.168 
Clinical outcomes  
LoS (days), median (IQR) 416 29 (13-56) 162 22 (10-44) 0.001 
disease (days), median (IQR) 416 14 (6-31) 162 12 (5-25) 0.122 
pre-test (days), median (IQR) 416 9 (2-22) 162 6 (1-17) <0.001 
Time to death (days),  
median (IQR) 
256 27 (6-76) 100 38 (10-111) 0.001 
Mortality hospitalisation (%) 416 157 (37.7) 171 43 (25.2) 0.353 
4 weeks (%) 416 135 (32.5) 171 43 (25.2) 0.333 
1 year (%) 416 256 (61.5) 171 100 (58.5) 0.040 
Hospitalisation costs (£), 
median (IQR) 
416 
4,387 
(3,507-9,367) 
133 
5,192 
(3,842-7,406) 
0.047 
IMD: Index of Multiple Deprivation, CCI: Charlson comorbidity index, HCAI: healthcare-associated 
infection, CDI: Clostridium difficile infection, LoS: length of stay. 
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2.4.3.3 Cohort phase I vs audit phase I 
Comparing audit patients and cohort patients phase I (Table 2.8), non-
recruited patients were older [79 years (IQR: 70-87) vs 75 years (IQR: 61-81), 
p<0.001] and with a higher proportion of HCAI [71% (n=297) vs 63% (n=161), 
p=0.018] and higher IMD score [40.7 (IQR: 25.6-59.4 vs 34.2 (IQR: 17.3-56.3), 
p=0.017]. Short-term, long-term and during hospitalisation mortality rates were 
four-times [32% (n=135) vs 7% (n=18), p<0.001), twice [62% (n=256) vs 32% 
(n=81), p<0.001] and four-times [38% (n=157) vs 9% (n=23), p<0.001] as high 
as cohort patients. 
 
Table 2.8 Comparison between CDI case patients of cohort phase I and audit phase I 
 
Cohort I Audit I  
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
p 
Demographics      
Age (years), median (IQR) 257 75 (61-81) 416 79 (70-87) <0.001 
gender (female, %) 257 149 (58) 416 240 (57.7) 0.942 
IMD (score), median (IQR) 229 
34.2 
(17.3-56.3) 
412 
40.7 
(25.6-59.4) 
0.017 
Clinical  
CCI (score), median (IQR) 256 1 (0-2) . . . 
mode of acquisition (HCAI, %) 257 161 (62.6) 416 297 (71.4) 0.018 
CDI severity (%) 257 107 (41.6) . . . 
CDI recurrence (%) 257 47 (18.3) 416 56 (13.5) 0.091 
Clinical outcomes  
LoS (days), median (IQR) 257 24 (12-46) 416 29 (13-56) 0.911 
disease (days), median (IQR) 257 14 (8-27) 416 14 (6-31) 0.223 
pre-test (days), median (IQR) 257 7 (1-17) 416 9 (2-22) 0.074 
Time to death (days),  
median (IQR) 
81 79 (31-159) 256 27 (6-76) 0.012 
Mortality hospitalisation (%) 257 23 (9.0) 416 157 (37.7) <0.001 
4 weeks (%) 257 18 (7.0) 416 135 (32.5) <0.001 
1 year (%) 257 81 (31.5) 416 256 (61.5) <0.001 
Hospitalisation costs (£), 
median (IQR) 
217 
4,563 
(3,394-8,789) 
416 
4,387 
(3,507-9,367) 
0.981 
IMD: Index of Multiple Deprivation, CCI: Charlson comorbidity index, HCAI: healthcare-associated 
infection, CDI: Clostridium difficile infection, LoS: length of stay. 
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2.4.3.4 Cohort phase II vs audit phase II 
Phase II audit patients compared to cohort patients (Table 2.9) also had higher 
median age [77 years (IQR: 63-84) vs 66 years (IQR: 56-79), p=0.007] and 
higher median IMD score [45.7 (IQR: 25.9-63.7) vs 29.9 (IQR: 17.3-49.2), 
p=0.001] compared to cohort patients. Short [25% (n=43) vs 4% (n=3), 
p<0.001] and long-term mortality [58% (n=100) vs 41% (n=32), p=0.010] and 
mortality during hospitalisation [25% (n=43) vs 8% (n=6), p=0.001] were also 
higher in audit patients. Levels of WCC and neutrophils were more elevated 
in audit patients and levels of albumin were lower when compared to recruited 
patients. CDI treatment was similar in both groups but PPI use was higher in 
cohort patients. 
 
2.5 Discussion 
This study was conducted at RLBUHT over two periods, epidemic (2008-2012) 
and endemic (2013-2015) phases. In total, 335 CDI case patients were 
recruited and the main difference found between them was in the mode of 
acquisition of bacteria, laboratory results and CDI treatment. Although clinical 
outcomes did not differ statistically, phase I patients had on average longer 
hospitalisation, higher mortality rates and incurred lower hospitalisation costs.  
A study conducted in 6 UK hospitals in 2013 and 2014 (Wilcox et al., 2017) 
showed similar results considering CDI severity (41% for patients with first   
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Table 2.9 Comparison between CDI case patients of cohort phase II and audit phase II 
 
Cohort II Audit II  
n 
Median (IQR) 
F(P) 
n 
Median (IQR) 
F(P) 
p 
Demographics      
Age (years), median (IQR) 78 66.5 (56-79) 171 77 (63-84) 0.007 
gender (female, %) 78 35 (44.9) 171 102 (59.6) 0.030 
IMD (score), median (IQR) 75 29.9 (17.3-
49.2) 
149 45.7 (25.9-
63.7) 
0.001 
Clinical  
CCI (score), median (IQR) 78 2 (0-3) . . . 
mode of acquisition (HCAI, 
%) 
78 39 (50.0) 171 100 (58.5) 0.211 
CDI severity (%) 78 34 (43.6) . . . 
CDI recurrence (%) 78 7 (9.0) 171 16 (9.4) 0.923 
Clinical outcomes  
LoS (days), median (IQR) 77 16 (7-32) 162 22 (10-44) 0.813 
disease (days), median (IQR) 77 10 (5-20) 162 12 (5-25) 0.774 
pre-test (days), median (IQR) 77 2 (1-12) 162 6 (1-17) 0.910 
Time to death (days),  
median (IQR) 
32 113.5 (46-201) 100 38 (10-111) 0.513 
Mortality hospitalisation (%) 78 6 (7.7) 171 43 (25.2) 0.001 
4 weeks (%) 78 3 (3.8) 171 43 (25.2) <0.001 
1 year (%) 78 32 (41.0) 171 100 (58.5) 0.010 
Hospitalisation costs (£),  
median (IQR) 
69 
5,192 
(3,842-7,379) 
133 
5,192 
(3,842-7,406) 
0.128 
Laboratory results, median (IQR)  
albumin baseline (g/L) 71 31 (27-36) 139 
28.0 (24.0-
32.0) 
0.004 
WCC baseline (109/L) 77 10.8 (7.1-13.9) 170 11.3 (7.9-19.0) 0.009 
Neutrophils baseline (109/L) 74 7.8 (4.6-13.0) 162 9.0 (6.0-16.3) 0.011 
eGFR baseline  
(mL/min/1.73m2) 
77 
59.0 (39.0-
84.0) 
152 
63.5 (34.0-
90.0) 
0.074 
CRP baseline (mg/L) 64 
61.5 
(36.5-195.5) 
97 
84.0 
(36.0-170.0) 
0.979 
Medicines (%)  
PPI 78 56 (71.8) 171 87 (50.9) 0.002 
CDI treatmentc 78 72 (92.3) 171 148 (86.6) 0.189 
Fidaxomicin 78 51 (65.4) 171 101 (59.1) 0.343 
Vancomycin 78 24 (30.8) 171 43 (25.2) 0.353 
Metronidazole 78 22 (28.2) 171 87 (50.9) 0.092 
IMD: Index of Multiple Deprivation, CCI: Charlson comorbidity index, HCAI: healthcare-associated 
infection, CDI: Clostridium difficile infection, LoS: length of stay, WCC: white cell count, eGFR: 
estimated glomerular filtration rate, CRP: C-reactive protein, PPI: Proton-pump inhibitor. 
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episode and 52% for patients with recurrent case) and median LoS (16-21 
days). However, overall costs (£6,294-7,539) and proportion of HCAI (81%) 
were higher than our cohort and audit groups. Median CCI score (1) and LoS 
(15 days) of French patients infected by C. difficile between 2007 and 2014 
were also similar compared to our patients (Barbut et al., 2017a). Between 
2014 and 2015, a study found similar CCI score (2) and mortality rates within 
30 days (18%) when considering both cohorts and audits, however, the 
proportion of HCAI was also higher (85%) and similar to the study in the UK 
(Barbut et al., 2017b). Short-term mortality was also reported as 11% in a 
Japanese cohort (Takahashi et al., 2014). 
Biomarker levels in all groups indicated a possible inflammatory process and 
bacterial infection with hypoalbuminemia (albumin>35g/L), neutrophilia 
(neutrophils>7.5x109/L) and elevated levels of CRP. Between 2006 and 2010, 
a cohort recruited in a hospital in the UK found similar results with median 
levels of 11.2x109/L for WCC, 8.9x109/L for neutrophils, 34g/L for albumin and 
84 mg/L for CRP (Eyre et al., 2012). Another study conducted between 2014 
and 2015 found lower levels of all these biomarkers: WCC (7.6x109/L), 
neutrophils (7.0x109/L), albumin (32g/L) and CRP (45mg/L) (Barbut et al., 
2017b). 
After submission of the audit, 587 CDI cases were included in this study. 
Comparing groups from phase I and II, phase I patients had longer 
hospitalisation, higher long-term mortality rate, lower hospitalisation costs and 
higher proportion of HCAI. Information about laboratory results and medicines 
were not collected for phase I audit patients.  
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The comparison between patients from cohort and audit showed that median 
age, short and long-term mortality rates and proportion of HCAI were higher 
in the audit and phase I group patients. The audit patients had a higher IMD 
score in both phases meaning that those patients were living in more deprived 
areas. 
The difference between phases can be explained by the virulent strain RT027 
that caused numerous outbreaks between 2006 and 2008 and it was 
associated with severe illness and increased death and recurrence rates 
(PHE, 2017). During this period, there was an increase of over 4-fold in the 
number of associated deaths (CDC, 2013). The difference between cohort and 
audit patients may be explained by inclusion and exclusion criteria of 
recruitment as the patient or a personal nominated consultee needed to be 
able to give informed consent to include the patient in the study. For instance, 
during phase I, 877 CDI cases were not recruited because: patients were 
unable to consent (414), were not admitted (229), were previously recruited 
(75), were discharged or died (63), decline to participate (49) or other reason 
(47) (Swale, 2014).  
The proportion of community-acquired infections increased in both phase II 
cohort and audit patients compared to phase I. Although the proportion of 
HCAI in our setting was lower than those found in published papers, this 
finding correlates with national figures that show that since 2010 the majority 
of CDI patients were not infected in healthcare settings and in 2015/2016, CAI 
reached 64% of the total number of cases (PHE, 2017). 
 
 
64 
 
FDX was approved to treat CDI patients in 2011 and currently it is the first-line 
treatment for all patients in this setting. Thus, the use of FDX was only possible 
to compare during phase II and the pattern of use was similar between cohort 
and audit patients. Standard treatment with either MTZ or VAN was also 
similar between these two groups. PPI, a potential risk factor for CDI was taken 
by at least 50% of all groups. Audit patients presented a lower rate of intake, 
but this information was collected electronically and only medicines 
administered during hospitalisations were recorded. For this reason, this rate 
could be underestimated.  
Although there are significant differences between cohort and audit patients, 
these differences were found in both phases which means that our recruitment 
excluded more debilitated patients and it may be a selection bias when only 
considering cohort patients, but some factors are impossible to control and 
avoid when consent is needed. A large number of patients who were screened 
to be eligible for recruitment declined to participate, and it is of course, 
important not to pressure or coerce patients in getting involved in research. 
Nevertheless, our recruited patients, with the associated biobank, represent a 
valuable resource by which to study inter-individual variability in both the 
infecting organism and host susceptibility.  
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Chapter 3 
An evaluation of the toxigenicity of 
Clostridium difficile isolates and clinical 
outcomes from GDH-positive specimens in 
a large hospital setting 
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3.1 Introduction 
Samples with a positive GDH test but a negative confirmatory TOX test are 
found routinely in clinical care, flagging up a new segment of patients 
characterised by either: i) C. difficile colonisation with a non-toxigenic variant; 
or ii) carriage of a toxigenic strain type producing no detectable levels of toxins 
(Shetty et al., 2011), which in some instances reflects an incipient disease 
state. Those individuals, so-called potential C. difficile ‘excretors’, may be an 
important reservoir of the organism in both healthcare settings and the 
community (Jones et al., 2013).  
Such samples ideally require a third screening test to rule out colonization by 
non-toxigenic strains, thus resolving potential discrepancies and optimizing 
resources. The test recommended by the Department of Health, to be used in 
combination with TOX, that could be used as a third and confirmatory 
diagnostic test is the nucleic acid amplification test (NAAT) for real-time 
detection of toxin genes (Department of Health, 2012).  
The policy in the RLBUHT NHS Trust was to treat all symptomatic patients 
with FDX, a high cost antibiotic.  The identification of the potential C. difficile 
‘excretors’ is relevant from a health economic perspective as patients carrying 
non-toxigenic isolates would not require expensive treatments and isolation 
measures. Thus, this study has been conducted to (i) investigate clinical 
outcomes and potential contribution of these individuals (GDH+/TOX-) as a 
reservoir for nosocomial transmission of CDI in a consecutive group of 
diarrhoea patients from a large hospital setting in Liverpool and (ii) assess the 
potential cost savings of implementing a third and confirmatory test. 
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3.2 Patients and methodology 
3.2.1 Patients 
Phase II patients with a GDH test result and all audit patients with clinical data 
were included in this study. Patient recruitment and data collection are 
described in section 2.2.3. 
 
3.2.2 Laboratory Testing 
During the period between May 2012 and January 2016 following the 
introduction of a two-step diagnostic algorithm, all faecal samples submitted 
to the medical microbiology laboratory for CDI testing were screened using a 
combined GDH and TOX test (Techlab C. diff Quik Chek Complete). GDH+ 
samples were cultured regardless of their TOX results and a multiplex PCR 
assay was performed to verify toxigenicity and identify ribotypes. NAAT test 
(Cepheid Xpert® C. difficile) was implemented as the third diagnostic test in 
this setting from 2015 only. 
 
3.3 Statistical Analysis 
3.3.1 Patient characteristics 
Descriptive analyses were undertaken to assess the differences in 
demographics, hospitalisation and microbiological characteristics, laboratory 
results and use of medicines in CDI cases, GDH+/TOX- patients (toxigenic 
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and non-toxigenic strains) and diarrhoea control patients. The characteristics 
are described by median and interquartile ranges (IQR) for continuous 
variables and frequency (F) and proportion (P) for categorical variables. 
ANOVA was employed to compare normally distributed continuous variables, 
Kruskal Wallis was employed to compare non-normally distributed continuous 
variables and the chi-square test was used to compare categorical variables. 
 
3.3.2 Multivariable analysis 
A univariate analysis was conducted to identify potential covariates to be 
included in the multivariable model. Outliers of hospitalisation costs were 
excluded when patients had an unrelated diagnostic test that resulted in high 
or low costs. All models were built using forward and backward stepwise 
regression with use of p<0.05 for inclusion and p>0.05 for exclusion of the 
relevant covariates. 
Logistic regression was chosen to analyse mortality rates (within 4 weeks and 
1 year) and severity of CDI. Multivariable Cox proportional hazards was 
performed to assess the time to discharge and time to mortality within 1 year 
after the TOX test. For time to discharge no censoring was applied, but 
patients who did not die within 365 days of TOX were censored for this 
analysis. A generalised linear model (GLM) with gamma distribution and log 
link was used to assess hospitalisation costs. Two analyses were performed 
including all patients and only patients infected by toxigenic strains for all 
clinical outcomes. All statistics were performed using STATA version 14.0 
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(StataCorp LP, College Station, Texas). Statistical significance was set at p 
<0.05. 
 
 
Figure 3.1 Total faecal samples tested between 
May 2012 and January 2016 
 
 
3.4 Laboratory profile at Liverpool Clinical Laboratory 
During the study period, a total of 14,277 faecal samples from both hospital 
and community patients were referred for CDI testing (Figure 3.1) at LCL. Of 
these, 664 (5%) tested GDH+/TOX+ and were confirmed to be CDI cases, 
1,124 (8%) had a GDH+/TOX- result and 12,489 (88%) tested negative for 
both GDH-/TOX-. Hospital patients (Figure 3.2) represented 64% (n=9,166) of 
the total number of samples, of which 419 (5%) were cases, 710 (8%) had 
discordant results and 8,037 (88%) were diarrhoea controls. A total of 785 
GDH+/TOX- and 484 GDH+/TOX+ samples were cultured in the same period 
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considering all samples, and 596 and 368 samples, respectively, considering 
the hospital patients only. 
 
 
Figure 3.2 Hospital faecal samples tested 
between May 2012 and January 2016 
 
3.5 Results 
3.5.1 Patients characteristics 
1,015 patients were selected for this study of which 27% (280) were control 
patients, 48% (485) were GDH+/TOX- patients and 25% (250) were case 
patients (Figure 3.3). Of those 485 GDH+/TOX- samples:  
 149 (31%) had a non-toxigenic isolate (GDH+/TOX-/PCR-),  
 237 (49%) contained an isolate possessing the toxin gene (GDH+/TOX-
/PCR+); and  
 from 99 (20%) patients, it was not possible to get this information and 
they were excluded from the study.  
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Thus, considering only patients with PCR results, non-toxigenic samples 
represented 39% (149/386) and toxigenic samples 61% (237/386) of total 
GDH+/TOX- samples. 
 
 
Figure 3.3 Patients recruited in this study by group 
 
Table 3.1 shows patients’ characteristics while Table 3.2 shows the 
differences between all groups and each group compared to CDI cases. The 
median age of diarrhoea control patients was 65 years (IQR: 51-76) and 48% 
(n=134) of them were female. Seventy years (IQR: 53-80) and 69 years (IQR: 
53-80) were the median ages of the GDH+/TOX-/PCR- and GDH+/TOX-
/PCR+ groups.  The proportion of females were 56% (n=83) and 57% (n=136), 
respectively. Case patients were older with a median age of 75 years (IQR: 
59-82) and 55% (n=137) were female patients. The four groups were similar 
in the IMD 2015 score , time to death within 1 year, prior use of proton-pump 
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inhibitors (PPI), zopiclone and immunosuppressive medicines, the last three 
being potential risk factors for the development of CDI.  
Laboratory results showed that the CDI case group presented with neutrophilia 
(neutrophils>7.5x109/L) and higher white cell counts (WCC) compared to other 
groups. Hypoalbuminaemia (albumin<35g/L) was seen in all GDH+ groups. 
CRP levels were above the reference range in all groups (CRP>5mg/L). Thus, 
case patients presented with laboratory results that were consistent with 
bacterial infection and an inflammatory process.      
GDH+/TOX-/PCR- patients presented with laboratory results that were more 
similar to CDI cases than those patients whose PCR test was positive. FDX, 
MTZ and VAN were used to treat 16% (n=24), 5% (n=8) and 8% (n=12) of 
PCR- patients; 44% (n=104), 8% (n=18) and 8% (n=20) of PCR+ patients; and 
61% (n=152), 22% (n=54) and 27% (n=67) of case patients, respectively. 
Prescription of nutritional supplements with antibiotic therapy is recommended 
in some NHS healthcare settings and it was used by 26% (n=71) of control, 
51% (n=76) of PCR-, 62% (n=149) of PCR+ and 82% (n=205) of case patients. 
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Table 3.1 Patients characteristics by group  
 
GDH-/TOX- (n=277)a 
GDH+/TOX-/ 
PCR- (n=149)b 
GDH+/TOX-/ 
PCR+ (n=239)c 
GDH+/TOX+ (n=249)d 
n 
Median (IQR)/ 
F(P) 
n 
Median(IQR)/ 
F(P) 
n 
Median(IQR)/ 
F(P) 
n 
Median (IQR)/ 
F(P) 
Demographics 
age (years) 277 65 (51-76) 149 70 (53-80) 239 69 (53-80) 249 75 (59-82) 
gender (female) 277 134 (48.4) 149 83 (55.7) 239 136 (56.9) 249 137 (55.0) 
IMD (score) 257 40.7 (20.8-57.6) 142 43.3 (21.6-61.6) 217 38.8 (21.4-58.6) 224 36.6 (21.4-59.7) 
Clinical outcomes 
LoS (days) 261 12 (6-27) 141 20 (10-38) 225 16 (7-34) 239 19 (9-41) 
disease (days) 260 8 (4-17) 141 13 (6-28) 225 11 (5-21) 239 12 (5-24) 
pre-test (days) 260 2 (1-8) 141 3 (1-15) 225 2 (1-10) 239 4 (1-16) 
time to death (days) 57 37 (16-127) 59 58 (18-139) 97 53 (18-139) 132 47.5 (15.5-125.5) 
mortality hospitalisation (%) 277 19 (6.9) 149 22 (14.8) 239 28 (11.7) 249 49 (19.7) 
mortality 4 weeks (%) 277 26 (9.4) 149 24 (16.1) 239 33 (13.8) 249 46 (18.5) 
mortality 1 year (%) 277 57 (20.6) 149 59 (39.6) 239 97 (40.6) 249 132 (53.0) 
hospitalisation costs (£) 217 
£3,221 
(2,442-4,558) 
109 
£3,842 
(3,109-7,599) 
179 
£4,571 
(3,190-6,237) 
198 
£5,192 
(3,842-7,135) 
mode of acquisition (HCAI, %) 260 114 (43.8) 141 77 (54.6) 225 104 (46.2) 239 125 (52.3) 
CDI severity (%) 0 
 
0 
 
31 7 (22.6) 78 34 (43.6) 
CDI recurrence (%) 0 
 
0 
 
0 
 
249 23 (9.2) 
Laboratory results, median (IQR) 
albumin baseline (g/L) 231 35 (30-39) 113 32 (26-37) 200 32.5 (27.5-38.0) 210 30 (26-34) 
WCC baseline (109/L) 273 9.4 (6.8-13.2) 146 9.5 (6.7-13.9) 233 9.3 (6.6-12.8) 247 11 (7.7-18.2) 
Neutrophils baseline (109/L) 272 7.0 (4.5-10.3) 144 7.2 (4.6-11.4) 229 6.9 (4.6-10.0) 236 8.3 (5.7-15.1) 
eGFR baseline 
(mL/min/1.73m2) 
250 74.5 (48-90) 135 72 (42-90) 213 64 (34-90) 229 59 (31-89) 
CRP baseline (mg/L) 185 33 (10-79) 80 54 (16-130) 149 54 (16-105) 161 77 (36-172) 
 
 
 
74 
 
Table 3.1 (continued) Patients characteristics by group  
 
GDH-/TOX- (n=277)a 
GDH+/TOX-/ 
PCR- (n=149)b 
GDH+/TOX-/ 
PCR+ (n=239)c 
GDH+/TOX+ (n=249)d 
n 
Median (IQR)/ 
F(P) 
n 
Median(IQR)/ 
F(P) 
n 
Median(IQR)/ 
F(P) 
n 
Median (IQR)/ 
F(P) 
Medicines (%) 
fidaxomicin 277 0 149 24 (16.1) 239 104 (43.5) 249 152 (61.0) 
metronidazole 277 5 (1.8) 149 8 (5.4) 239 18 (7.5) 249 54 (21.7) 
vancomycin 277 0 149 12 (8.1) 239 20 (8.4) 249 67 (26.9) 
other antibiotic 277 27 (9.8) 149 24 (16.1) 239 15 (6.3) 249 27 (10.8) 
nutritional complement 277 71 (25.6) 149 76 (51.0) 239 149 (62.3) 249 205 (82.3) 
zopiclone 277 29 (10.5) 149 13 (8.7) 239 25 (10.5) 249 20 (8.0) 
PPI 277 159 (57.4) 149 79 (53.0) 239 134 (56.1) 249 143 (57.4) 
immunosuppressive 277 39 (14.1) 149 22 (14.8) 239 28 (11.7) 249 22 (8.8) 
GDH: Glutamate Dehydrogenase test; TOX: toxin test; IMD: index of multiple deprivation; LoS: length of stay; HCAI: healthcare-associated infection; 
WCC: white cell count; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein; PPI: Proton-pump inhibitor. 
a diarrhoea control patients b non-toxigenic patients c toxigenic patients d CDI cases 
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Table 3.2 Comparison between all groups and between each group and 
CDI cases 
 
all groups 
GDH- 
TOX-a 
GDH+ 
TOX- 
PCR-b 
GDH+ 
TOX- 
PCR+c 
Demographics 
age <0.001 <0.001 0.025 0.006 
gender (female) 0.207 0.128 0.894 0.675 
IMD 0.876 0.952 0.484 0.850 
Hospitalisation 
LoS 0.028 0.020 0.486 0.292 
disease 0.196 0.313 0.118 0.862 
pre-test 0.007 0.002 0.634 0.042 
time to death 0.782 0.579 0.595 0.661 
mortality hospitalisation <0.001 <0.001 0.215 0.016 
4 weeks 0.023 0.002 0.548 0.162 
1 year <0.001 <0.001 0.010 0.006 
hospitalisation costs <0.001 <0.001 0.850 0.028 
mode of acquisition 0.102 0.059 0.663 0.191 
CDI severity 0.041 . . 0.041 
recurrence . . . . 
Laboratory results 
albumin <0.001 <0.001 0.004 <0.001 
WCC <0.001 <0.001 0.057 0.001 
neutrophils <0.001 <0.001 0.002 <0.001 
eGFR <0.001 <0.001 0.017 0.377 
CRP <0.001 <0.001 0.100 0.002 
Medicines 
fidaxomicin <0.001 <0.001 <0.001 <0.001 
metronidazole <0.001 <0.001 <0.001 <0.001 
vancomycin <0.001 <0.001 <0.001 <0.001 
other antibiotic 0.020 0.679 0.128 0.072 
optifibre <0.001 <0.001 <0.001 <0.001 
zopiclone 0.733 0.337 0.808 0.354 
PPI 0.820 0.995 0.391 0.761 
immunosuppressive 0.210 0.061 0.068 0.294 
GDH: Glutamate Dehydrogenase test; TOX: toxin test; IMD: index of multiple 
deprivation; LoS: length of stay; HCAI: healthcare-associated infection; WCC: 
white cell count; eGFR: estimated glomerular filtration rate; CRP: C-reactive 
protein; PPI: Proton-pump inhibitor. 
a diarrhoea control patients b non-toxigenic patients c toxigenic patients  
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3.5.2 Microbiological data 
Of 304 isolates cultured from GDH+/TOX- faecal samples in the LCL, 204 
(67%) were found to carry genes for toxin B, whilst 100 (32.9%) were deemed 
non-toxigenic. Among the 193 toxigenic isolates obtained from GDH+/TOX- 
patients, PCR-ribotype RT014 (16%, n=31) was the most frequently identified, 
followed by RT002 (10%, n=19), RT020 (10%, n=19), RT015 (8%, n=16), 
RT078 (6%, n=12) and RT005 (6%, n=12) (Table 3.3). 
Among the 223 isolates cultured from CDI patients who tested GDH+/TOX+ 
ribotype profiles were similar but RT078 (14%, n=31) was the most frequent, 
followed by RT002 (11%, n=25), RT014 (11%, n=24), RT015 (10%, n=23), 
RT005 (7%, n=16), and RT020 (3.6%, n=8) (Table 3.3).  The ribotypes RT001, 
RT002, RT003, RT005, RT010, RT012, RT014, RT015, RT017, RT018, 
RT020, RT023, RT026, RT027, RT046, RT056, RT078, RT081, RT087, and 
RT106 were also identified in these patients, and were grouped as others 
(Figure 3.4). RT078 was comparatively more commonly found in stools of 
patients who tested GDH+/TOX+, but it was also be isolated from the stools 
of GDH+/TOX- patients, indicating that these individuals can serve as a 
potential reservoir for these strains. Furthermore, RT014 was more frequently 
associated with patients who tested GDH+/TOX- than those found to be 
GDH+/TOX+. From a clinical point of view, there was no consistent pattern to 
the clinical outcomes with the different ribotypes, although statistically it is 
possible to observe random significance with a small number of individuals 
(Table 3.4). 
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Table 3.3 Ribotypes profile by group 
Ribotypes GDH+/TOX-/PCR+a GDH+/TOX+b 
RT002 19 (9.8) 25 (11.2) 
RT005 12 (6.2) 16 (7.2) 
RT014 31 (16.1) 24 (10.8) 
RT015 16 (8.3) 23 (10.3) 
RT020 19 (9.8) 8 (3.6) 
RT027 3 (1.6) 11 (4.9) 
RT078 12 (6.2) 31 (13.9) 
Other 81 (42.0) 85 (38.1) 
Total 193 (100) 223 (100) 
a carrier patients b CDI cases 
 
Table 3.4 Comparison of ribotypes and different outcomes 
 Time to 
discharge 
Mortality 
4 weeks 
Mortality 
1 year 
Time to death CDI severity CDI recurrence 
Hospitalisation 
costs 
HZ p-value OR p-value OR p-value HZ p-value OR p-value OR p-value expβ p-value 
RT002 1.00  1.00  1.00  1.00  1.00  1.00  1.00  
RT005 0.75 0.290 0.54 0.396 0.52 0.181 0.74 0.382 0.67 0.672 1.05 0.962 1.48 0.037 
RT014 0.93 0.764 0.88 0.812 0.58 0.179 1.06 0.830 0.29 0.185 1.05 0.957 1.42 0.024 
RT015 1.43 0.165 1.35 0.582 0.48 0.102 1.06 0.853 0.67 0.697 0.70 0.709 1.07 0.683 
RT020 1.27 0.365 0.36 0.220 0.24 0.008 0.40 0.030 0.67 0.733 1.00  1.24 0.254 
RT027 0.53 0.091 2.50 0.179 1.25 0.730 0.86 0.693 1.00  1.63 0.624 1.38 0.251 
RT078 0.71 0.192 1.55 0.405 1.43 0.420 1.06 0.835 0.10 0.022 0.51 0.476 1.17 0.346 
Other 0.90 0.585 0.76 0.542 0.57 0.103 0.79 0.311 0.31 0.107 0.66 0.567 1.25 0.080 
HZ: hazard ratio; OR: odds ratio; expβ: exponential of β. 
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Figure 3.4 Distribution of ribotypes by group 
 
3.5.3 Hospitalisation period/time to discharge 
PCR- patients were in hospital [20 days (IQR: 10-38)] for the same amount of 
time as case patients [19 days (IQR: 9-41)] and PCR+ patients [16 days (IQR: 
7-34)], while diarrhoea control patients stayed in hospital on average for 12 
days (IQR: 6-27). All groups stayed in hospital for a similar time after the C. 
difficile test [CDI case 12 (IQR: 5-24) vs PCR+ 11 (IQR: 5-21) vs PCR- 13 
(IQR: 6-28) vs control 8 days (IQR: 4-17)]. Nevertheless, time to be tested was 
on average higher in case patients [4 days (IQR: 1-16)] compared to PCR+ [2 
days (IQR: 1-10)] and control patients [2 days (IQR: 1-8)] and similar to PCR- 
patients [3 days (IQR: 1-15)]. 
A Cox regression analysis for time to discharge was performed using CDI 
status, age, gender, levels of serum albumin and mode of acquisition as 
covariates for the initial model (Table 3.5). Variables associated with discharge 
GDH+/TOX-/PCR+ GDH+/TOX+
RT002 RT005
RT014 RT015
RT020 RT027
RT078 Other
Graphs by tox
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rates were GDH+/TOX-/PCR- (HR=0.60, 95% CI: 0.46-0.77), GDH+/TOX-
/PCR+ (HR=0.73, 95% CI: 0.59-0.90), CDI cases (HR=0.76, 95% CI: 0.61-
0.95), decreased age (HR=0.99, 95% CI: 0.98-0.99), increased levels of 
serum albumin (HR=1.04, 95% CI: 1.03-1.05), and community-acquired 
infection (HR=0.34, 95% CI: 0.29-0.41) (Table 3.5). 
 
Table 3.5 Univariate analysis of LoS 
LoS 
All patients Toxigenic strains 
n Coef (95% CI) p n Coef (95% CI) p 
CDI status 844 2.39 (1.06-3.73) <0.001 452 2.54 (-2.10-7.19) 0.282 
gender 944 -1.01 (-4.00-1.99) 0.509 452 -1.57 (-6.25-3.11) 0.510 
age 944 0.16 (0.08-0.23) <0.001 452 0.12 (-0.01-0.25) 0.069 
IMD score 878 0.01 (-0.06-0.08) 0.752 415 0.04 (-0.06-0.15) 0.429 
mode of 
acquisition 
933 
20.95 
(18.25-23.65) 
<0.001 452 
24.27 
(20.20-28.34) 
<0.001 
CDI 
severity 
  
 102 -1.43 (-11.12-8.27) 0.771 
disease 933 1.13 (1.08-1.18) <0.001 452 1.12 (1.05-1.20) <0.001 
pre-test 933 1.21 (1.13-1.29) <0.001 452 1.17 (1.06-1.28) <0.001 
mortality  
4 weeks 
944 -0.60 (-4.84-3.64) 0.780 452 -4.27 (-10.44-1.91) 0.175 
mortality  
1 year 
944 9.09 (6.06-12.11) <0.001 452 7.81 (3.21-12.41) 0.001 
albumin 791 -0.99 (-1.20--0.79) <0.001 379 -1.12 (-1.46--0.78) <0.001 
WCC 936 -0.02 (-0.19-0.16) 0.831 448 -0.13 (-0.38-0.12) 0.314 
neutrophils 919 0.11 (-0.11-0.32) 0.347 436 -0.05 (-0.36-0.25) 0.733 
CRP 607 0.01 (-0.01-0.03) 0.248 290 0.01 (-0.02-0.04) 0.472 
IMD: index of multiple deprivation; WCC: white cell count; eGFR: estimated glomerular 
filtration rate; CRP: C-reactive protein.  
 
Considering toxigenic strains, the initial model included the presence of toxin, 
age, gender, serum levels of albumin and mode of acquisition. The final model 
found positive association with time to discharge and decreased age 
(HR=0.99, 95% CI: 0.98-1.00), increased levels of serum albumin (HR=1.06, 
95% CI: 1.04-1.08) and community-acquired infection (HR=0.36, 95% CI: 
0.28-0.46) (Table 3.6). 
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Table 3.6 Cox proportional hazards of multivariable analysis for time to discharge 
Time to discharge 
All patients (n=707) Toxigenic strains 
(n=383) Haz Ratio p Haz Ratio p 
GDH-/TOX-a  1.00       
GDH+/TOX-/PCR-b 0.60 (0.46-0.77) <0.001     
GDH+/TOX-/PCR+c 0.73 (0.59-0.90) 0.004     
GDH+/TOX+d 0.76 (0.61-0.95) 0.014     
toxin     1.12 (0.89-1.52) 0.328 
age 0.99 (0.98-0.99) <0.001 0.99 (0.98-1.00) 0.008 
mode of acquisition 0.34 (0.29-0.41) <0.001 0.36 (0.28-0.46) <0.001 
albumin 1.04 (1.03-1.05) <0.001 1.06 (1.04-1.08) <0.001 
a diarrhoea control patients b non-toxigenic patients c toxigenic patients d CDI 
cases 
 
3.5.4 Mortality rates 
3.5.4.1 Short-term mortality (within 4 weeks) 
The short-term mortality (within 4 weeks after TOX) was slightly higher for case 
patients (18%, n=46) compared to PCR+ (14%, n=33), and PCR- (16%, n=24) 
patients, but was double that seen in control patients (9%, n=26). Causes of 
death were not accessed in this study, and thus it is not possible to determine 
if CDI contributed directly or indirectly to the death of those patients.  
A logistic regression analysis was performed and covariates included in the 
initial model were CDI status, gender, age, disease and pre-test periods, levels 
of WCC, albumin and CRP for mortality within 4 weeks (Table 3.7). 
Considering only case and colonised patients, toxin, gender, age, disease, 
levels of WCC, albumin and CRP (Table 3.7), were included in the initial 
model. The variables gender and toxin were included in the models as they 
were considered potential confounders while the neutrophil count was 
excluded from the model due to the high degree of collinearity with WCC. 
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Table 3.7 Univariate analysis of short-term mortality 
Short-term 
mortality 
All patients Toxigenic strains 
n Odds ratio p n Odds ratio p 
CDI 
status/toxin 
1,015 1.47 (1.15-1.89) 0.003 489 1.41 (0.87-2.29) 0.169 
gender 1,015 1.24 (0.86-1.78) 0.245 489 1.27 (0.78-2.08) 0.336 
age 1,015 1.04 (1.03-1.05) <0.001 489 1.03 (1.02-1.05) <0.001 
IMD score 931 1.01 (1.00-1.02) 0.121 441 1.01 (1.00-1.02) 0.103 
mode of 
acquisition 
1,015 1.31 (0.92-1.88) 0.137 465 0.96 (0.59-1.57) 0.885 
CDI severity    109 3.44 (0.30-
39.13) 
0.320 
disease 957 0.97 (0.96-0.99) <0.001 465 0.96 (0.93-0.98) <0.001 
pre-test 957 1.01 (1.00-1.01) 0.042 465 1.01 (1.00-1.02) 0.111 
albumin 847 0.87 (0.84-0.90) <0.001 411 0.89 (0.85-0.93) <0.001 
WCC 997 1.05 (1.03-1.07) <0.001 481 1.04 (1.01-1.06) 0.003 
neutrophils 977 1.07 (1.05-1.10) <0.001 466 1.06 (1.03-1.08) <0.001 
CRP 642 1.01 (1.00-1.01) <0.001 311 1.01 (1.00-1.01) 0.004 
IMD: index of multiple deprivation; WCC: white cell count; eGFR: estimated glomerular 
filtration rate; CRP: C-reactive protein.  
 
In the final model (Table 3.8), short-term mortality was associated with 
increased age (OR=1.05, 95% CI: 1.03-1.07), decreased duration of 
hospitalisation after TOX (OR=0.94, 95% CI: 0.91-0.97) and decreased levels 
of serum albumin (OR=0.83, 95% CI: 0.79-0.88). Considering only toxigenic 
strains, increased age (OR=1.04, 95% CI: 1.02-1.07), decreased duration of 
hospitalisation time after TOX (OR=0.94, 95% CI: 0.90-0.97) and decreased 
levels of serum albumin (OR=0.86, 95% CI: 0.81-0.92) showed an association 
with short-term mortality. 
 
Table 3.8 Final model of multivariable analysis for short-term mortality  
Short-term 
mortality 
All patients (n=487) Toxigenic-strains (n=269) 
Odds ratio p Odds ratio p 
age 1.05 (1.03 -1.07) <0.00
1 
1.04 (1.02-1.07) 0.001 
albumin 0.83 (0.79-0.88) <0.00
1 
0.86 (0.81-0.92) <0.001 
disease 0.94 (0.91-0.97) <0.00
1 
0.94 (0.90-0.97) 0.001 
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3.5.4.2 Long-term mortality (within 1 year) 
After 1 year, more than half of case patients had died (53%, n=132), while 21% 
(n=57) of control patients and 41% of PCR+ (n=97) and 40% (n=59) of PCR- 
patients died in the same period. Considering long-term mortality, CDI status, 
gender, age, disease and pre-test periods, levels of WCC, albumin and CRP 
and mode of acquisition (Table 3.9) were included in the initial model 
considering all patients.  Toxin, age, gender, disease, pre-test levels of serum 
WCC, albumin and CRP (Table 3.9) were included in the logistic regression 
model when considering toxigenic strains for mortality within 1 year as the 
outcome. 
For mortality within 1 year after TOX, increased age (OR=1.04, 95% CI: 1.03-
1.06), decreased level of serum albumin (OR=0.92, 95% CI: 0.89-0.95), 
GDH+/TOX-/PCR+ (OR=2.34, 95% CI: 1.30-4.24) and GDH+/TOX+ 
(OR=3.04, 95% CI: 1.71-5.41) versus diarrhoea control patients were the 
variables associated positively with outcome (Table 3.10). Considering only 
toxigenic strains, increased age (OR=1.04, 95% CI: 1.02-1.06) and decreased 
levels of serum albumin (OR=0.92, 95% CI: 0.89-0.96) were associated with 
the outcome (Table 3.10). 
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Table 3.9 Univariate analysis of long-term mortality 
Long-term 
mortality  
 
All patients Toxigenic strains 
n Odds ratio p n Odds ratio p 
CDI 
status/toxin 
1,015 2.06 (1.71-2.49) <0.001 489 1.64 (1.14-2.34) 0.007 
gender 1,015 0.93 (0.72-1.20) 0.597 489 0.88 (0.62-1.26) 0.483 
age 1,015 1.04 (1.03-1.05) <0.001 489 1.04 (1.02-1.05) <0.001 
IMD score 931 1.01 (1.00-1.01) 0.084 441 1.01 (1.00-1.02) 0.145 
mode of 
acquisition 
1,015 1.40 (1.08-1.81) 0.010 465 1.26 (0.88-1.81) 0.214 
CDI 
severity 
   109 0.99 (0.44-2.22) 0.985 
disease 957 1.01 (1.00-1.01) 0.011 465 1.00 (1.00-1.01) 0.241 
pre-test 957 1.02 (1.01-1.03) <0.001 465 1.01 (1.00-1.02) 0.021 
albumin 847 0.91 (0.89-0.93) <0.001 411 0.90 (0.88-0.93) <0.001 
WCC 997 1.04 (1.02-1.05) <0.001 481 1.03 (1.01-1.06) 0.004 
neutrophils 977 1.04 (1.02-1.06) <0.001 466 1.03 (1.01-1.06) 0.010 
CRP 642 1.00 (1.00-1.01) 0.001 311 1.00 (1.00-1.01) 0.011 
IMD: index of multiple deprivation; WCC: white cell count; eGFR: estimated 
glomerular filtration rate; CRP: C-reactive protein.  
 
Table 3.10 Final model of multivariable analysis for long-term mortality 
Long-term mortality 
All patients (n=487) Toxigenic-strains (n=269) 
Odds ratio p Odds ratio p 
GDH-/TOX-a  1.00       
GDH+/TOX-/PCR-b 1.34 (0.64-2.82) 0.435     
GDH+/TOX-/PCR+c 2.34 (1.30-4.24) 0.005     
GDH+/TOX+d 3.04 (1.71-5.41) <0.001     
age 1.04 (1.03-1.06) <0.001 1.04 (1.03-1.06) <0.001 
albumin 0.92 (0.89-0.95) <0.001 0.92 (0.88-0.96) <0.001 
a diarrhoea control patients b non-toxigenic patients c toxigenic patients d CDI cases 
 
3.5.4.3 Time to death within 1 year 
For the Cox regression analysis, CDI status, gender, age, serum levels of 
WCC and albumin (Table 3.11) were considered in the model for all patients.  
Presence of toxin, gender, age, serum levels of WCC and albumin (Table 3.11) 
were considered in the model for only cases and colonised patients. When 
considering time to death within 1-year, increased age (HR=1.01, 95% CI: 
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1.00-1.02), increased serum WCC levels (HR=1.02, 95% CI: 1.01-1.04) and 
decreased serum albumin levels (HR=0.96, 95% CI: 0.94-0.97) had a positive 
association with the outcome (Table 3.12). For patients infected by toxigenic 
strains, time to death within 1 year was associated with increased levels of 
serum WCC (HR=1.03, 95% CI: 1.01-1.05) and decreased levels of serum 
albumin (HR=0.96, 95% CI: 0.93-0.98) (Table 3.12).  
 
Table 3.11 Univariate analysis of time to death within 1 year 
Time to death 
All patients Toxigenic-strains 
n Coef p n Coef p 
CDI status/toxin 345 1.29 (-8.04-10.61) 0.786 229 -5.52 (-30.33-19.29) 0.661 
gender 381 -5.82 (-24.98-13.33 0.550 229 -2.22 (-28.83-22.39) 0.859 
age 381 -0.69 (-1.29--0.08) 0.026 229 -0.58 (-1.39-0.22) 0.156 
IMD score 351 -0.24 (-0.68-0.20) 0.284 207 -0.43 (-0.99-0.13) 0.131 
mode of 
acquisition 
371 -5.56 (-25.13-14.01) 0.577 223 2.38 (-22.73-27.49) 0.852 
CDI severity       40 -4.79 (-63.63-54.05) 0.870 
disease 371 0.13 (-0.08-0.34) 0.217 223 0.25 (-0.13-0.64) 0.193 
pre-test 371 -0.05 (-0.39-0.29) 0.776 223 -0.20 (-0.65-0.24) 0.367 
albumin 314 3.16 (2.00-4.31) <0.001 196 3.62 (1.72-5.52) <0.001 
WCC 377 -1.61 (-2.52--0.70) 0.001 227 -1.27 (-2.39--0.16) 0.025 
neutrophils 364 -2.27 (-3.46--1.07) <0.001 218 -1.83 (-3.27-0.39) 0.013 
CRP 220 -0.12 (-0.27-0.03) 0.122 139 -0.09 (-0.26-0.08) 0.304 
IMD: index of multiple deprivation; WCC: white cell count; eGFR: estimated glomerular filtration 
rate; CRP: C-reactive protein.  
 
Table 3.12 Final model of survival analysis for time to death within 1 year 
Time to death 
All patients (n=344) Toxigenic-strains (n=230) 
Haz Ratio p Haz Ratio p 
GDH-/TOX-a  1.00       
GDH+/TOX-
/PCR-b 
1.26 (0.82-1.92) 0.290     
GDH+/TOX-
/PCR+c 
1.26 (0.88-1.81) 0.210     
GDH+/TOX+d 1.15 (0.81-1.62) 0.432     
toxin     0.94 (0.70-1.25) 0.656 
age 1.01 (1.00-1.02) 0.036     
albumin 0.96 (0.94-0.97) <0.001 0.96 (0.93-0.98) <0.001 
WCC 1.02 (1.01-1.03) <0.001 1.02 (1.01-1.04) <0.001 
a diarrhoea control patients b non-toxigenic patients c toxigenic patients d CDI 
cases 
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3.5.5 CDI severity  
Severity was only assessed in the cohort CDI cases and colonised patients as 
we did not have access to clinical information from the audit patients. Severe 
disease was present in 44% (n=34) and 23% (n=7) of patients, respectively. 
In the univariate analysis, presence of toxin, levels of serum WCC, neutrophils 
and CRP (Table 3.13) were associated with CDI severity. Levels of WCC were 
not included in the model, as this variable is used for categorising CDI severity. 
The final logistic regression model (Table 3.14) suggested that there was an 
association between CDI severity and the presence of the C. difficile toxins 
(OR=3.18, 95% CI: 1.05-9.60). 
 
Table 3.13 Univariate analysis of CDI severity 
CDI severity n Odds ratio p 
toxin 109 2.65 (1.02-6.87) 0.045 
gender 109 1.38 (0.64-3.01) 0.415 
age 109 1.00 (0.97-1.02) 0.858 
IMD score 100 1.00 (0.98-1.02) 0.918 
mode of acquisition 107 0.68 (0.31-1.50) 0.340 
disease 107 1.00 (0.98-1.01) 0.676 
pre-test 107 0.99 (098-1.01) 0.449 
mortality 4 weeks 109 3.44 (0.30-39.13) 0.320 
1 year 109 0.99 (0.44-2.22) 0.985 
albumin 99 0.98 (0.92-1.04) 0.494 
WCC 107 1.14 (1.06-1.23) <0.001 
neutrophils 103 1.16 (1.07-1.27) <0.001 
CRP 87 1.01 (1.00-1.01) 0.052 
fidaxomicin 109 0.82 (0.37-1.81) 0.626 
metronidazole 109 1.79 (0.74-4.33)  0.195 
vancomycin 109 2.19 (0.91-5.31) 0.082 
food supplement 109 1.10 (0.34-3.54) 0.875 
zopiclone 109 0.38 (0.08-1.91) 0.242 
PPI 109 0.48 (0.21-1.12) 0.088 
immunosuppressors 109 1.77 (0.53-5.91) 0.352 
IMD: index of multiple deprivation; WCC: white cell count; 
eGFR: estimated glomerular filtration rate; CRP: C-reactive 
protein; PPI: Proton-pump inhibitor. 
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Table 3.14 Final model of multivariable analysis 
for CDI severity 
CDI severity 
Toxigenic strains (n=87) 
Odds ratio p 
toxin 3.18 (1.05-9.60) 0.041 
 
3.5.6 Hospitalisation costs  
Median hospitalisation costs were higher for case patients (£5,192; IQR: 
£3,842-7,135), followed by PCR+ (£4,571; IQR: £3,190-6,237), PCR- (£3,842; 
IQR: £3,109-7,599) and control patients (£3,221; IQR: £2,442-4,558) when 
outliers were excluded. 
 
Table 3.15 Univariate analysis of hospitalisation costs 
Hospitalisation 
costs 
All patients Toxigenic strains 
n expβ p n expβ p 
CDI status 
toxin 
703 1.11 (1.06-1.16) <0.001 377 1.16 (1.02-1.34) 0.027 
gender 787 0.95 (0.85-1.06) 0.381 377 0.91 (0.79-1.04) 0.164 
age 787 1.00 (1.00-1.01) 0.004 377 1.00 (1.00-1.01) 0.398 
IMD score 770 1.00 (1.00-1.00) 0.962 371 1.00 (1.00-1.00) 0.991 
mode of 
acquisition 
774 1.72 (1.55-1.89) <0.001 376 1.73 (1.54-1.95) <0.001 
CDI severity    85 1.13 (0.83-1.53) 0.442 
disease 774 1.02 (1.02-1.02) <0.001 376 1.02 (1.02-1.02) <0.001 
pre-test 774 1.02 (1.02-1.03) <0.001 376 1.02 (1.02-1.02) <0.001 
mortality  
4 weeks 
787 0.99 (0.85-1.16) 0.897 377 0.95 (0.80-1.13) 0.555 
mortality  
1 year 
787 1.24 (1.10-1.38) 0.001 377 1.14 (0.99-1.30) 0.065 
albumin 647 0.98 (0.97-0.98) <0.001 309 0.97 (0.96-0.98) <0.001 
WCC 780 1.00 (0.99-1.01) 0.876 374 1.00 (0.99-1.01) 0.743 
neutrophils 767 1.00 (0.99-1.01) 0.559 363 1.00 (1.00-1.01) 0.595 
CRP 539 1.00 (1.00-1.00) 0.003 251 1.00 (1.00-1.00) 0.127 
IMD: index of multiple deprivation; WCC: white cell count; eGFR: estimated glomerular 
filtration rate; CRP: C-reactive protein; PPI: Proton-pump inhibitor. 
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Based on univariate analysis (Table 3.15) and including important variables 
for the outcome, an initial GLM model with gamma distribution and link log was 
performed with CDI status, age, gender, disease and pre-test periods, 
mortality within 1 year, levels of serum albumin and CRP and mode of 
acquisition as covariates. Increased duration of hospitalisation prior 
(expβ=1.01, 95% CI: 1.01-1.02) and post (expβ=1.02, 95% CI: 1.01-1.02) TOX 
and healthcare-associated infection (expβ=1.24, 95% CI: 1.13-1.35) were 
positively associated with hospitalisation costs (Table 3.16). GDH+/TOX-
/PCR- patients were 10% (£5,166±3,374), GDH+/TOX-/PCR+ patients were 
18% (£5,531±3,612) and GDH+/TOX+ patients were 25% (£5,848±3,820) 
more expensive than GDH-/TOX- patients (£4,680±3,057). 
Considering only toxigenic strains, toxin, disease and pre-test periods, 
albumin and mode of acquisition were included in the initial model. In the final 
model, increase in duration of hospitalisation prior (expβ=1.01, 95% CI: 1.01-
1.02) and post (expβ=1.02, 95% CI: 1.01-1.02) and presence of healthcare-
associated infection (expβ=1.20, 95% CI: 1.09-1.42) were the variables 
associated with hospitalisation costs (Table 3.16). The presence of a toxin 
positive result was not significant to this model and the predicted costs of the 
model were £5,695±3,585. 
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Table 3.16 Final model of multivariable analysis for hospitalisation costs 
Hospitalisation costs 
All patients (n=699) Toxigenic strains (n=376) 
expβ p expβ p 
GDH-/TOX-a  1.00  
  
GDH+/TOX-/PCR-b 1.10 (0.98-1.25) 0.112 
 
 
GDH+/TOX-/PCR+c 1.18 (1.07-1.31) 0.002 
 
 
GDH+/TOX+d 1.25 (1.13-1.38) <0.001 
 
 
mode of acquisition 1.24 (1.13-1.35) <0.001 1.20 (1.09-1.33) <0.001 
disease 1.02 (1.01-1.02) <0.001 1.02 (1.01-1.02) <0.001 
pre-test 1.01 (1.01-1.02) <0.001 1.01 (1.01-1.02) <0.001 
a diarrhoea control patients b non-toxigenic patients c toxigenic patients d CDI cases 
 
3.5.7 Cost savings with implementation of NAAT assay 
FDX has become the first line treatment for CDI in this setting and between 
2013 and 2015, 24 non-toxigenic strain patients were unnecessarily treated 
with FDX (Table 3.17). Considering that the NAAT test (£40 per assay) should 
have been performed after every GDH+/TOX- result and not excluding 
duplicates and tests performed more than once in a short period, in the same 
period, the hospital could have saved £9,640 by not treating any non-toxigenic 
strain patients.  
 
Table 3.17 Number and costs of GDH+/TOX- results and treatment with 
fidaxomicin for non-toxigenic strains and non-severe disease 
Year 
GDH+/TOX- test Non-toxigenic strain Non-severe disease 
Number Costs Number Costs Number Costs 
2012 127 £5,080 0 £0 0 £0 
2013 179 £7,160 1 £1,350 7 £9,450 
2014 199 £7,960 15 £20,250 20 £27,000 
2015 191 £7,640 8 £10,800 16 £21,600 
2016 14 £560 0 £0 0 £0 
Total 710 £28,400 24 £32,400 43 £58,050 
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In 2015 when the test was implemented, 8 of those patients were treated with 
FDX, indicating a decrease by 50% compared to the previous year but it still 
shows that unnecessary treatment has been given to some patients. This 
amount can increase if we consider that non-severe CDI patients were also 
treated with FDX, which is not recommended by PHE. 
 
3.6 Discussion 
GDH+/TOX-/PCR- had on average worse clinical outcomes compared to 
GDH+/TOX-/PCR+ patients. The latter group showed significantly lower 
mortality rates during hospitalisation and within 1 year, CDI severity and 
hospitalisation costs compared with CDI cases. Similar results were found in 
studies conducted in the UK and US (Planche et al., 2013, Polage et al., 2012, 
Polage et al., 2015). In the multivariate analysis, no differences related to CDI 
status were observed in all-cause mortality within 4 weeks after TOX. 
However, GDH+/TOX-/PCR+ were 2.3 times and CDI cases were 3.0 times 
more likely to die within 1 year after the test compared to diarrhoea control 
patients. Long-term mortality rate was considered in this thesis but of course 
this may be more related to comorbidities than to the infection by C. difficile. It 
also actually highlights that patients with comorbidities are more susceptible 
to C. difficile infection.   
Comparing only patients infected by a toxigenic strain, the presence of toxin 
was not significant in the model, in contrast to a study conducted in 4 UK 
hospitals that suggested a poor outcome related to the presence of toxin 
(Planche et al., 2013). Time to discharge was similar in the GDH+/TOX-/PCR+ 
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and GDH+/TOX+ groups and lower compared to GDH+/TOX-/PCR- by 0.7, 
0.8 and 0.6 times when compared to control patients. Hospitalisation costs 
were 18% and 25% more expensive for GDH+/TOX-/PCR+ and CDI cases 
respectively, compared to control patients. CDI severity was the only clinical 
outcome where the presence of a positive result for toxin test was significant 
compared to those patients who only presented with the gene for toxigenic 
strain. In this case, toxin positive patients were 3.2 times more likely to present 
with severe disease.  
Ribotype profile was similar in GDH+/TOX-/PCR+ and CDI case groups and 
matched England’s profile from 2008 to 2015 that showed the emergence of 
the RT078, RT002, RT005, RT014/020 and RT015 strains (PHE, 2016). 
Moreover, they were similar to the European profile in 2008 when RT014/020 
and RT078 were the most commonly found strains in 34 countries, while the 
UK was experiencing an outbreak with RT027 (Bauer et al., 2011). This 
epidemic strain was present in only 1.6% of CDI cases and 4.9% of toxigenic 
patients during the period of this study. 
Although UK Department of Health guidelines currently advise that 
GDH+/TOX- patients are unlikely to have CDI and are therefore not subject to 
mandatory reporting (Department of Health, 2012a), in our setting GDH+/TOX- 
results were predominantly caused by toxigenic strains. These patients 
carrying a toxigenic strain constitute a clinically significant segment of 
individuals as they encompass an important reservoir and potential source of 
CDI transmission. Symptomatic toxigenic patients often display dysbiosis and 
are likely to shed a high load of C. difficile in their stools, thus contributing to 
increased skin and environmental contamination when compared to 
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asymptomatic colonised individuals (Alasmari et al., 2014, Sethi et al., 2010). 
Studies have suggested potential transmission from symptomatic (Planche et 
al., 2013, Mawer et al., 2017) and asymptomatic (Blixt et al., 2017, Curry et 
al., 2013, Longtin et al., 2016) toxigenic patients in different countries. An 
aggravating risk factor is that symptomatic patients usually stay longer in 
hospital waiting for the right diagnosis and adequate treatment. Thus, 
preventive measures are indicated for those patients to avoid transmission and 
new cases (Planche et al., 2013, Mawer et al., 2017, Longtin et al., 2016) but 
the decision to treat these patients should be based on individual clinical 
assessment (Planche et al., 2013). 
The combination of GDH detection, TOX and molecular tests appears to be a 
good diagnostic option, as it can overcome all limitations of each test 
performed alone, and it can also confirm the identification of the toxigenic 
isolates. However, this test is more complex, needs more laboratory 
equipment to be performed and it is about five to ten times more expensive 
(Planche et al., 2013). Although some researchers support the use of only 
NAAT for diagnosis of CDI because of its high NPV, it may not be performed 
alone as it is not specific for CDI, not distinguishing disease from colonisation 
and it may thus be responsible for over-diagnosis (Planche et al., 2013, Polage 
et al., 2015). An ultrasensitive assay for detection and quantification of toxins 
has been developed in the US as a new tool that would have not only the 
potential to overcome the limitations of current diagnostics but would also have 
prognostic value identifying severe patients that need more attention. New 
studies have been undertaken to improve, optimise and refine the assay (Song 
et al., 2015, Pollock, 2016). 
 
 
92 
 
Of those 237 toxigenic isolates identified, 131 (55%) received CDI treatment 
with FDX, VAN or MTZ. NAAT assay was implemented at RLBUHT in 2015, 
when 84% of toxigenic samples were treated as a CDI case and in the first 
month of 2016, 75% of samples were treated in the same way. However, 24 
non-toxigenic isolates were over treated with FDX, corresponding to £32,400 
of unnecessary spending. It is known that more C. difficile tests are done in 
the UK than in other European countries (Bauer et al., 2011), but even if a 
NAAT test were performed for all 569 GDH+/TOX- result, this would have 
saved £9,640 between 2013 and 2015. Furthermore, given the PHE 
recommendations for CDI treatment, 30 CDI cases and 13 toxigenic isolates 
were also over treated with FDX as they presented with mild or moderate CDI, 
resulting in an additional overspend of £58,050.  
The study does have some limitations. Ninety-nine patients were excluded as 
the PCR result was not available to categorise them. It was only possible to 
derive CDI severity for cohort patients as all clinical information was collected 
by the nurses and was available in the patients’ CRFs. Medical records of audit 
patients were not accessed, and all information was collected from electronic 
databases (iPM, ICE and EPMA). Clinical outcomes considered in this study 
were not always related to CDI; cause of death was not accessed during the 
study, and thus it is not possible to affirm when the bacterial infection was 
directly or indirectly responsible for deaths especially since the patients in this 
study were mainly elderly and had known comorbidities, LoS was longer than 
usual and sometimes related to chronic and serious conditions; also, costs of 
hospitalisation do not represent the real cost of the patients as they were 
based on HRG codes and national tariff values. Lastly, the study did not cover 
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a large period after the implementation of NAAT assay, and thus meaningful 
comparison, before and after, of treatment given to patients cannot be made. 
In summary, GDH+/TOX- should be treated appropriately as we show that in 
our setting, more than 60% were infected by a toxigenic strain. The 3-step 
algorithm appears to be the best screening option, as it combines the 
identification of toxin positive patients as well as C. difficile producers of toxins. 
This combination may be able to prevent transmission, avoid unnecessary 
treatment and thereby prevent unnecessary healthcare and resource 
spending.  
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Chapter 4 
Procalcitonin as a screening test for early 
stratification and prognosis of 
hospitalised patients infected by 
Clostridium difficile. 
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4.1 Introduction 
Procalcitonin (PCT) is a biomarker of 114 to 116 amino acids, and is the 
precursor of the hormone calcitonin (Davies, 2015, Meisner, 2010). It is an 
immune modulator produced by the thyroid, and can be induced by severe 
systemic inflammation, its production being activated in all parenchymal 
tissues (Meisner, 2014). PCT can be used for the diagnosis of severe bacterial 
infections and sepsis, evaluation of the severity of infection, evaluation of the 
course of disease and indication and follow up of antibiotic therapy, including 
in helping make clinical decisions to stop antibiotics (Meisner, 2014, Meisner, 
2010).  
In the last decade, PCT has gained increasing acceptance with many studies 
published comparing the use of PCT with CRP for diagnostic and prognostic 
evaluation of diseases (Liu et al., 2015, Meisner, 2010). Although PCT has 
been employed in many countries in Europe, it has not been tested routinely 
in the UK yet. In the local hospital, the current tests used include CRP and 
WCC.  
For CDI, only four studies have been published comparing levels of PCT and 
CDI severity (Dazley et al., 2015, Rao et al., 2013), diagnosis and PCR 
positivity (Shapiro et al., 2017, Popiel et al., 2015). High levels of PCT were 
associated with CDI severity in both studies, but no association was found with 
other outcomes. Thus, because of the limited analysis conducted so far with 
CDI, we have undertaken this study to assess the performance of PCT as a 
screening test for early stratification and determining the prognosis of 
hospitalised patients infected by C. difficile.  
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4.2 Patients and methods 
4.2.1 Patient cohort 
The cohort of patients from both phases I and II of our CDI studies were 
included in this PCT study. They have been fully described in Chapter 2. 
Covariates used in this chapter were described in section 2.2.3. 
 
4.2.2 PCT measurement 
Salvaged serum samples collected during recruitment, follow-up 1 (around 2 
weeks after recruitment) and follow-up 2 (4 to 6 weeks after recruitment) were 
used to measure PCT levels retrospectively. All samples were stored at -80°C. 
PCT was measured by an eletrochemiluminescence immunoassay 
(ELECYSIS BRAHMS kit) at LCL, RLBUHT, which is a clinically accredited 
laboratory. Samples were measured regardless of the date of collection (same 
as recruitment date).  
According to the manufacturer, the sensitivity of assay is <0.02ng/mL and intra 
and inter-assay variation ranges from 1 to 9% and 3 to 16%, respectively. Also, 
sensitivity was 96%, specificity 66%, positive predictive value (PPV) 78% and 
NPV 93% when considering the cut-off value of 0.5ng/mL. The assay takes 18 
minutes  in the laboratory (Roche Diagnostics and Cobas, 2009). In general, 
healthy patients have PCT levels below 0.05ng/mL, levels above 0.5ng/mL 
suggest the possibility of a systematic infection, while severe sepsis is 
associated with levels between 2 to 10ng/mL (ThermoFischer Scientific, 
2017). 
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4.2.3 Clinical outcomes 
CDI diagnosis, time to discharge, short-term mortality (within 4 weeks) and 
long-term mortality (within 1 year), time to death within 1 year, CDI severity 
and CDI recurrence were assessed in this study. The definitions of the clinical 
outcomes have been described in section 2.2.4, and in previous publications 
on this cohort of patients (Swale et al., 2014b, Swale et al., 2014a). 
 
4.3 Statistical analysis 
4.3.1 Patient characteristics 
PCT and CRP results are initially presented as median and IQR by groups 
according to diagnostic tests (GDH, TOX and PCR). Results above reference 
range were also presented for both measurements. For the analysis, clinical 
information and outcomes were presented as median and interquartile range 
(IQR), or frequency (F) and percentage (P) for continuous and categorical 
variables, respectively, by TOX results. T-test and ANOVA were employed to 
compare normally distributed continuous variables and Mann-Whitney U test 
or Kruskal Wallis to compared non-normally distributed variables between all 
groups and groups categorised according to TOX, respectively, and chi-
square test to compare categorical variables. 
 
4.3.2 Multivariable analysis 
A univariate analysis was performed for every clinical outcome to identify 
potential covariates for the multivariable analysis. All statistically significant 
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variables were included in the initial model and variables were excluded one 
by one according to the highest p-value until all remained covariates were 
significant. A new model with remaining variables was performed after each 
exclusion and statistical significance was set at p <0.05.  
Two models were utilised to assess the potential association of PCT and CRP 
with each outcome, and thus these variables were included in all models 
regardless of the p-value. Logistic regression was used to assess CDI 
diagnosis, mortality within 4 weeks and 1 year, CDI severity and CDI 
recurrence. Multivariable Cox proportional hazards analysis was performed for 
time to discharge and time to death within 1 year, no censoring was applied 
for time to discharge but patients who did not die within 1 year after diagnosis 
were censored.  
As the day of blood sample collection for PCT and CRP measurements was 
not standardised, a sensitivity analysis was performed in both models 
including patients by time from toxin test to PCT or CRP measurement. PCT 
and CRP kinetic graphs published in the literature (Póvoa, 2002, 
ThermoFischer Scientific, 2017) were used to identify the period when 
biomarkers were elevated in bacterial infections. Considering that PCT levels 
in general start decreasing around day 3 after the infection and CRP levels 
between days 3 to 7 after the infection, patients were included in the analysis 
when tests were performed within 2 to 5 days after the toxin test and CRP 
results were included when the test was performed within 0 to 8 days. 
Additionally, one analysis was undertaken including all samples regardless of 
the time point at which PCT or CRP tests were performed. All statistical 
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analyses were performed using STATA version 14.0 (StataCorp LP, College 
Station, Texas).  
 
4.4 Results 
4.4.1 PCT results in CDI patients 
1,042 samples from 715 patients were tested. Patients were recruited between 
2008 and 2015 and during this period, C. difficile clinical diagnostic methods 
changed twice, and so it was not possible to group all patients accurately. The 
levels of PCT and CRP in patients with different diagnostic patterns are shown 
in Table 4.1. The median levels of serum PCT were on average similar in CDI 
cases (0.22ng/L, IQR: 0.09-0.58), GDH+/TOX-/PCR- (0.21ng/L, IQR: 0.08-
0.48) and GDH+/TOX-/PCR+ (0.20ng/L, IQR: 0.09-0.34) patients. All groups 
showed a decrease in PCT levels during follow-up at 2 weeks (follow-up 1) 
and 4 to 6 weeks (follow-up 2). TOX- patients had the same median value at 
baseline and follow-up 1, but only 8 patients were included in the 2-week 
follow-up.  
Conversely, analysis of CRP levels (Table 4.1) showed that the levels were on 
average higher in CDI cases (85mg/L, IQR: 39-183) and GDH+/TOX-/PCR+ 
(62mg/L, IQR: 22-115) than in GDH+/TOX-/PCR- (36mg/L, IQR: 16-74), GDH-
/TOX- (32mg/L, IQR: 12-123) and TOX- (38mg/L, IQR: 9-124) patients.  
As both variables were skewed (Figure 4.1), they were log transformed (log10) 
for the multivariable analysis. A summary of CRP and PCT values log10 
transformed at baseline and PCT at follow-ups 1 and 2 are shown in Figure 
 
 
100 
 
4.2 and the comparison between all groups and CDI cases are shown in Table 
4.2.  
 
 
Figure 4.1 (A) Histogram of PCT absolute values (B) Histogram of 
log transformed PCT values (C) Histogram of CRP absolute values 
(D) Histogram of log transformed CRP values. 
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Table 4.1 PCT and CRP results by groups and time points 
 
Healthy control TOX-a GDH-/TOX-b 
GDH+/TOX- 
PCR-c 
GDH+/TOX- 
PCR+d 
GDH+/TOX+e 
n 
Median  
(IQR) 
n 
Median  
(IQR) 
n 
Median  
(IQR) 
n 
Median  
(IQR) 
n 
Median  
(IQR) 
n 
Median  
(IQR) 
PCT baseline 
(ng/L) 
74 
0.03 
(0.02-0.05) 
188 
0.11 
(0.06-0.32) 
57 
0.12 
(0.06-0.34) 
16 
0.21 
(0.08-0.48) 
35 
0.20 
(0.09-0.34) 
304 
0.22 
(0.09-0.58) 
PCT follow-up 1 
(ng/L) 
0 . 8 
0.11 
(0.09-0.17) 
31 
0.07 
(0.04-0.19) 
9 
0.06 
(0.04-0.20) 
23 
0.08 
(0.05-0.16) 
61 
0.10 
(0.06-0.27) 
PCT follow-up 2 
(ng/L) 
64 
0.04 
(0.03-0.05) 
36 
0.05 
(0.03-0.06) 
46 
0.05 
(0.04-0.08) 
5 
0.12 
(0.04-0.18) 
20 
0.06 
(0.04-0.09) 
65 
0.09 
(0.05-0.19) 
CRP baseline 
(mg/L) 
0 . 189 
38 
(9-124) 
61 
32 
(12-123) 
13 
36 
(16-74) 
37 
62 
(22-115) 
321 
85 
(39-183) 
TOX: toxin test, GDH: glutamate dehydrogenase test, PCR: polymerase chain reaction.  
a diarrhoea control patients tested before 2012. b diarrhoea control patients. c diarrhoea control patients colonized by a C. difficile non-toxigenic strain. d 
carrier patients colonized by a C. difficile toxigenic strain. e CDI cases. 
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Figure 4.2 (A) CRP baseline (log10) results by group, (B) PCT baseline 
(log10) results by group, (C) PCT follow-up 1 (log10) results by group, 
(D) PCT follow-up 2 (log10) results by group.  
 
 
CDI case patients had CRP values (log10) higher than all groups while PCT 
values (log10) in CDI cases at baseline were only higher compared to the 
healthy control group, the group not tested for GDH but TOX- and the GDH-
/TOX- group. Four to 6 weeks after recruitment, the CDI case group had similar 
PCT values (log10) compared to the non-toxigenic group (GDH+/TOX-/PCR-) 
but higher compared to all others.  
For further analyses, patients were categorised according to the toxin test 
result (TOX- and TOX+) and healthy control patients were excluded. A 
summary of log10 transformed values of baseline CRP and PCT and follow-up 
1 and follow-up 2 PCT is shown in Figure 4.3. Patient characteristics are 
presented in Table 4.3.  
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Table 4.2 Comparison between p-value of CDI case and others groups 
 
all 
groups 
healthy 
control 
TOX-a 
GDH 
TOX-b 
GDH+ 
TOX- 
PCR-c 
GDH+ 
TOX- 
PCR+d 
p p p p p p 
PCT baseline 
(log10) 
<0.001 <0.001 <0.001 0.009 0.455 0.166 
PCT follow-up 1 
(log10) 
0.517 . 0.865 0.153 0.360 0.359 
PCT follow-up 2 
(log10) 
<0.001 <0.001 0.001 0.004 0.826 0.050 
CRP baseline 
(log10) 
<0.001 . <0.001 <0.001 0.014 0.042 
TOX: toxin test, GDH: glutamate dehydrogenase test, PCR: polymerase chain reaction.  
a diarrhoea control patients tested before 2012. b diarrhoea control patients. c diarrhoea 
control patients colonized by a C. difficile non-toxigenic strain. d carrier patients colonized 
by a C. difficile toxigenic strain.  
 
 
 
Figure 4.3 (A) CRP baseline (log10) results by toxin test, (B) PCT baseline (log10) 
results by toxin test, (C) PCT follow-up 1 (log10) results by toxin test, (D) PCT 
follow-up 2 (log10) results by toxin test.  
  
The median age of TOX+ group was higher (73 vs 64 years, p<0.001) and 
median Los was twice as high as the diarrhoea control patients (22 vs 11 days, 
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p<0.001). 42% (n=141) of TOX+ patients and 21% of TOX- (n=8) patients 
presented with severe disease as categorised in section 2.2.4. Mortality was 
also higher during hospitalisation [7% (n=23) vs 3% (n=9), p=0.023] and within 
1 year after the toxin test [31% (n=104) vs 15% (n=45), p<0.001]. These 
patients also presented with leucocytosis (WCC>11×109cells/L) and 
hypoalbuminemia (albumin<35g/L).  
The median CRP levels were twice as high in the CDI cases compared to the 
TOX- patients [88 (IQR: 40-183) vs 36 (IQR: 10-114) mg/L]. CRP levels were 
above the reference range for all patients, apart from 2 samples, while PCT 
levels were higher in CDI cases [0.22 (IQR: 0.09-0.59) vs 0.12 (IQR=0.06-
0.33) ng/mL). 103 of 334 (31%) of CDI case samples and 59 of 291 (20%) of 
diarrhoea control samples had levels higher than 0.5ng/mL which may indicate 
a potential systemic infection (Meisner, 2014). When log transformed, this 
difference was significant for both CRP (p<0.001) and PCT (p<0.001) levels. 
Moreover, 93% (n=313) of patients who tested positive for TOX were treated 
with either FDX, VAN or MTZ.  
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Table 4.3 Patients characteristics by toxin result 
 TOX-a (n=305) TOX+b (n=335) 
 
 
n 
Median(IQR) 
F (P) 
(IQR/Perc) 
n 
Median(IQR) 
F (P) 
 
p 
Demographics 
Age (years), median (IQR) 305 64 (48-74) 335 73 (59-80) <0.001 
gender (female, %) 305 169 (55.4) 335 185 (55.2) 0.962 
IMD score (score), median (IQR) 276 37.3 (18.5-57.8) 266 33.2 (17.3-55.8) 0.317 
Clinical 
CCI (score), median (IQR) 305 1 (0-2) 335 1 (0-2) <0.001 
mode of acquisition (HCAI, %) 305 147 (48.2) 335 199 (59.4) 0.063 
CDI severity (%) 38 8 (21.0) 335 141 (42.1) 0.026 
CDI recurrence (%) 0  335 55 (16.4)  
Hospitalisation      
Study phase (phase II, %) 305 166 (54.4) 334 78 (23.3) <0.001 
LoS (days), median (IQR) 292 11 (6-24) 334 22 (11-44) <0.001 
disease (days), median (IQR) 282 7 (4-15) 334 13 (7-26) <0.001 
pre-test (days), median (IQR) 282 3 (1-9) 334 5 (1-17) <0.001 
Time to death (days), median (IQR) 86 336.5 (127-700) 168 234.5 (75.5-615.5) 0.307 
Mortality hospitalisation (%) 305 9 (3.0) 335 23 (6.9) 0.023 
4 weeks (%) 305 8 (2.6) 335 18 (5.4) 0.078 
1 year (%) 305 45 (14.8) 335 104 (31.0) <0.001 
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Table 4.3 (continued) Patients’ characteristics by toxin result 
 TOX-a (n=305) TOX+b (n=335) 
 
n 
Median(IQR) 
F (P) 
(IQR/Perc) 
n 
Median(IQR) 
F (P) 
 
p 
Laboratory results, median (IQR) 
WCC baseline (109/L) 299 8.8 (6.4-12.5) 334 11.4 (7.9-17.1) <0.001 
albumin baseline (g/L) 285 34 (26-39) 328 29 (24-34) 0.018 
CRP baseline (mg/L) 294 35.5 (10-114) 327 88 (40-183) <0.001 
(log10) 294 3.6 (2.3-4.7) 325 4.5 (3.7-5.2) <0.001 
(>5 mg/L) 294 35.5 (10-114) 325 89 (40-183) <0.001 
time to test (days) 221 0 (-1-2) 301 0 (-1-2) 0.901 
PCT baseline (ng/mL) 291 0.12 (0.06-0.33) 334 0.22 (0.09-0.59) 0.092 
(log10) 291 -2.1 (-2.81--1.12) 334 -1.5 (-2.4--0.5) <0.001 
(>0.5 ng/mL) 59 1.36 (0.72-3.23) 103 1.16 (0.74-3.26) 0.442 
time to test (days) 288 3 (2-4) 365 3 (3-5) <0.001 
follow-up 1 (ng/mL) 71 0.08 (0.05-0.17) 81 0.10 (0.05-0.27) 0.169 
(log10) 71 -2.5 (-3--1.75) 81 -2.30 (-3.02--1.31) 0.115 
follow-up 2 (ng/mL) 107 0.05 (0.04-0.08) 82 0.08 (0.04-0.16) 0.201 
(log10) 107 -3.0 (-3.32--2.51) 82 -2.5 (-3.2--1.9) 0.001 
Medicines (%) 
CDI treatmentc  305 56 (18.4) 335 313 (93.4) <0.001 
Fidaxomicin  305 26 (8.5) 335 51 (15.2) 0.009 
Vancomycin  305 23 (7.5) 335 250 (74.6) <0.001 
Metronidazole  305 18 (5.9) 335 135 (40.3) <0.001 
TOX: toxin test, IMD: index of multiple deprivation, CCI: Charlson comorbidity index, LoS: length of stay, WCC: white cell 
count, CRP: C-reactive protein, PCT: procalcitonin. 
a diarrhoea control patients, b CDI case patients, c treatment with any antibiotic (standard treatment or fidaxomicin) 
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4.4.2 Multivariable analyses 
4.4.2.1 CDI diagnosis 
Initially, a univariate analysis (Table 4.4) was performed to guide the inclusion 
of covariates for the multivariable models. Thus, the initial model included age, 
pre-test period, Charlson comorbidity index (CCI) score, concentration of 
serum albumin, WCC, PCT and CRP. 
 
Table 4.4 Univariate analysis of CDI diagnosis as clinical outcome 
variables n Odds Ratio 95% CI p 
age 640 1.03 1.02-1.034 <0.001 
gender (female) 640 0.99 0.73-1.36 0.962 
IMD score 2015 542 1.00 0.99-1.00 0.316 
CCI 2011 640 1.28 1.14-1.43 <0.001 
mode of acquisition 616 1.35 0.98-1.86 0.064 
pre-test 616 1.02 1.01-1.03 0.001 
albumin 613 0.99 0.97-1.00 0.018 
WCC 633 1.06 1.03-1.08 <0.001 
PCT (log10) 625 1.26 1.13-1.41 <0.001 
CRP (log10) 619 1.58 1.39-1.81 <0.001 
 
A relationship between PCT levels and the presence of C. difficile toxins was 
found when patients tested within 2 days of the toxin test were included 
(OR=1.63, 95% CI: 1.04-2.58) (Table 4.5). This association did not remain 
when more time points were included in the model. Increased age also showed 
an association with diagnosis in this model. Increased levels of WCC were 
associated in all other models, increased CCI score showed association when 
patients were tested within 4 and 5 days after the toxin test and at all time 
points after the toxin test. Increased pre-test period was a covariate when 
patients were tested within 5 days after the toxin test and all time points were 
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included. The results of all multivariable analysis for each clinical outcome and 
time point are presented in the Appendix (3-107). 
 
Table 4.5 Multivariable and sensitivity analysis of PCT (log10) as covariate and 
CDI diagnosis as clinical outcome 
PCTa n Odds Ratio 95% CI p covariates 
<2 64 1.76 1.04-2.58 0.035 age 
<3 226 1.19 0.98-1.44 0.075 age, WCC 
<4 358 1.13 0.97-1.32 0.110 age, CCI, WCC 
<5 444 1.12 0.98-1.29 0.089 age, pre-test, CCI, WCC 
all 557 1.12 0.99-1.27 0.075 age, pre-test, CCI, WCC 
a time point: time between toxin test and PCT test 
 
Levels of CRP were associated with CDI diagnosis when patients were tested 
within 3 (OR=1.29, 95% CI: 1.08-1.53), 4 (OR=1.32, 95% CI: 1.12-1.56), 5 
(OR=1.33, 95% CI: 1.13-1.56), 6 (OR=1.35-95% CI: 1.15-1.59), 7 (OR=1.35-
95% CI: 1.14-1.58), and 8 (OR=1.34, 95% CI: 1.14-1.58) days after the toxin 
test and all time points (OR=1.35-95% CI: 1.16-1.57) were included (Table 
4.6). An increased pre-test period and increased levels of WCC also showed 
associations in all these models. Increased CCI score was associated with the 
outcome when patients were tested within 3 days after the toxin test and all 
time points were included. There was also a relationship between increased 
age and CDI diagnosis when all time points were included in the model. 
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Table 4.6 Multivariable analysis and sensitivity of CRP (log10) as covariate and 
CDI diagnosis as clinical outcome 
CRPa n Odds Ratio 95% CI p covariates 
<0 168 1.16 0.89-1.53 0.271 pre-test 
<1 287 1.13 0.91-1.39 0.277 pre-test, WCC 
<2 353 1.18 0.98-1.42 0.072 pre-test, WCC 
<3 414 1.29 1.08-1.53 0.005 pre-test, CCI, WCC 
<4 445 1.32 1.12-1.56 0.001 pre-test, WCC 
<5 471 1.33 1.13-1.56 0.001 pre-test, WCC 
<6 476 1.35 1.14-1.58 <0.001 pre-test, WCC 
<7 477 1.35 1.15-1.59 <0.001 pre-test, WCC 
<8 478 1.34 1.14-1.58 <0.001 pre-test, WCC 
all 542 1.35 1.16-1.57 <0.001 age, pre-test, CCI, WCC 
a time point: time between toxin test and CRP test 
 
4.4.2.2 Time to discharge 
In the initial model, toxin, age, mode of acquisition, recruitment phase (when 
patients were recruited), serum levels of albumin, CRP and PCT were included 
according to the univariate analysis (Table 4.7). 
 
Table 4.7 Univariate analysis of time to discharge as clinical outcome 
variable n Coef 95% CI p 
toxin 626 17.23 10.78-23.67 <0.001 
age 638 0.19 0.01-0.37 0.038 
gender (female) 638 -4.36 -10.88-(-2.17) 0.190 
IMD score 2015 547 0.07 -0.07-0.21 0.344 
CCI 2011 638 -0.09 -2.20-2.02 0.933 
mode of acquisition 628 29.70 23.48-35.91 <0.001 
albumin 616 -0.51 -0.75-(-0.26) <0.001 
WCC 635 0.07 -0.21-0.34 0.631 
PCT baseline (log10) 598 2.60 0.36-4.84 0.023 
PCT follow-up 1 (log10) 130 7.53 0.78-14.28 0.029 
PCT follow-up 2 (log10) 158 13.03 7.32-18.74 <0.001 
CRP (log10) 620 4.34 1.81-6.88 0.001 
Recruitment phase 638 -11.54 -18.25-(-4.83) 0.001 
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Increased levels of PCT were associated with increased risk of delayed 
discharge when considering patients tested within 3 (HR=0.87, 95% CI: 0.80-
0.95) and 5 (HR=0.93, 95% CI: 0.87-0.99) days after the toxin test and all time 
points (HR=0.93, 95% CI: 0.88-0.99) (Table 4.8). Considering these 3 models, 
covariates positively associated with time to discharge were decreased age 
and CAI; toxin negative test, decreased age, increased levels of albumin and 
CAI; and toxin negative test, increased levels of albumin and CAI, respectively. 
Measurement of follow-up 1 and 2 were not included in the models because 
of the low number of samples tested. 
 
Table 4.8 Multivariable and sensitivity analysis of PCT (log10) as covariate and time 
to discharge as clinical outcome 
PCTa n Haz ratio 95% CI p covariates 
<2 64 1.07 0.88-1.31 0.480 mode of acquisition 
<3 225 0.87 0.80-0.95 0.002 age, mode of acquisition 
<4 354 0.93 0.87-1.00 0.061 toxin, age, mode of acquisition 
<5 440 0.93 0.87-0.99 0.028 
toxin, age, albumin, mode of 
acquisition 
all 548 0.93 0.88-0.99 0.029 toxin, albumin, mode of acquisition 
a time point: time between toxin test and PCT test 
 
Serum levels of CRP had no association with time to discharge in any 
scenario. However, toxin negative test, CAI and increased levels of serum 
albumin decreased the risk of delayed discharge, as observed in the models 
below (Table 4.9). 
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Table 4.9 Multivariable and sensitivity analysis of CRP (log10) as covariate and 
time to discharge as clinical outcome 
CRPa n Haz ratio 95% CI p covariates 
<0 168 0.93 0.81-1.07 0.307 toxin, mode of acquisition 
<1 287 0.98 0.89-1.09 0.746 
toxin, albumin, mode of 
acquisition 
<2 353 0.98 0.90-1.07 0.627 
toxin, albumin, mode of 
acquisition 
<3 411 0.94 0.87-1.02 0.152 toxin, mode of acquisition 
<4 440 0.96 0.88-1.04 0.275 
toxin, albumin, mode of 
acquisition 
<5 466 0.93 0.86-1.01 0.071 
toxin, albumin, mode of 
acquisition 
<6 471 0.93 0.86-1.01 0.096 
toxin, albumin, mode of 
acquisition 
<7 472 0.94 0.86-1.01 0.100 
toxin, albumin, mode of 
acquisition 
<8 473 0.94 0.86-1.01 0.098 
toxin, albumin, mode of 
acquisition 
all 534 0.94 0.86-1.01 0.098 
toxin, albumin, mode of 
acquisition 
a time point: time between toxin test and CRP test 
 
4.4.2.3 Mortality rates 
4.4.2.3.1 Short-term mortality (within 4 weeks) 
Initial models included the presence of toxin, age, CCI, mode of acquisition, 
recruitment phase), serum levels of albumin, PCT and CRP. Covariates were 
chosen after univariate analysis (Table 4.10). 
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Table 4.10 Univariate analysis of short-term mortality as clinical outcome 
Mortality 4 weeks n Odds ratio 95% CI p 
toxin 640 2.11 0.90-4.92 0.085 
age 652 1.03 1.00-1.06 0.020 
gender (female) 652 0.94 0.43-2.07 0.886 
IMD score 2015 551 1.00 0.98-1.02 0.924 
CCI 2011 652 1.38 1.14-1.67 0.001 
mode of acquisition 628 2.69 1.07-6.80 0.036 
LoS 638 1.00 0.98-1.01 0.599 
disease 628 0.99 0.97-1.01 0.353 
pre-test 628 1.00 0.98-1.02 0.824 
albumin 625 0.97 0.94-1.00 0.022 
WCC 645 1.01 0.98-1.03 0.589 
PCT baseline (log10) 612 1.30 1.04-1.61 0.019 
PCT follow-up 1 (log10) 132 0.15 0.00-7.07 0.332 
PCT follow-up 2 (log10) 172 1.38 0.29-6.62 0.689 
CRP (log10) 631 1.48 1.04-2.11 0.031 
Recruitment phase 652 0.49 0.19-1.24 0.130 
 
Table 4.11 shows that serum levels of PCT were only statistically significant 
after inclusion of patients who were tested within 4 (OR=1.33, 95% CI: 1.00-
1.76) and 5 (OR=1.30, 95% CI: 1.02-1.66) days after TOX, and at all time 
points (OR=1.28, 95% CI: 1.01-1.62). In the first model, no covariates were 
included, but increased CCI was associated in the last two models and HCAI 
were also associated with mortality within 4 weeks in the last model. 
 
Table 4.11 Multivariable and sensitivity analysis of PCT (log10) as covariate 
and short-term mortality as clinical outcome 
PCTa n Odds ratio 95% CI p covariates 
<2 64 1.69 0.64-4.48 0.291 CCI 
<3 226 1.32 0.96-1.81 0.086 CCI 
<4 358 1.33 1.00-1.76 0.048 . 
<5 444 1.30 1.02-1.66 0.033 CCI 
all 557 1.28 1.01-1.62 0.038 
CCI, mode of 
acquisition 
a time point: time between toxin test and PCT test 
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Peak levels of serum CRP were only associated with mortality within 4 weeks 
when patients who were tested on the same day or before the toxin test 
(OR=1.01, 95% CI: 1.00-1.01) were included. No covariates were included in 
the model (Table 4.12), but HCAI and increased CCI score were related to 
mortality within 4 weeks in other models. 
 
Table 4.12 Multivariable and sensitivity analysis of CRP (log10) as covariate 
and short-term mortality as clinical outcome 
CRPa n Odds ratio 95% CI p covariates 
<0 168 3.03 1.09-8.44 0.034 . 
<1 287 1.85 0.95-3.62 0.073 . 
<2 353 1.66 0.91-3.02 0.097 mode of acquisition 
<3 414 1.42 0.90-2.24 0.128 mode of acquisition 
<4 445 1.40 0.92-2.12 0.116 CCI, mode of acquisition 
<5 471 1.35 0.91-2.01 0.136 CCI, mode of acquisition 
<6 476 1.35 0.91-2.01 0.137 CCI, mode of acquisition 
<7 477 1.35 0.91-2.00 0.139 CCI, mode of acquisition 
<8 478 1.35 0.91-2.01 0.136 CCI, mode of acquisition 
all 544 1.42 0.96-2.10 0.079 CCI, mode of acquisition 
a time point: time between toxin test and CRP test 
 
4.4.2.3.2 Long-term mortality (within 1 year) 
When mortality within 1 year was the outcome, toxin, age, CCI, LoS, mode of 
acquisition, recruitment phase, levels of albumin, PCT and CRP were included 
in the initial multivariable model (Table 4.13). 
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Table 4.13 Univariate analysis of long-term mortality as clinical outcome 
Mortality 1 year n Odds ratio 95% CI p 
toxin 640 2.60 1.76-3.85 <0.001 
age 652 1.03 1.02-1.05 <0.001 
gender (female) 652 0.87 0.61-1.26 0.465 
IMD score 2015 551 1.00 0.99-1.01 0.818 
CCI 2011 652 1.60 1.42-1.81 <0.001 
mode of acquisition 628 1.67 1.14-2.45 0.008 
LoS 638 1.00 1.00-1.01 0.025 
disease 628 1.00 1.00-1.01 0.092 
pre-test 628 1.01 1.00-1.02 0.056 
albumin 625 0.98 0.97-0.99 0.002 
WCC 645 1.01 1.00-1.03 0.112 
PCT baseline (log10) 612 1.25 1.11-1.41 <0.001 
PCT follow-up 1 (log10) 132 1.35 1.03-1.77 0.029 
PCT follow-up 2 (log10) 172 2.31 1.52-3.51 <0.001 
CRP (log10) 631 1.27 1.09-1.48 0.002 
Recruitment phase 652 0.90 0.62-1.31 0.581 
 
Mortality within 1 year was related to increased levels of PCT (Table 4.14), 
increased CCI score and decreased levels of serum albumin when considering 
patients tested within 3 days (OR=1.40, 95% CI: 0.85-2.29) after toxin test, to 
increased level of PCT, increased age, increase CCI score and HCAI when 
considering patients tested within 4 (OR=1.33, 95% CI: 1.12-1.58) and 5 days 
(OR=1.28, 95% CI: 1.10-1.48) after toxin test and all time points (OR=1.22-
95% CI: 1.06-1.40). 
  
Table 4.14 Multivariable and sensitivity analysis of PCT (log10) as covariate and 
long-term mortality as clinical outcome 
PCTa n Odds ratio 95% CI p covariates 
<2 64 1.40 0.85-2.29 0.188 CCI 
<3 226 1.43 1.15-1.77 0.001 CCI, albumin 
<4 358 1.33 1.12-1.58 0.001 age, CCI, mode of acquisition 
<5 444 1.28 1.10-1.48 0.002 age, CCI, mode of acquisition 
all 557 1.22 1.06-1.40 0.005 age, CCI, mode of acquisition 
a time point: time between toxin test and PCT test 
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Increased levels of serum CRP (Table 4.15), increased age and increased CCI 
score were associated with mortality within 1 year considering patients tested 
within 1 (OR=1.33, 95% CI: 1.01-1.75), 2 (OR=1.41, 95% CI: 1.11-1.80) and 
3 (OR=1.27-95% CI: 1.03-1.56) days after toxin test. Also, HCAI was 
associated with the outcome in the last model. 
 
Table 4.15 Multivariable and sensitivity analysis of CRP (log10) as covariate and 
long-term mortality as clinical outcome 
CRPa n Odds ratio 95% CI p covariates 
<0 168 1.32 0.92-1.90 0.136 age, CCI 
<1 287 1.33 1.01-1.75 0.040 age, CCI 
<2 353 1.41 1.11-1.80 0.005 age, CCI 
<3 414 1.27 1.03-1.56 0.026 age, CCI, mode of acquisition 
<4 445 1.22 1.00-1.48 0.055 age, CCI, mode of acquisition 
<5 471 1.15 0.95-1.39 0.141 age, CCI, mode of acquisition 
<6 476 1.17 0.97-1.41 0.094 age, CCI, mode of acquisition 
<7 477 1.17 0.97-1.41 0.097 age, CCI, mode of acquisition 
<8 478 1.16 0.97-1.40 0.110 age, CCI, mode of acquisition 
all 544 1.18 0.99-1.40 0.066 age, CCI 
a time point: time between toxin test and CRP test 
 
4.4.2.3.3 Time to death within 1 year 
The same variables of mortality within 1 year were included in the initial model, 
as all variables were not significant in the univariate analysis (Table 4.16): 
toxin, age, CCI, LoS, mode of acquisition, recruitment phase, levels of serum 
albumin, PCT and CRP. 
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Table 4.16 Univariate analysis of time to death within 1 year as clinical 
outcome 
Time to death n Coef 95% CI p 
toxin 149 -15.79 -49.97-18.39 0.363 
age 152 -0.45 -1.53-0.64 0.417 
gender (female) 152 17.69 -14.06-49.43 0.273 
IMD score 2015 142 0.02 -0.74-0.78 0.956 
CCI 2011 152 0.02 -8.64-8.68 0.997 
mode of acquisition 151 -18.58 -52.15-14.99 0.276 
LoS 151 -0.12 -0.49-0.26 0.540 
disease 151 -0.101 -0.66-0.44 0.698 
pre-test 151 -0.28 -1.05-0.48 0.464 
albumin 145 0.44 -0.80-1.68 0.485 
WCC 152 -0.47 -1.34-0.39 0.281 
PCT baseline (log10) 139 -9.03 -19.98-1.92 0.105 
PCT follow-up 1 (log10) 28 -14.24 -32.63-4.14 0.123 
PCT follow-up 2 (log10) 28 -8.18 -46.71-30.36 0.666 
CRP (log10) 146 -13.18 -26.76-0.39 0.057 
Recruitment phase 152 8.31 -24.91-41.53 0.622 
 
Levels of serum PCT were not associated with time to death within 1 year 
(Table 4.17), however, peak of serum CRP were positively associated (Table 
4.18) in almost all time points. Considering patients tested within 1 (HR=1.29, 
95% CI: 1.01-1.64) or 2 (HR=1.34, 95% CI: 1.09-1.65) days after toxin test any 
other variable was included. Between 4 and 8 days after test and including all 
time points, increased CCI was a covariate in all models and the only one 
when considering patients tested within 4 days (HR=1.26, 95% CI: 1.05-1.50). 
HCAI was significant when patients were tested within 3 days after toxin test 
(HR=1.00, 95% CI: 1.00-1.00). Also, phase II patients were more likely to be 
dead within 1 year when patients were tested within 5 (HR=1.00, 95% CI: 1.00-
1.00), 6 (HR=1.23, 95% CI: 1.05-1.44), 7 (HR=1.23, 95% CI: 1.05-1.44), 8 
(HR=1.23, 95% CI: 1.05-1.44) days after toxin test and at all time points 
(HR=1.20, 95% CI: 1.03-1.40). 
 
 
 
117 
 
Table 4.17 Multivariable and sensitivity analysis of PCT (log10) as covariate 
and time to death within 1 year as clinical outcome 
PCTa n Haz ratio 95% CI p covariates 
<2 28 1.26 0.82-1.94 0.295 . 
<3 93 1.14 0.98-1.32 0.083 CCI 
<4 142 1.14 1.00-1.30 0.056 CCI 
<5 180 1.11 0.99-1.25 0.068 recruitment phase, CCI 
all 229 1.09 0.98-1.21 0.126 recruitment phase, CCI 
a time point: time between toxin test and PCT test 
 
Table 4.18 Multivariable and sensitivity analysis of CRP (log10) as covariate 
and time to death within 1 year as clinical outcome 
CRPa n Haz ratio 95% CI p covariates 
<0 68 1.37 0.98-1.92 0.064 . 
<1 119 1.29 1.01-1.64 0.040 . 
<2 144 1.34 1.09-1.65 0.005 . 
<3 175 1.26 1.05-1.50 0.011 
recruitment phase, mode of 
acquisition 
<4 196 1.26 1.06-1.49 0.009 CCI 
<5 209 1.22 1.04-1.44 0.014 recruitment phase, CCI 
<6 212 1.23 1.05-1.44 0.011 recruitment phase, CCI 
<7 212 1.23 1.05-1.44 0.011 recruitment phase, CCI 
<8 213 1.23 1.05-1.44 0.012 recruitment phase, CCI 
all 223 1.20 1.03-1.40 0.018 recruitment phase, CCI 
a time point: time between toxin test and CRP test 
 
4.4.2.4 CDI severity 
Toxin, age, gender, mode of acquisition, recruitment phase, levels of serum 
albumin, PCT and CRP were included in the initial model (Table 4.19). Level 
of serum WCC was part of categorization of CDI severity and not included in 
the multivariable analysis. 
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Table 4.19 Univariate analysis of CDI severity as clinical outcome 
CDI severity n Odds ratio 95% CI p 
toxin 367 2.60 1.09-6.17 0.031 
age 367 0.99 0.98-1.01 0.331 
gender (female) 367 1.08 0.71-1.65 0.711 
IMD score 2015 292 1.00 0.99-1.01 0.678 
CCI 2011 367 0.97 0.85-1.10 0.608 
mode of acquisition 365 0.73 0.48-1.12 0.154 
LoS 365 1.00 1.00-1.00 0.783 
disease 365 1.00 1.00-1.01 0.604 
pre-test 365 0.99 0.98-1.00 0.156 
Mortality 4 weeks 367 0.41 0.13-1.26 0.119 
Mortality 1 year 367 0.68 0.43-1.08 0.099 
albumin 357 1.00 0.98-1.01 0.662 
WCC 365 1.14 1.10-1.19 <0.001 
PCT baseline (log10) 339 1.32 1.13-1.56 <0.001 
PCT follow-up 1 (log10) 84 1.00 0.76-1.33 0.979 
PCT follow-up 2 (log10) 85 1.30 0.86-1.97 0.212 
CRP (log10) 356 1.45 1.18-1.77 <0.001 
Recruitment phase 367 0.83 0.53-1.31 0.435 
 
CDI severity was associated with the level of serum PCT (Table 4.20) when 
considering patients tested within 3 (OR=1.56, 95% CI: 1.18-2.07), 4 
(OR=1.33, 95% CI: 1.09-1.63) and 5 (OR=1.22, 95% CI: 1.03-1.45) days and 
at all time points (OR=1.30, 95% CI: 1.11-1.52).  
 
Table 4.20 Multivariable and sensitivity analysis of PCT (log10) as 
covariate and CDI severity as clinical outcome 
PCTa n Odds ratio 95% CI p covariates 
<2 34 1.57 0.86-2.87 0.143 . 
<3 118 1.56 1.18-2.07 0.002 . 
<4 191 1.33 1.09-1.63 0.006 . 
<5 250 1.22 1.03-1.45 0.020 . 
all 328 1.30 1.11-1.52 0.001 . 
a time point: time between toxin test and PCT test 
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Levels of serum CRP were also associated (Table 4.21) with CDI severity 
when patients tested within 1 (OR=1.44, 95% CI: 1.07-1.93), 2 (OR=1.53, 95% 
CI: 1.17-1.99), 3 (OR=1.59, 95% CI: 1.23-2.05), 4 (OR=1.54, 95% CI: 1.21-
1.96), 5 (OR=1.54, 95% CI: 1.22-1.94), 6 (OR=1.54, 95% CI: 1.22-1.94), 7 
(OR=1.54, 95% CI: 1.22-1.94) and 8 days (OR=1.52, 95% CI: 1.21-1.92) after 
toxin test and all time points (OR=1.40, 95% CI:1.13-1.73) were included. Any 
covariate was included in the models. 
 
Table 4.21 Multivariable and sensitivity analysis of CRP (log10) as 
covariate and CDI severity as clinical outcome 
CRPa n Odds ratio 95% CI p covariates 
<0 100 1.29 0.84-1.98 0.245 . 
<1 181 1.44 1.07-1.93 0.017 . 
<2 222 1.53 1.17-1.99 0.002 . 
<3 259 1.59 1.23-2.05 <0.001 . 
<4 279 1.54 1.21-1.96 <0.001 . 
<5 294 1.54 1.22-1.94 <0.001 . 
<6 296 1.54 1.22-1.94 <0.001 . 
<7 296 1.54 1.22-1.94 <0.001 . 
<8 297 1.52 1.21-1.92 <0.001 . 
all 321 1.40 1.13-1.73 0.002 . 
a time point: time between toxin test and PCT test 
 
4.4.2.5 CDI recurrence  
In the initial model, age, gender, mortality within 1 year, LoS, recruitment 
phase and serum levels of PCT and CRP were included as independent 
variables (Table 4.22). 
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Table 4.22 Univariate analysis of CDI recurrence as clinical outcome 
CDI recurrence n Odds ratio 95% CI p 
toxin . . . . 
age 367 1.04 1.02-1.07 <0.001 
gender (female) 367 1.24 0.69-2.22 0.475 
IMD score 2015 292 1.00 0.98-1.01 0.522 
CCI 2011 292 0.92 0.77-1.11 0.399 
mode of acquisition 365 0.87 0.49-1.56 0.645 
LoS 365 1.01 1.00-1.02 <0.001 
disease 365 1.02 1.01-1.02 <0.001 
pre-test 365 1.01 1.00-1.02 0.232 
Mortality 1 year 367 3.68 2.04-6.64 <0.001 
albumin 357 0.99 0.97-1.02 0.564 
WCC 365 1.00 0.99-1.02 0.569 
PCT baseline (log10) 363 1.00 0.82-1.21 0.962 
PCT follow-up 1 (log10) 104 0.53 0.22-1.30 0.165 
PCT follow-up 2 (log10) 102 1.52 1.00-2.29 0.048 
CRP (log10) 356 1.17 0.90-1.53 0.236 
Recruitment phase 397 0.27 0.12-0.59 0.001 
 
The only variable that showed association with recurrence rate was increased 
age. No relationship between serum levels of PCT or CRP (Tables 4.23 and 
4.24) and CDI recurrence was found in this cohort. 
 
Table 4.23 Multivariable and sensitivity analysis of PCT (log10) as 
covariate and CDI recurrence as clinical outcome 
PCTa n Odds ratio 95% CI p covariates 
<2 34 0.80 0.33-1.94 0.620 . 
<3 118 0.94 0.55-1.59 0.806 age 
<4 191 1.21 0.89-1.66 0.225 age 
<5 250 1.06 0.81-1.39 0.647 age 
all 328 1.01 0.81-1.26 0.960 age 
a time point: time between toxin test and PCT test 
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Table 4.24 Multivariable and sensitivity analysis of CRP (log10) as 
covariate and CDI recurrence as clinical outcome 
CRPa n Odds ratio 95% CI p covariates 
<0 100 1.47 0.65-3.32 0.360 age 
<1 181 1.13 0.73-1.75 0.596 age 
<2 222 1.20 0.83-1.72 0.333 age 
<3 259 1.30 0.91-1.86 0.145 age 
<4 279 1.28 0.91-1.80 0.153 age 
<5 294 1.22 0.88-1.69 0.229 age 
<6 296 1.24 0.90-1.72 0.185 age 
<7 296 1.24 0.90-1.72 0.185 age 
<8 297 1.25 0.90-1.73 0.180 age 
all 321 1.10 0.82-1.48 0.505 age 
a time point: time between toxin test and CRP test 
 
4.5 Discussion 
CRP is the most recognized and widely used biomarker for monitoring 
bacterial infection, but it can also be elevated in viral infections and is a 
traditional biomarker of inflammation (Vikse et al., 2015). CRP starts rising 
after 12 to 24 hours, reaches a peak around 20 to 72 hours after the stimulus 
and remains elevated for 3 to 7 days (Schneider and Lam, 2007, Vikse et al., 
2015, Simon et al., 2004). As a non-specific biomarker, in our cohort only two 
patients had CRP levels within the reference range. One study in intensive 
care unit patients found that CRP levels remained high (80mg/L) at the end of 
antibiotic therapy (Deliberato et al., 2013). Moreover, 3 patients with an 
unfavourable outcome in a pneumonia study (de Jager et al., 2009) had 
elevated PCT levels while CRP levels were decreasing during the 7 day 
period.  
PCT is an accurate biomarker for severe bacterial infection and sepsis (Simon 
et al., 2004, Nargis et al., 2014). After 2 to 4 hours of infection, levels of PCT 
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start rising, peak after 24 to 48 hours and start decreasing around 2 to 3 days 
when response to antibiotic treatment is effective (Vikse et al., 2015, Banerjee 
et al., 2002, ThermoFischer Scientific, 2017). The half-life of PCT is 22 to 30 
hours (Lee, 2013, Jin and Khan, 2010), but its levels can persist until 
completely recovery (Lee, 2013). 
Considering that PCT levels can remain elevated until day 3 while CRP can 
remain elevated until day 7, PCT levels were positively associated with CDI 
diagnosis, time to discharge, long-term mortality and CDI severity while CRP 
levels were positively associated with time to death within 1 year and CDI 
severity. It is important to highlight that associations were observed at some 
time points when other clinical outcomes were analysed. When considering 
absolute values, PCT levels were higher in the CDI case group, but no 
difference was found between groups. On the other hand, CRP levels were 
higher in CDI cases than in controls, however, and above the reference range 
in almost all patients. Similar results were previously found in a study of 50 
patients in Israel (Shapiro et al., 2017). Also, no difference in PCT levels were 
found comparing TOX-/PCR+ and TOX-/PCR- in a Canadian study with 64 
subjects (Popiel et al., 2015). In our multivariable analysis, results were not 
consistent for CRP as it was associated with CDI diagnosis only when we 
included patients tested 3 days after the toxin test.  
Although time to discharge was negatively associated with PCT levels in our 
study, this association was not found in a previous study with CDI patients 
(Rao et al., 2013), also, NICE guidance (NICE, 2015b) concluded based on 7 
studies that PCT measurement may not be a reliable method to assess LoS 
as it is multifactorial and highly influenced by local policy and clinicians’ 
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preferences. In studies with 101 (Stolz et al., 2009), 81 (Deliberato et al., 2013) 
and 58 (Annane et al., 2013) patients with pneumonia and sepsis, no 
differences were observed between groups comparing control and PCT-based 
algorithm groups. 
PCT was also related to long-term mortality in our study. Short-term mortality 
showed an association in some scenarios when more patients were included. 
In cancer patients with bacterial infection, PCT levels showed an association 
with mortality during the study, but no association was found for CRP and 
WCC levels (Murat Sedef et al., 2016). Prognosis of mortality for septic 
patients is still unclear, but two studies with 86 (Meng et al., 2009) and 54 
patients (Jain et al., 2014) showed an association with elevated levels of PCT 
during admission and mortality within 4 weeks (Jain et al., 2014). 
CDI severity has previously been associated with PCT levels (Rao et al., 2013, 
Dazley et al., 2015). The definition of severity was different in each study and 
TOX+ patients were included when PCT levels were drawn within 24 hours 
(Dazley et al., 2015), and with TOX+ and TOX-/PCR+ patients with PCT 
measurement carried out between 24 to 72 hours (Rao et al., 2013). Also, CDI 
could be identified as severe when PCT was higher than 0.2 ng/mL (Rao et 
al., 2013) and 0.5 ng/mL (Dazley et al., 2015). PCT is also associated with 
severity from other bacterial infections including pneumonia (de Jager et al., 
2009, Kim et al., 2013, Don et al., 2007), cellulitis (Noh et al., 2016), paediatric 
bacterial meningitis (Hu et al., 2015) and pyelonephritis (Park et al., 2013). 
The PCT assay is not considered an expensive test and economic evaluation 
studies have concluded that the use of the new biomarker could decrease 
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costs of hospitalisation (Ito et al., 2017, Stojanovic et al., 2017, Schuetz et al., 
2015, Balk et al., 2017) and could be cost-effective when used to guide 
antibiotic therapy for acute respiratory tract infections (Michaelidis et al., 2014), 
sepsis (Westwood et al., 2015, Harrison and Collins, 2015) and 
meningococcal disease (Bell et al., 2015). 
Our study has several limitations. Firstly, PCT measurement was conducted 
retrospectively. We assumed that all the process of sampling and storage 
conditions did not influence the stability of our aliquots. As the samples were 
collected during patient recruitment, the time between C. difficile testing and 
recruitment was variable and in some cases, it took longer than 3 days. Also, 
the day of C. difficile test may not be the day when symptoms started nor even 
when the patient was infected. A sensitivity analysis was conducted to include 
more patients and also assess a potential association between timings. While 
the study was being undertaken over an 8 year period, the diagnostic method 
and algorithm changed twice, and thus some patients could not be properly 
categorised. Furthermore, our cohort was recruited in two different phases, the 
first during an epidemic phase (2008-2012) after the 2006-2007 outbreak, 
tended to be more severe with higher mortality and recurrence rates. The 
second cohort was recruited during an endemic phase (2013-2015) when the 
number of cases reached a plateau. The medical diagnosis of diarrhoea 
control patients was not exhaustively assessed in this study and another 
bacterial infection cannot be excluded.  
In summary, this study has identified several potential new associations 
between serum PCT and clinical outcomes in CDI patients. Further studies 
with PCT measured at the same time as CDI diagnosis, or after the initial 
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symptoms, are required. Furthermore, a randomised controlled trial would be 
required to determine whether the measurement of PCT represented a 
clinically effective and cost-effective test in the clinical management of CDI.  
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Chapter 5 
Interventions for Clostridium difficile 
Infection: A Systematic Review of 
Economic Evaluations 
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5.1 Introduction 
C. difficile strains have acquired resistance to many antibiotics and 
disinfectants, further contributing to high transmissibility and contamination 
(CDC, 2013). Infection significantly increases morbidity, mortality and is 
associated with excess hospital stays. Moreover, CDI remains endemic in 
several hospitals and continues to be a major problem for healthcare systems 
(NICE, 2015a). 
A recent systematic survey (Lytvyn et al., 2016) found five published 
guidelines for the prevention of CDI: Health Protection Agency/Department of 
Health (Department of Health & Health Protection Agency, 2008), European 
Society for Clinical Microbiology and Infectious Disease (Vonberg et al., 2008), 
American College of Gastroenterology (Surawicz et al., 2013), Association of 
Professionals in Infection Control and Epidemiology (APIC, 2013), and Society 
for Healthcare Epidemiology of America/Infectious Diseases to Society of 
America (Dubberke et al., 2014). Strategies to control and prevent the infection 
involve mainly two approaches: (1) a reduction in the environmental burden of 
C. difficile and minimisation of its spread (deep cleaning and disinfection of 
environment, personnel hygiene, use of protective clothing and containment 
methods), and (2) rationalisation of antibiotics use (implementation of 
stewardship programs, monitor antimicrobial resistance). The most recent 
guideline (Dubberke et al., 2014) also recommends implementation of a 
laboratory-based alert system for notification of new cases to healthcare 
professionals, active surveillance and reporting of CDI data, education of 
healthcare staff, environmental service personnel, hospital administration, 
patients with CDI and their families, and measurement of compliance with 
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Center for Disease Control and Prevention (CDC) or World Health 
Organization (WHO) recommendations. 
In the UK, several initiatives have been implemented in hospitals since 2003 
to decrease the levels of exposure and the risk of recurrent infections (Marufu 
et al., 2015, Hughes et al., 2013). However, there remain uncertainties 
surrounding their effectiveness, and the optimal use of healthcare resources. 
The NICE guidance on the use of FDX from 2012 (NICE, 2012), for instance, 
focuses on safety and efficacy, and not its cost-effectiveness, though the All 
Wales Medicines Strategy Group (AWMSG) and Scottish Medicines 
Consortium (SMC) have recently published appraisals recommending the use 
of FDX for treatment of CDI patients with first recurrence (AWMSG, 2012, 
SMC, 2012) or severe disease (AWMSG, 2012), based on economic 
evidence. 
This chapter aims to review the economic evidence in order to highlight current 
evidence on the cost-effectiveness of strategies to limit C. difficile spread and 
infection, and to identify methodological limitations. 
 
5.2 Methods 
The protocol of this study has been registered with the International 
Prospective Register of Systematic Reviews (PROSPERO) under registration 
number CRD42016024893. The study is reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
statement (Moher et al., 2009). 
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5.2.1 Eligibility criteria 
The review considered published, original economic evaluations of 
interventions for the prevention, management or treatment of CDI in 
healthcare settings. Pre-clinical studies, reviews, commentaries and 
conference abstracts were excluded from our analysis. There was no 
language restriction. 
 
5.2.2 Search strategy 
A systematic search was performed in January 2016 using 6 different 
databases: MEDLINE and Embase (via OVID), EconLit (via EBSCO), and the 
Database of Abstracts of Reviews of Effects, NHS Economic Evaluation 
database and Health Technology Assessment database (each via CRD). 
The search strategy (appendix 106) included terms related to CDI and 
economics, according to keywords utilised in previously published reviews 
(Glanville et al., 2009, Nanwa et al., 2015).  
 
5.2.3 Study selection 
Two reviewers worked independently to conduct the searches and verify the 
studies. Titles and abstracts were initially screened for eligibility, full-texts were 
screened when potential relevant studies reporting interventions for CDI were 
identified. Full economic evaluations were included if they compared both the 
costs and consequences of two or more strategies (NICHSR, 2003). 
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5.2.4 Data extraction 
The following study characteristics were extracted: year of publication, country 
of publication, nature of the intervention, comparators, type of study, type of 
economic evaluation, costing perspective, time horizon, currency and cost 
year. The following study results were extracted: mean total costs for each 
intervention and outcomes, expressed as quality-adjusted life years (QALYs), 
disability-adjusted life years (DALYs) or other, according to the study.  
 
5.2.5 Study adherence to the CHEERS statement 
We used the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) statement guidelines (Husereau et al., 2013) to assess the quality 
of reporting of included studies. Specific attention was paid to items 
concerning methodology: target population and subgroups, setting and 
location, study perspective, comparators, time horizon, discount rate, choice 
of health outcomes, measurement of effectiveness, measurement and 
valuation of preference based outcomes, estimating resources and costs, 
currency, price date, and conversion, choice of model, assumptions, and 
analytical methods.  
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5.3 Results 
5.3.1 Study selection 
Our search identified 2,229 unique studies of which the majority (2,200) were 
excluded after title and abstract screening as they were not specific to the 
species Clostridium difficile or did not assess interventional measures (Figure 
5.1). After full text screening, 18 further studies were excluded for not reporting 
a full economic evaluation, leaving 11 studies for inclusion in our systematic 
review.  
 
5.3.2 Study characteristics 
Studies mainly focused on treatment, including FDX (Bartsch et al., 2013, 
Stranges et al., 2013, Konijeti et al., 2014, Nathwani et al., 2014, Wagner et 
al., 2014, Marković, 2014) and faecal microbiota transplant (FMT) (Varier et 
al., 2014, Varier et al., 2015, Konijeti et al., 2014). Other studies considered 
the cost-effectiveness of probiotics (Allen et al., 2013), vaccination of at-risk 
patients (Lee et al., 2010), and screening hospital admission (Bartsch et al., 
2012a). All identified studies were published between 2010 and 2015. The 
majority were from US (Lee et al., 2010, Bartsch et al., 2012a, Bartsch et al., 
2013, Stranges et al., 2013, Konijeti et al., 2014, Varier et al., 2014, Varier et 
al., 2015), followed by UK (Allen et al., 2013, Nathwani et al., 2014) and a 
single study each from Canada (Wagner et al., 2014) and Serbia (Marković, 
2014).  
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Figure 5.1 Flowchart of study selection process
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Characteristics relating to the methods of each study are presented in Table 
5.1. All studies were cost-effectiveness (CEA) or cost utility analysis (CUA), 
10 were based on decision analytical models and 1 was a clinical trial. A third-
party payer perspective was used in 6 studies from the US (Lee et al., 2010, 
Bartsch et al., 2012a, Bartsch et al., 2013, Stranges et al., 2013, Varier et al., 
2014, Varier et al., 2015), healthcare system perspective in 4 studies from the 
UK, Canada and Serbia (Allen et al., 2013, Nathwani et al., 2014, Wagner et 
al., 2014, Marković, 2014), hospital perspective in 2 studies from the US 
(Bartsch et al., 2012a, Lee et al., 2010) and societal perspective in 2 studies 
from the US (Lee et al., 2010, Konijeti et al., 2014). Economic outcomes 
considered included cost per QALY gained (Bartsch et al., 2012a, Bartsch et 
al., 2013, Allen et al., 2013, Konijeti et al., 2014, Nathwani et al., 2014, Varier 
et al., 2014, Varier et al., 2015, Stranges et al., 2013), cost per DALY averted 
(Lee et al., 2010), cost per recurrence avoided (Wagner et al., 2014), cost per 
life-year saved (Marković, 2014), and cost per avoided colectomy (Marković, 
2014). 
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Table 5.1 Characteristics of economic evaluation studies included in the systematic review 
Study Country Context Comparator 
Type of 
study 
Type of 
evaluation 
Perspective 
view 
Time 
horizon 
Currency 
and year 
CHEERS 
Lee 
et al, 
2010 
US Vaccines 
(1) vaccines 
for patients 
at risk 
(2) vaccines 
for CDI 
patients to 
prevent 
recurrences 
Decision 
analytic 
model 
CEA 
Societal, 
hospital and 
third-party 
payers 
N/R 
2009 US 
dollars 
11/14 
Bartsch 
et al, 
2012 
US 
Screening 
admissions 
PCR assay 
Decision 
analytic 
model 
CEA 
Hospital and 
third-party 
payers 
N/R 
2011 US 
dollars 
9/14 
Allen 
et al, 
2013 
UK Prevention 
Placebo and 
Probiotics 
multicentre, 
randomised, 
double-
blind, 
placebo-
controlled, 
parallel-arm 
trial 
CUA 
Healthcare 
provider 
1 year 
2011 
GBP 
9/14 
Bartsch 
et al, 
2013 
US Treatment 
(1) M and V 
(2) F for all 
(3) F based 
on strain 
type 
Decision 
analytic 
model 
CEA 
Third-party 
payer 
N/R 
2012 US 
dollars 
11/14 
Stranges 
et al, 
2013 
US Treatment V and F 
Decision 
analytic 
model 
CUA 
Third-party 
payer 
23 
years 
2011 US 
dollars 
11/14 
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Table 5.1 (continued) Characteristics of economic evaluation studies included in the systematic review 
Study Country Context Comparator 
Type of 
study 
Type of 
evaluation 
Perspective 
view 
Time 
horizon 
Currency 
and year 
CHEERS 
Konijeti 
et al, 
2014 
US 
Treatment 
for 
recurrence 
(1) M, V, F 
and FMT via 
colonoscopy 
(2) M, V, F 
and FMT via 
duodenal 
infusion 
(3) M, V, F 
and FMT via 
enema 
(4) M, V, F 
and FMT all 
via 
(5) M, V and 
F 
Decision 
analytic 
model 
CEA Societal 1 year 
2012 US 
dollars 
11/14 
Nathwani 
et al, 
2014 
UK 
Treatment 
for severe 
disease 
and 
recurrence 
(1) V and F 
for severe 
CDI 
(2) V and F 
for first 
recurrence 
Decision 
analytic 
model 
CEA 
Healthcare 
provider 
1 year 
2010/2011 
GBP 
12/14 
Varier 
et al, 
2014 
US 
Treatment 
for 
recurrence 
(1) M and 
FMT 
(2) V and 
FMT 
Decision 
analytic 
model 
CEA 
Third-party 
payer 
90 days 
2011 US 
dollars 
12/14 
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Table 5.1 (continued) Characteristics of economic evaluation studies included in the systematic review 
Study Country Context Comparator 
Type of 
study 
Type of 
evaluation 
Perspective 
view 
Time 
horizon 
Currency 
and year 
CHEERS 
Wagner 
et al, 
2014 
Canada 
Treatment 
for severe 
disease 
and 
recurrence 
(1) V and F 
for severe 
CDI 
(2) V and F 
for first 
recurrence 
Decision 
analytic 
model 
CEA 
Healthcare 
provider 
60 days 
US 
dollars 
10/14 
Markovic 
et al, 
2014 
Serbia Treatment V and F 
Decision 
analytic 
model 
CEA 
Healthcare 
provider 
90 days 
Republic 
of Servia 
dinars 
(RSD) 
12/14 
Varier et 
al, 2015 
US 
Treatment 
for 
recurrence 
V and FMT 
Decision 
analytic 
model 
CEA 
Third-party 
payer 
90 days 
2011 US 
dollars 
13/14 
US: United States, UK: United Kingdom, PCR: Polymerase chain reaction, M: Metronidazole, V: Vancomycin, F: Fidaxomicin, FMT: 
faecal microbiota transplant, CEA: cost-effectiveness analysis, CUA: cost-utility analysis, GBP: British pounds, N/R: Not reported 
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5.3.3 Quality of reporting 
The methods and quality of reporting are summarised in Table 5.1. The quality 
of reporting was generally high. Study population was described in four studies 
(Lee et al., 2010, Nathwani et al., 2014, Wagner et al., 2014, Allen et al., 2013). 
Setting and location was reported in just one study (Allen et al., 2013). Three 
studies (Bartsch et al., 2012a, Bartsch et al., 2013, Lee et al., 2010) did not 
mention time horizon of the model and two studies (Marković, 2014, Wagner 
et al., 2014) did not specify the year adopted for costs of interventions. Only 
one study (Allen et al., 2013) used a preference-based method for estimate 
utility scores. All other items were reported in all selected studies however not 
always with a full description, justification or information of model choices 
being given explicitly.  
 
5.3.4 Results of individual studies 
The results of selected studies were summarised in the Table 5.2 according 
to the interventional measure addressed in the studies. 
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Table 5.2 Results of economic evaluation studies included in the systematic review 
Study Costs 
Additional 
information 
QALY/DALY ICER Cost-effective intervention 
Lee 
et al, 
2010 
Costs per 
vaccine: 
$100 to $1,600 
Vaccine efficacy 
model: 25 to 
100% 
C. difficile risk 
model: 0.1 to 
25% 
DALYs by 
infection 
statusa: 
1st recurrence: 
-0.0029 
2nd 
recurrence: -
0.0043 
CDI: -0.0014 
< $80,412/DALY 
prevented for all rates of 
vaccine efficacy when 
$25 and risk >2.5%  
$50 and risk >10% y 
$100 and risk >15%  
cost < $400 
Depends on C. difficile risk, 
vaccine costs and 
efficacies. Cost-effective on 
different scenarios. 
Bartsch 
et al, 
2012 
Screening (per 
testa): $7.66 
Gloves (per 
paira): $0.0861 
Gown: $0.922 
Technician 
wage (per 
houra): $17.96 
Nurse wage 
(per houra): 
$31.10 
C. difficile 
colonization on 
admission 
model: 0.5 to 
20% 
Contact isolation 
compliance 
model: 25 to 
75% 
QALYs by 
severitya: 
Mild CDI: 0.88 
Severe CDI: 
0.817 
Colectomy: 
0.536 
< $256/QALY on all 
scenarios 
Screening 
Allen 
et al, 
2013 
Cost per 
patientb: 
Pl: £8,010 
Pr: £8,420 
N/A 
QALYs gainsb: 
Pr - Pl: <0.0014 
£189,662/QALY Placebo 
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Table 5.2 (continued) Results of economic evaluation studies included in the systematic review 
Study Costs 
Additional 
information 
QALY/DALY ICER 
Cost-effective 
intervention 
Bartsch 
et al, 
2013 
Cost per 
treatmenta: 
M: 585 
V: $1,032 
F: $3,360 
N/A 
QALYs by 
severitya: 
Non severe 
CDI: 0.88 
Severe CDI: 
0.817 
(1) >$8.8 million/QALY 
(2) dominated 
(3) >$43.7 million/QALY 
Given the current costs of 
fidaxomicin, it is not cost-
effective 
Stranges 
et al, 
2013 
Cost per 
patientb: 
V: $12,306 
F: $13,422 
N/A 
QALYs per 
patientb: 
V: 16.551 
F: 16.568 
$67,576/QALY F 
Konijeti 
et al, 
2014 
Cost per 
patientb: 
M: $3,941 
V: $2,912 – 
3,531  
F: $4,261 – 
4,628  
FMT: $3,149 
– 4,208 
N/A 
QALYs by 
groupb: 
M: 0.8292 
V: 0.8484 – 
0.8580 
F: 0.8596 – 
0.8653 
FMT: 0.8543 – 
0.8719 
(1) V x FMT colonoscopy 
$17,016/QALY  
(2) V x FMT via duodenal 
infusion $97,352/QALY 
(3) V x FMT 
$17,016/QALY 
(4) V x F $184,023/QALY 
FMT via colonoscopy 
Nathwani 
et al, 
2014 
Costs per 
patientb: 
(1) V: £571 
F: £2,567 
(2) V: £800 
F: £3,630 
N/A 
QALYs by 
groupb: 
(1) V: 0.705 
F: 0.715 
(2) V: 0.692 
F:0.711 
(1) £16,529/QALY 
(2) -£21,079/QALY 
F in both cases 
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Table 5.2 (continued) Results of economic evaluation studies included in the systematic review 
Study Costs 
Additional 
information 
QALY/DALY ICER 
Cost-effective 
intervention 
Varier 
et al, 
2014 
Cost per 
patientb: 
M: $1,167 
V: $1,890 
FMT: $1,669 
N/A 
QALYs by 
groupb: 
M: 0.238 
V: 0.241 
FMT: 0.242 
(1) $124,964/QALY 
(2) dominant 
(1) M 
(2) FMT 
Wagner 
et al, 
2014 
Total costs for 
1000 
patientsb: 
(1) V: 
$8,866,593 
F: 
$10,677,167 
(2) V: 
$9,056,376 
F: 
$11,119,038 
n of patients with 
recurrence/1000 
patientsb 
V: 230 
F: 93 
n of patients 
experiencing second 
recurrence/1000 
patientsb 
V: 301 
F: 188 
N/A 
(1) $13,202/recurrence 
avoided 
(2) $18,190/recurrence 
avoided 
Sensitive to the 
recurrence rate, the 
duration of fidaxomicin 
treatment and proportion 
of NAP1/B1/027 strain 
cases. 
Markovic 
et al, 
2014 
Cost per 
patientb: 
V: RSD25,873 
F: RSD48,106 
Mortality rateb 
V: 0.057 
F: 0.050 
Total colectomyb 
V: 0.016 
F: 0.014 
N/A 
RSD2,977,621/life-year 
saved 
RSD10,276,757/avoided 
colectomy 
F if the outcome is live-
year saved, but not for 
number of avoided 
colectomies. 
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Table 5.2 (continued) Results of economic evaluation studies included in the systematic review 
Study Costs 
Additional 
information 
QALY/DALY ICER 
Cost-effective 
intervention 
Varier 
et al, 
2015 
Cost per 
patientb: 
V: $3,788 
FMT: $1,669 
N/A 
QALYS by 
groupb: 
V: 0.235  
FMT: 0.242 
-$302,714/QALY FMT 
QALY: quality-adjusted life year, DALY: disability-adjusted life year, ICER: incremental cost-effectiveness ratio, M: Metronidazole, V: 
Vancomycin, F: Fidaxomicin, FMT: faecal microbiota transplant, Pl: placebo, Pr: probiotic, N/A: not applicable. 
a Data inputs b Base case results
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5.3.4.1 Probiotics 
Probiotics are live microorganism that can provide health benefit on the host 
when administered in adequate doses (Sanders, 2008). Lactobacillus, 
Bifidobacterium and Saccharomyces are the most common species used for 
the treatment of CDI (Khanna and Pardi, 2012). A UK trial-based economic 
evaluation (Allen et al., 2013) concluded that lactobacilli and bifidobacteria 
given to elderly patients who have been admitted to hospital and exposed to 
antibiotics, was not cost-effective compared with the use of placebo with an 
incremental cost-effectiveness ratio (ICER) of £189,662 per QALY gained. 
Costs were similar in both arms of the trial, but the use of probiotics was not 
effective in preventing diarrhoea (relative risk 1.04, 95% CI: 0.84-1.28). 
 
5.3.4.2 Screening hospital admissions 
A strategy of screening patients at hospital admission by conducting peri-rectal 
swabbing, pre-amplification in a selective medium and the use of real time-
PCR assay for toxin detection, was evaluated in one study (Bartsch et al., 
2012a). Patients with positive tests were treated with precautions, including 
the use of gloves and gowns. Patients who developed CDI received standard 
therapy (MTZ or VAN). Screening on admission was economically dominant 
compared to no screening from both hospital and third-party payer 
perspectives. Different scenarios considering C. difficile colonization on 
admission, contact isolation compliance and probability of infection after 
colonization rates, all resulted in ICER <$256 per QALY gained. The authors 
adopted a conservative model underestimating the health impact of CDI and 
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the potential benefits of screening, they also limited the number of CDI 
episodes, did not include comorbidities and rare complications, and included 
only costs during hospitalisation. Extrapolating across the US, they suggested 
that screening for C. difficile on admission could save between $152 million to 
$1.6 billion annually.  
 
5.3.4.3 Vaccines 
Lee et al (Lee et al., 2010) constructed a simulation model to analyse the cost-
effectiveness of universal vaccination of: (1) all at-risk patients, and (2) only 
CDI patients receiving antibiotic treatment. Vaccination compared to no 
vaccination could be dominant for combinations of C. difficile risk of 
colonization >10% based on local prevalence, cost of vaccination between $25 
and $100, and vaccine efficacy rates ranged between 25% and 100%. 
Vaccination was projected to be cost-effective in preventing recurrences if the 
cost of vaccination was below $800 and efficacy above 50%. The authors 
concluded that vaccination could prevent both cases and recurrences and 
save money of society, third-party payers and hospitals, hence supporting 
investment on this area. However, as a simulation model without evidence on 
the effectiveness of vaccination, there remains uncertainty as to whether these 
benefits would be realised in practice. 
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5.3.4.4 Treatment with fidaxomicin  
FDX is indicated for the treatment of CDI having demonstrated lower rates of 
recurrence and deaths compared to MTZ or VAN. It has been appraised by 
different agencies, including the NICE (NICE, 2012), AWMSG (AWMSG, 
2012) and SMC (SMC, 2012) and is the first line treatment option in some UK 
hospitals. 
Economic evaluations of FDX have considered its comparison with VAN in: 
CDI patients (Stranges et al., 2013), patients with colitis induced by C. difficile 
who did not respond to MTZ (Marković, 2014), patients with severe CDI or with 
first recurrence (Nathwani et al., 2014), and patients with severe CDI (Wagner 
et al., 2014). Bartsch et al (Bartsch et al., 2013) compared the treatment of 
CDI patients in three scenarios: (1) no FDX, (2) only FDX, and (3) FDX based 
on strain type. The other study that assessed FDX is presented with FMT 
findings. 
Markovic et al study (Marković, 2014) found FDX to be cost-effective at a cost 
of RSD2.98 million per life-year gained (threshold of RSD53.3 million per life-
year gained) compared with VAN, but not cost-effective when the outcome 
was the number of avoided colectomies, even if the price is decreased by 50%. 
This study did not consider patients with severe complications and it was 
conducted in a low income country where the costs of labour are low compared 
to the high costs of FDX. The analysis by Nathwani et al (Nathwani et al., 2014) 
indicated FDX to be cost-effective for both severe CDI (with an ICER of 
£16,529 per QALY gained) and first CDI recurrence (dominant) compared with 
VAN. Stranges et al (Stranges et al., 2013) found similar results with an ICER 
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of $67,576 per QALY gained. However, FDX was no longer cost-effective if 
cure rates decrease or with improvement in response to oral VAN (Stranges 
et al., 2013). The model may have overestimated the cost of FDX and 
recurrence rates in outpatients and underestimated in inpatients. It also did not 
include the risk of colonization and infection. Wagner et al study (Wagner et 
al., 2014) concluded that FDX may be a cost-effective option for the treatment 
of CDI but this was sensitive to clinical cure, recurrence rates and number of 
cases caused by the NAP1/B1/027 strain. This study took into account only 
first or second recurrence and severity and length of them were similar to initial 
episode. In contrast to these studies, Bartsch study (Bartsch et al., 2013) found 
that FDX was not cost-effective as first line treatment for CDI patient (ICER 
>$8.8 million per QALY gained). To be cost-effective, FDX needed to cost less 
than US$150 to treat all CDI patients and between US$160 and US$400 to 
treat non-NAP/B1/027 cases. 
 
5.3.4.5 Treatment with Faecal microbiota transplant  
FMT also known as faecal bacteriotherapy consists of the infusion of a faecal 
suspension from a healthy donor to restore the balance of bacteria in the gut 
of patients with recurrent CDI (RCDI). Currently, FMT is indicated for recurrent 
cases after their third episode of mild or moderate CDI, after the second 
episode of severe CDI, moderate or severe cases not responding to VAN for 
2 weeks or 48 hours, respectively (Bakken et al., 2011), or recurrent cases 
that have failed on antibiotic therapy or other treatments (NICE, 2014). 
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Three economic evaluations of FMT were identified. Konijeti et al (Konijeti et 
al., 2014) assessed the use of FMT in different scenarios for RCDI: (1) FMT 
via colonoscopy compared with MTZ, VAN and FDX, (2) FMT via duodenal 
infusion compared with all 3 antibiotic therapies, (3) FMT via enema compared 
with all 3 antibiotic therapies, (4) FMT all delivery via compared with all 3 
antibiotic therapies, and (5) the 3 antibiotic therapies alone. Varier et al 
compared the use of FMT with MTZ and VAN for initial CDI (Varier et al., 
2014), and compared FMT to VAN at the third RCDI (Varier et al., 2015). 
FMT via colonoscopy was the most cost-effective option among those 
assessed by Konjieti et al (Konijeti et al., 2014), with an ICER of $17,016 per 
QALY gained compared with antibiotic therapy. Varier et al (Varier et al., 2014) 
concluded that FMT via colonoscopy is cost-effective (dominant) compared 
with VAN, but not cost-effective compared with MTZ (ICER $124,964 per 
QALY gained) in initial CDI. Moreover, in third RCDI, FMT is less costly and 
more effective (dominant) compared with VAN (Varier et al., 2015). While the 
first study (Konijeti et al., 2014) compared all antibiotic therapies and different 
methods of FMT delivery, Varier et al (Varier et al., 2014, Varier et al., 2015) 
did not include FDX. Moreover, they considered only patients without serious 
conditions and FMT delivered only via colonoscopy. 
 
5.4 Discussion 
This review identified 11 economic evaluation studies on CDI prevention with 
the use of probiotics, vaccination of patients, and screening hospital 
admission, and on treatment with FDX and FMT. Interventions were 
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considered cost-effective depending on different scenarios, e.g. perspectives, 
costs, intervention to be compared. The use of probiotics was the only 
intervention not cost-effective. Only treatment with FDX and FMT were 
assessed in more than one study; FMT was compared with standard therapy 
in three studies conducted by two different groups whose findings were similar, 
FDX was assessed by five different groups and although only one study found 
it not cost-effective, in general their findings were variable.  
Probiotics were not considered effective or cost-effective in the trial, however 
stool samples were not tested for C. difficile toxin in 41% of patients which may 
account for the low rate of CDI (~1%). Consequently, NICE, Food and Drug 
Administration (FDA), SHEA and IDSA do not recommend its use for 
preventing recurrent CDI (Cohen et al., 2010, Surawicz et al., 2013, PHE, 
2013). However, further research is needed to confirm the findings, identify the 
population at risk of CDI and determine the influence of probiotics on the 
quality of life (38).  
One study found that a strategy of screening on admission followed by 
antibiotic treatment to be a cost-effective approach even with high probabilities 
of colonization on admission or infection after colonization, and lower contact 
isolation compliance rate. Although routine screening in hospitalised patients 
without diarrhoea is not recommended (Bartsch et al., 2012a, Bartsch et al., 
2012b) detection of asymptomatic carriers may reduce the transmission and 
the number of new colonisations and CDI cases (Lanzas and Dubberke, 
2014). This study also suggested additional benefit of screening as more 
attention is given to the cleaning of previously occupied rooms. Decision 
makers should consider this strategy when colonization is present in ≥10% of 
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patients with identifiable risk factors (Leekha et al., 2013), however, further 
economic evidence is warranted to assess the value of routine surveillance for 
controlling transmission and preventing new cases. 
Vaccines from Pfizer and Valneva are currently in development. There is still 
no published information about prices, efficacies and target population but the 
decision analytic model considered a wide range of plausible values and 
indicated vaccination as a potentially cost-effective treatment for prevention of 
cases and recurrences, showing promising results for recurrences even with 
high prices.  
Included economic evaluations of FDX were conducted in US, Canada, UK 
and Serbia and varied in terms of healthcare system and costs, patient 
characteristics, rates of transmission and endemicity (Marković, 2014). Cost 
perspectives and time horizon of analysis were different across studies making 
comparisons among studies difficult. However, with the exception of one study 
(Bartsch et al., 2013), FDX was generally cost-effective. Two studies (Bartsch 
et al., 2013, Wagner et al., 2014) concluded that FDX was not the most cost-
effective treatment option for first episode and first recurrence of patients 
infected by NAP1/B1/027 strains mainly owing to the high price of FDX 
(Bartsch et al., 2013). This situation might change with the future availability 
of generic FDX. While FDX is recommended as first line treatment in some UK 
hospitals, there remains uncertainty surrounding its cost-effectiveness in this 
context. 
FMT via colonoscopy is cost-effective compared with standard antibiotic 
therapy in various contexts of use, i.e. first recurrence, initial treatment and, 
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third recurrence, following the American guideline (Surawicz et al., 2013). All 
studies were conducted in the US. As with any decision analytic models, 
several assumptions were required and although there are differences 
between models, their findings were similar and could indicate a new treatment 
option for initial CDI and RCDI. However, the potential for the use of FMT 
requires further confirmatory evidence as not all costs related to the FMT 
process were included in the economic evaluations and it is possible that other 
methods of delivery could be more efficient and safer. NICE also recommends 
more research related to optimal dosage, mode of administration and choice 
of donor (NICE, 2014). A clinical trial completed recently is evaluating the 
potential cost-effectiveness of faecal microbial transplant in the first episode 
of CDI (NIH, 2017).  
Our review has limitations. Firstly, the evidence base is not extensive, being 
limited to 11 studies. This may indicate that interventions for prevention other 
than FDX are not effective. While the number of CDI cases has been 
decreasing in recent years, effective measures for infection control remains 
challenging in some healthcare settings and evidence on clinical effectiveness 
alone are often not sufficient to support the introduction of health technologies 
(Rawlins and Culyer, 2004). 
Secondly, as with any review of economic evaluations conducted in different 
jurisdictions, meaningful comparison between studies are not possible 
because of differences in practice, healthcare systems, patient case-mix and 
disease characteristics. 
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Finally, methodological weaknesses in the studies were mainly related to the 
models employed, which represent the decision problem, but are typically 
reliant on a number of assumptions and are limited in the range of outcomes, 
costs and interventions that may be compared. Comorbidities were not usually 
included in the models. No data of FMT efficacy for initial CDI were available 
and RCDI data were used instead. There are no health utilities published for 
CDI, thus in all modelling studies those values were estimated comparing with 
other causes of diarrhoea. There were limitations in respect to the reporting of 
analyses, with items such as time horizon, population and setting and location 
not reported in some studies. 
The review identified studies which suggest the following interventions may be 
cost-effective: screening patients on hospital admission, vaccination (but 
depending on cost, efficacy and C. difficile risk), FMT via colonoscopy, and 
FDX in some specific conditions, as price and duration of treatment. The use 
of probiotics to prevent CDI was the only intervention measure considered not 
cost-effective in this review. The lack of studies identified in this review and 
the focus on treatment in the majority reinforces the need and importance of 
economic studies in the prevention of CDI.  
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Chapter 6 
Cost of illness analysis of Clostridium 
difficile infection in Liverpool in 2008-2012 
and 2012-2016 
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6.1 Introduction 
As mentioned before, the 2006-2008 outbreak caused by the spread of 
hypervirulent strain RT027 was associated with severe illness and increased 
death and recurrence rates. The transition between an epidemic to an endemic 
phase was observed after 2008 when the number of cases dropped from 
33,000 in 2007/2008 to 20,000 in 2008/2009, reaching a stable incidence after 
2013/2014 when 5,000 cases where reported in England (PHE, 2017). 
Comprehensive reports of costs associated with C. difficile related 
hospitalisation in the UK are limited to two studies (Wilcox et al., 2017, Wilcox 
et al., 1996). The original 1996 analysis covers the period prior to the 
emergence of major outbreaks in North America and Europe. This study 
included 50 CDI cases recruited between 1994 and 1995 and additional costs 
for these patients compared to matched controls were £4,107. Costs were 
based on average difference in LoS, use of antibiotics and laboratory tests 
between groups. The same group recently published another study including 
64 CDI recurrent patients and 64 first CDI case patients between 2012 and 
2014 and median costs per patient during 28 day post-index period were 
£7,539 (£5,617-9,730) and £6,294 (£2,700-9,216). Hospital bed night was the 
major cost component (87%) in this study, as costs varied between £275 
(medical ward) and £1,400 (intensive care) per night. Additionally, 
investigations, procedures and laboratory costs were considered in the cost 
calculation. 
The economic impact of Clostridium difficile on the NHS of several epidemic 
seasons has yet to be determined in more detail as no studies have included 
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the period prior or post the RT027 outbreak. Thus, the aim of this chapter was 
to estimate costs associated with CDI episodes through different seasons 
(2008-2012 and 2012-2016) in hospitalised patients at RLBUHT from the 
perspective of the healthcare provider/hospital.  
 
6.2 Patients and methodology 
6.2.1 Patient cohort 
Cohort and audit patients from phases I and II were included in this study. The 
methods of patient recruitment are described in section 2.2.1. 
 
6.2.2 Data collection 
Demographic (age, gender and IMD score), clinical (CCI score, mode of 
acquisition, CDI severity and CDI recurrence) and hospitalisation data 
(hospitalisation periods, mortality rates and hospitalisation costs) described in 
section 2.2.3, were used in this chapter.  
For phase II patients, the health status was measured by the EuroQol five 
dimension questionnaire (EQ-5D-3L), and the visual analogue scale (EQ-
VAS). The EQ-5D-3L asks patients about their perceptions related to mobility, 
self-care, usual activities, pain and discomfort and anxiety and depression 
according to three levels (no, some, extreme problems) (van Reenen and 
Janssen, 2015). Combined results were used to obtain single index value with 
5-digit number and were converted to a value set between 0 (death) and 1 (full 
health) according to the UK population (Szende and Williams, 2004, van 
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Reenen and Janssen, 2015). The EQ-VAS uses a scale from 0 to 100 to 
indicate how the health is on the day (van Reenen and Janssen, 2015).  
 
6.3 Statistical analysis 
6.3.1 Patient characteristics 
Descriptive analyses were undertaken to assess the difference in 
demographic, clinical and hospitalisation characteristics between CDI cases 
(TOX+) and control patients (TOX-) for phase I, and between CDI cases 
(GDH+/TOX+), potential C. difficile carriers (GDH+/TOX-) and diarrhoea 
controls (GDH-/TOX-) for phase II. Data were described by mean and 95% 
confidence intervals (CI) for continuous variables and frequency (F) and 
percentage (P) for categorical variables. Hospitalisation costs calculation were 
described in the section 2.2.4 and were presented as the nearest pound 
sterling (£) and for hospitalisation costs and hospitalisation period, a non-
parametric bootstrap sampling with 2,000 replications was used to estimate 
CIs and bias corrected and accelerated (Bca) confidence intervals were 
presented. T-test or ANOVA test were employed to compare normally 
distributed continuous variables, Mann-Whitney U test or Kruskal Wallis test 
to compare non-normally distributed continuous variables, and chi-square test 
to compare categorical variables. Different tests were employed for different 
phases as phase I has 2 groups and phase II has 3 groups. 
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6.3.2 Multivariable analysis 
Outliers (<2.5 and >97.5 percentiles) of outcome variables were excluded from 
the model after confirmation that those patients were exceptions compared to 
the whole cohort and with unrelated diagnostic and high cost medical 
conditions and treatment, e.g. leukaemia, myeloma, lymphoma, rheumatoid 
arthritis. Low costs were related to day case patients. As costs data are 
skewed and mean costs are the interest, a generalized linear model (GLM) 
was the method chosen to evaluate the cost difference associated with the 
infection by C. difficile. Studies have shown that GLM is a good option to 
assess costs and deal with non-normally distributed outcomes instead of 
employing normal and bootstrapped multiple linear regression, median 
regression or normal linear regression of log costs (Dodd et al., 2006, Moran 
et al., 2007, Barber and Thompson, 2004). Potential covariates were used to 
control the analysis and varied according to the different models. Covariates 
were chosen according to relevance for the outcome and based on individual 
significance after univariate analysis. The final model was built using stepwise 
regression with use of p<0.05 for inclusion criteria and p>0.05 for exclusion 
criteria.  
Gamma distribution and link log is usually the model chosen to assess costs. 
However, modified Park test was used to assess appropriateness of family 
chosen for each model, with a non-significant p-value and a small value of chi-
squared indicating the family to be chosen (Manning and Mullahy, 2001, 
Jones, 2010). Model performance was assessed through graphical analysis 
using a probability of standard deviance residual distribution against costs and 
a plot of square root of standard deviance residuals against predicted values 
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to confirm the normality and homoscedasticity of model residuals, respectively 
(Montgomery et al., 2012, Jones, 2010). The first plot should present an 
approximate straight line and the second plot should show an equal variability 
across the variables.  
Cohort patients were tested alone in a first model and with audit patients in a 
second model, also the different phases (July 2008 – March 2012 and April 
2012 – January 2016) were analysed separately as shown in Table 6.1. These 
phases represent different epidemiological periods and may incur different 
hospitalisation costs. Moreover, a new diagnostic test (GDH) and the use of 
FDX as a first-line treatment were implemented in 2012 when recruitment of 
phase II patients started. Also, models with both cohort and audit patients (3 
and 4) included only those who had hospitalisation information and costs 
available obtained from information and finance departments. Thus, patients 
with missing data were not considered in the models. All data were analysed 
using STATA version 14.0 (StataCorp LP, College Station, Texas). Statistical 
significance was set at p<0.05. 
 
Table 6.1 Patients included for models performed in this chapters 
Model Phase Year Recruitment Patients 
1 
I  
(epidemic) 
2008-2012 cohort 
257 CDI cases 
139 controls 
2 
II  
(endemic) 
2013-2015 cohort 
78 CDI cases 
57 potential carriers 
164 controls 
3 
I  
(epidemic) 
2008-2012 
cohort 
audit 
633 CDI cases 
132 controls 
4 
II  
(endemic) 
2012-2016 
cohort 
audit 
204 CDI cases 
383 potential carriers 
3,703 controls 
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6.4 Results 
6.4.1 Cohort phase I recruitment 
6.4.1.1 Patient characteristics  
257 CDI cases and 139 antibiotic-associated controls were recruited in phase 
I. Their demographic, clinical and hospitalisation characteristics and laboratory 
results are presented in Table 6.2. CDI case patients were significantly older 
than controls [70 (68-72) vs 65 (62-68) years, p=0.011], but no difference in 
gender was shown between groups and most of the patients were female. 
Disease was severe in 42% (n=107) of cases and CDI recurrence presented 
in 18% (n=47) cases. 
Mean LoS was 39.9 days (95% CI: 34.9-47.2) for cases patients and 23.6 days 
for controls (95% CI: 19.8-29.7, p<0.001) and disease period was higher for 
CDI cases [26.3 (95% CI: 21.5-31.1) vs 14.7 days (95% CI: 11.7-20.0), 
p<0.001]. Time of hospitalisation within 6 months prior to index episode for 
CDI cases was twice as high as for control patients [12.4 (95% CI: 9.6-15.2) 
vs 6.4 (95% CI: 4.5-9.4) days, p=0.001]. Case group presented higher 
mortality rates; there was no significant difference in mortality within 4 weeks 
between case and control group [7% (n=18) vs 4% (n=5), p=0.167), but the 
difference was significant during hospitalisation [9% (n=24) vs 4% (n=5), 
p=0.036] and within 1 year [31.5% (n=81) vs 17% (n=24), p=0.002]. Mean 
unadjusted hospitalisation costs were significantly higher for cases [£6,247 
(95% CI: 5,649-6,942) vs £4,141 (95% CI: 3,689-4,779), p=0.003] when 
omitting outliers (costs model). Hospitalisation costs during 6 months prior to 
index episode (LoS before) were also higher for CDI group than diarrhoea  
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Table 6.2 Patient characteristics of cohort phase I 
 
control (n=139) CDI case (n=257) 
n 
M (95% CI) 
F (P) 
n 
M (95% CI) 
F (P) 
p 
Demographics 
Age (years) 139 65 (62-68) 257 70 (68-72) 0.011 
gender (female, %) 139 78 (56.1) 257 149 (58.0) 0.721 
IMD (score) 135 
39.8 
(36.2-43.4) 
229 
38.0 
(35.4-40.9) 
0.438 
Clinical 
CCI (score) 139 1.2 (1.1-1.5) 256 1.4 (1.2-1.7) 0.270 
mode of acquisition (HCAI, %) 139 102 (73.4) 257 161 (62.6) <0.001 
CDI severity (%) 0  257 107 (41.6) . 
CDI recurrence (%) 0  257 47 (18.3) . 
Hospitalisation 
LoS (days)a 139 
23.6 
(19.8-29.7) 
257 
39.9 
(34.9-47.2) 
<0.001 
disease (days)a 139 
4.75 
(11.7-20.0) 
257 
26.3 
(22.5-32.5) 
<0.001 
pre-test (days)a 139 8.9 (6.9-12.9) 257 
13.6 
(11.4-16.8) 
0.160 
LoS before (days)a 139 6.4 (4.5-9.4) 257 
12.4 
(9.8-15.5) 
0.001 
LoS after (days)a 139 
12.9 
(8.1-30.0) 
257 
10.2 
(7.4-13.5) 
0.508 
Time to death (days) 24 
144 
(107-188) 
81 
111 
(92-134) 
0.182 
Mortality hospitalisation (%) 139 5 (3.6) 257 24 (9.3) 0.036 
4 weeks (%) 139 5 (3.6) 257 18 (7.0) 0.167 
1 year (%) 139 24 (17.3) 257 81 (31.5) 0.002 
Costs index (£)a 132 
£4,726 
(4,082-5,655) 
217 
£7,721 
(6,770-9,343) 
<0.001 
model (£)a 126 
£4,141 
(3,689-4,779) 
203 
£6,246 
(5,649-6,942) 
0.003 
before (£)a 132 
£2,532 
(1,836-3,632) 
204 
£4,153 
(3,164-5,869) 
0.047 
after (£)a 132 
£3,487 
(2,264-6,484) 
204 
£2,680 
(2,096-3,377) 
0.820 
CDI: Clostridium difficile infection, IMD: index of multiple deprivation score, CCI: Charlson 
comorbidity index, HCAI: healthcare-associated infection, LoS: length of stay, LoS before: number 
of hospitalised days 6 months prior to index hospitalisation, LoS after: number of hospitalised days 
6 months post to index hospitalisation, Costs index: costs of index hospitalisation, Costs model: 
hospitalisation costs excluding outliers (5%), Costs before: costs of hospitalisation 6 months prior 
to index hospitalisation, Costs after: costs of hospitalisation 6 months post to index hospitalisation. 
a bias corrected and accelerated confidence intervals 
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6.4.1.1 Multivariable analysis 
A univariate analysis (Table 6.3) was performed to help choose the covariates. 
Age, gender and mortality during hospitalisation were included in all models 
as they were considered potential confounders. Initially, CDI status (case or 
control), age, gender, CCI, mode of acquisition, disease and pre-test periods 
and LoS before, mortality during hospitalisation were included in the model as 
covariates. 
 
Table 6.3 Univariate analysis of cohort phase I patients 
 n β (SE) expβ (95% CI) p 
CDI status 349 0.49 (0.12) 1.63 (1.29-2.07) <0.001 
age 360 -0.00 (0.00) 0.99 (0.99-1.00) 0.068 
gender 358 -0.06 (0.13) 0.94 (0.73-1.21) 0.611 
IMD  345 0.00 (0.00) 1.00 (1.00-1.01) 0.904 
CCI 359 -0.05 (0.04) 0.95 (0.88-1.03) 0.219 
mode of acquisition 360 0.77 (0.12) 2.16 (1.70-2.75) <0.001 
disease 360 0.02 (0.00) 1.02 (1.01-1.02) <0.001 
pre-test 360 0.02 (0.00) 1.02 (1.02-1.03) <0.001 
LoS before 360 0.00 (0.00) 1.00 (1.00-1.01) 0.713 
Mortality hospitalisation 360 0.32 (0.24) 1.38 (0.87-2.20) 0.193 
4 weeks 360 -0.45 (0.25) 0.64 (0.39-1.04) 0.071 
1 year 360 -0.05 (0.14) 0.95 (0.73-1.24) 0.707 
IMD: index of multiple deprivation score, CCI: Charlson comorbidity index, LoS before: 
number of hospitalised days within 6 months prior to index hospitalisation. 
 
The stepwise process to choose the best model is summarised in Table 6.4. 
The variables excluded from the model were mortality during hospitalisation, 
CCI, age, gender and LoS before. 
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Table 6.4 Stepwise process to choose the best model of phase I 
Initial CDI status, age, gender, CCI, mode of acquisition, disease, pre-test, 
LoS before, mortality hospitalisation 
Final CDI status, mode of acquisition, disease, pre-test, LoS before   
Step Residual df AIC BIC p 
1 Initial  323 18.96 -1808.58  
2 mortality hospitalisation 324 18.96 -1814.39 0.915 
3 CCI 325 18.95 -1820.19 0.865 
4 age 326 18.95 -1825.66 0.247 
5 gender 327 18.94 -1831.25 0.344 
6 LoS before 328 18.94 -1836.31 0.080 
CCI: Charlson comorbidity index, Before LoS: number of hospitalised days within 6 months 
prior to index hospitalisation.  
 
Gamma distribution whose variance is proportional to the square of the mean 
was chosen as family and performed with a link log. The relationship between 
outcome and predictors is defined as: E(y)=exp(β0+β1X1+β2X2+…). In this 
model, presence of toxin (expβ=1.17, 95% CI: 1.05-1.31), increased disease 
period (expβ=1.02, 95% CI: 1.02-1.02) and pre-test period (expβ=1.02, 95% 
CI: 1.01-1.02) and health-care associated infections (expβ=1.30, 95% CI: 
1.13-1.49) were associated with higher hospitalisation costs of cohort phase I 
patients (Table 6.5). Between 2008 and 2012, control patients with diarrhoea 
by no confirmed CDI cost £4,924±3,568 while a CDI case patient incurred 
higher cost of £5,761±4,176. 
 
Table 6.5 GLM with family gamma and link log model of cohort phase I 
 β (SE) expβ (95% CI) p 
CDI status 0.16 (0.06) 1.17 (1.05-1.31) 0.006 
mode of acquisition 0.26 (0.07) 1.30 (1.13-1.49) <0.001 
Disease 0.02 (0.00) 1.02 (1.02-1.02) <0.001 
pre-test 0.02 (0.00) 1.02 (1.01-1.02) <0.001 
Before LoS: number of hospitalised days within 6 months prior to index 
hospitalisation.  
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To assess the goodness of fit of the model, the modified Park test was 
performed (Table 6.6) and showed gamma as the best choice for the model. 
Plot of probability of standard deviance residual distribution against costs and 
a plot of square root of standard deviance residuals against predicted values 
(Figure 6.1 and 6.2) were analysed and both normality and homoscedasticity 
of model residuals were confirmed. 
 
Table 6.6 Modified Park test to assess choice 
of family for GLM model of cohort phase I 
 Chi2 P 
Gaussian 42.16 <0.001 
Poisson 5.98 0.014 
Gamma 2.56 0.109 
Inverse Gaussian 31.89 <0.001 
 
 
 
Figure 6.1 Plot of probability of standard deviance residual 
distribution against costs of cohort phase I model 
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Figure 6.2 Plot of square root of standard deviance residual 
against linear prediction of cohort phase I model 
 
6.4.2 Phase II cohort 
6.4.2.1 Patient characteristics  
78 CDI cases, 57 C. difficile carriers and 164 controls were recruited in phase 
II cohort and all patients’ characteristics are summarized in Table 6.7. There 
was no difference on age, gender and IMD score between groups, but CCI 
was higher for cases than carriers and controls [1.9 (95% CI: 1.5-2.3) vs 1.3 
(95% CI: 0.9-1.6) vs 0.5 (95% CI: 0.3-0.6), p<0.001). Mean LoS, disease and 
pre-test periods were similar on cases and carriers and significantly higher 
than controls [LoS 31.8 (95% CI: 23.6-48.8) vs 30.9 (95% CI: 23.3-41.7) vs 8.8 
95% CI: 7.2-10.9) days, p<0.001; disease period 18.4 95% CI: 14.1-24.8) vs 
19.0 (95% CI: 14.4-26.2) vs 8.0 days (95% CI: 6.8-9.8), p<0.001; pre-test 13.4 
(95% CI: 8.8-23.6) vs 11.9 (95% CI: 7.3-17.7) vs 3.2 days (95% CI: 2.3-5.2), 
p=0.003]. Hospitalisation prior to index hospitalisation was higher on cases 
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than other groups [10.8 (95% CI: 7.5-16.6) vs 8.2 (95% CI: 4.4-16.0) vs 2.4 
95% CI: 1.2-4.5), p<0.001]. Although there was no difference in mortality within 
4 week, case patients were more likely to die during hospitalisation [8% (n=6) 
vs 4% (n=2) vs 1% (n=2), p=0.032] and within 1 year [41% (n=32) vs 28% 
(n=16) vs 4% (n=6), p<0.001) compared to potential carriers and control 
patients. 
Excluding outliers, mean unadjusted costs of case group were £6,056 (95% 
CI: 5,228-7,248), potential carrier group £5,745 (95% CI: 4,491-7,713) and 
control group £3,374 (95% CI: 3,000-3,902, p<0.001). Cost of hospitalised 
days within 6 months prior to index hospitalisation were higher for potential 
carriers [£6,363 (95% CI: 3,616-12,868)] compared to cases [£4,922 (95% CI: 
3,251-7,833)] and controls [£1,679 (95% CI: 849-3,806), p<0.001].  
The two instruments to measure health status showed a better health state 
according to patient’s view in control patients than carriers and cases [EQ-5D-
3L 0.661 (95% CI: 0.592-0.729) vs 0.590 (95% CI: 0.499-0.681) vs 0.441 (95% 
CI: 0.334-0.549), p>0.001; EQ-VAS adapted 57.4 (95% CI: 52.1-62.6) vs 56.1 
(95% CI: 50.3-61.9) vs 46.0 (95% CI: 40.4-51.5), p<0.001]. Compared to 
national population norm aged between 55 and 64 years, all groups had lower 
values of EQ-5D-3L (0.804-0.819) and EQ-VAS (81.7). Moreover, results of 
EQ-5D-3L by CDI status are shown on Table 6.8 and CDI cases showed 
higher rates of extreme problems in all dimensions. Usual activities and self-
care were dimensions that CDI cases had more problems while diarrhoea 
control and potential carrier patients had more problems in usual activities and 
pain dimensions.  
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Table 6.7 Patients characteristics of cohort phase II 
 
control (n=164) carrier (n=57) case (n=78)  
n M (95% CI) / F (P) n M (95% CI) / F (P) n M (95% CI) / F (P) p 
Demographics  
Age (years) 164 62 (59-64) 57 59 (54-63) 78 65 (61-68) 0.101 
gender (female, %) 164 85 (51.8) 57 30 (52.6) 78 35 (44.9) 0.550 
IMD (score) 146 34.8 (31.2-38.3) 50 33.9 (28.1-40.9) 75 33.2 (29.1-37.9) 0.870 
Clinical  
CCI (score) 164 0.5 (0.3-0.6) 57 1.3 (0.9-1.6) 78 1.9 (1.5-2.3) <0.001 
mode of acquisition (HCAI, %) 164 106 (64.6) 57 33 (57.9) 78 39 (50.0) 0.032 
CDI severity (%) 0  0  78 34 (43.6) . 
CDI recurrence (%) 0  0  78 7 (9.0) . 
Hospitalisation  
LoS (days)a 164 8.8 (7.2-10.9) 57 30.9 (23.3-41.7) 78 31.8 (23.6-48.8) <0.001 
disease (days)a 164 8.0 (6.8-9.8) 57 19.0 (14.4-26.2) 78 18.4 (14.1-24.8) <0.001 
pre-test (days)a 164 3.2 (2.3-5.2) 57 11.9 (7.3-17.7) 78 13.4 (8.8-23.6) 0.003 
LoS before (days)a 164 2.4 (1.2-4.5) 57 8.2 (4.4-16.0) 78 10.8 (7.5-16.6) <0.001 
LoS after (days)a 164 12.6 (6.0-25.6) 57 10.1 (4.2-27.0) 78 8.7 (4.3-22.6) 0.834 
Time to death (days) 6 122 (55-196) 16 149 (111-202) 32 132 (100-165) 0.777 
Mortality hospitalisation (%) 164 2 (1.2) 57 2 (3.5) 78 6 (7.7) 0.032 
4 weeks (%) 164 2 (1.2) 57 1 (1.8) 78 3 (3.8) 0.391 
1 year (%) 164 6 (3.7) 57 16 (28.1) 78 32 (41.0) <0.001 
Costs index (£)a 164 £3,374 (3,000-3,902) 57 £12,845 (8,922-18,274) 78 £7,778 (6,361-10,8827) <0.001 
model (£)a 84 £3,374 (3,000-3,902) 57 £5,745 (4,491-7,713) 64 £6,056 (5,228-7,248) <0.001 
before (£)a 164 £1,679 (849-3,806) 57 £6,363 (3,616-12,868) 78 £4,922 (3,251-7,833) <0.001 
after (£)a 164 £3,881 (2,351-6,989) 57 £4,683 (2,022-11,101) 78 £2,9998 (1,722-6,152) 0.640 
Economics 
EQ-5D 85 0.661 (0.592-0.729) 48 0.590 (0.499-0.681) 66 0.441 (0.334-0.549) <0.001 
EQ-VAS 85 57.4 (52.1-62.6) 48 56.1 (50.3-61.9) 66 46.0 (40.4-51.5) <0.001 
Medicines  
Fidaxomicin (%) 164 0 57 26 (45.6) 78 51 (65.4) <0.001 
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Table 6.8 Scores of EQ-5D-3L dimensions by CDI status 
Dimension Problems Diarrhoea control Potential carriers CDI cases 
Mobility 
No 55 (49.1) 24 (48.0) 24 (32.4) 
Some 56 (50.0) 25 (50.0) 37 (50.0) 
Extreme 1 (0.9) 1 (2.0) 13 (17.6) 
Self-care 
No 92 (82.1) 40 (80.0) 39 (52.7) 
Some 18 (16.1) 8 (16.0) 15 (20.3) 
Extreme 2 (1.8) 2 (4.0) 20 (27.0) 
Usual 
activities 
No 59 (52.7) 21 (42.0) 17 (23.0) 
Some 44 (39.3) 19 (38.0) 28 (37.8) 
Extreme 9 (8.0) 10 (20.0) 29 (39.2) 
Pain 
Discomfort 
No 36 (31.9) 19 (38.0) 33 (44.6) 
Some 53 (46.9) 24 (48.0) 29 (39.2) 
Extreme 24 (21.2) 7 (14.0) 12 (16.2) 
Anxiety 
Depression 
No 70 (62.5) 27 (54.0) 43 (58.1) 
Some 39 (34.8) 22 (44.0) 23 (31.1) 
Extreme 3 (2.7) 1 (2.0) 8 (10.8) 
 
6.4.2.2 Multivariable analysis 
After univariate analysis (Table 6.9), the covariates used in initial model were 
CDI status, age, gender, CCI, IMD score, mode of acquisition, disease and 
pre-test periods, number of hospitalised days within 6 months prior the index 
hospitalisation and mortality during hospitalisation.  
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Table 6.9 Univariate analysis of cohort phase II patients  
 n β (SE) expβ (95% CI) p 
CDI status 200 0.45 (0.12) 1.57 (1.23-2.01) <0.001 
age 213 -0.00 (0.00) 1.00 (0.99-1.01) 0.618 
gender 213 -0.12 (0.19) 0.89 (0.61-1.30) 0.540 
IMD score 210 -0.01 (0.00) 0.99 (0.98-1.00) 0.021 
CCI 213 0.19 (0.06) 1.21 (1.07-1.37) 0.003 
mode of acquisition 203 0.79 (0.17) 2.21 (1.58-3.10) <0.001 
disease 203 0.04 (0.01) 1.04 (1.02-1.05) <0.001 
pre-test 203 0.03 (0.01) 1.03 (1.01-1.05) <0.001 
LoS before 213 0.00 (0.00) 1.00 (0.99-1.02) 0.419 
Mortality hospitalisation 213 1.12 (0.47) 3.06 (1.22-7.64) 0.017 
4 weeks 213 0.69 (0.57) 2.00 (0.65-6.15) 0.225 
1 year 213 0.56 (0.22) 1.74 (1.12-2.71) 0.013 
EQ-5D-3L 199 -0.32 (0.26) 0.73 (0.44-1.22) 0.226 
EQ-VAS 193 -0.01 (0.00) 0.99 (0.98-1.00) 0.097 
Fidaxomicin 213 0.56 (0.21) 1.75 (1.15-2.65) 0.009 
IMD: index of multiple deprivation score, CCI: Charlson comorbidity index, LoS before: 
number of hospitalised days within 6 months prior to index hospitalisation, EQ-5D-3L: 
EuroQol five dimensions questionnaire, EQ-VAS: EuroQol visual analogue scales. 
 
Table 6.10 Stepwise process to choose the best model of cohort phase II 
Initial CDI status, age, gender, CCI, IMD, mode of acquisition, disease, pre-
test, LoS before, mortality hospitalisation 
Final CDI status, disease, pre-test    
Step Residual df AIC BIC p 
1 Initial  175 18.79 -884.14  
2 IMD 176 18.78 -889.36 0.960 
3 mortality hospitalisation 177 18.77 -894.59 0.920 
4 CCI 178 18.76 -899.77 0.612 
5 gender 179 18.75 -904.90 0.440 
6 age 180 18.74 -910.01 0.408 
7 LoS before 181 18.73 -914.98 0.194 
8 mode of acquisition 182 18.72 -919.82 0.125 
CCI: Charlson comorbidity index, LoS before: number of hospitalised days within 6 
months prior to index hospitalisation, IMD: index of multiple deprivation score.  
 
Table 6.10 shows the stepwise process with all excluded variables from the 
model. Thus, the final model included only CDI status and disease and pre-
test periods. As patients who were treated with FDX had the costs of antibiotic 
 
 
167 
 
treatment added to costs of hospitalisation, the interaction between CDI status 
and use of FDX was used in the model. 
The best model to predict the costs of patients was a GLM with gamma 
distribution and link log and had included CDI status interacting with the use 
of FDX and disease and pre-test periods (Table 6.11). In this model, the 
variables positively associated with outcome were treatment with FDX in a 
GDH positive test (expβ=1.36, 95% CI: 1.09-1.69), treatment with FDX and 
presence of toxin positive test (1.51, 95% CI: 1.30-1.75) and increased 
disease (expβ=1.02, 95% CI: 1.02-1.03) and pre-test (expβ=1.01, 95% CI: 
1.01-1.02) periods. During the period of 2013 and 2015, hospitalisation costs 
were on average £4,227±4,963 for diarrhoea control patients, £4,504±5,288 
for potential carrier patients that did not receive FDX, £5,746±6,746 for 
potential carrier patients who received FDX, £5,011±5,883 for CDI cases not 
treated with FDX and £6,355±7,473 for CDI case patients treated with FDX.  
 
Table 6.11 GLM with family gamma and link log model of cohort phase II 
 β (SE) expβ (95% CI) p 
NF - GDH+/TOX-a 0.06 (0.10) 1.07 (0.88-1.29) 0.514 
F - GDH+/TOX-a 0.31 (0.11) 1.36 (1.09-1.69) 0.005 
NF - GDH+/TOX+b 0.17 (0.10) 1.19 (0.97-1.45) 0.098 
F - GDH+/TOX+b 0.41 (0.08) 1.51 (1.30-1.75) <0.001 
disease 0.02 (0.00) 1.02 (1.02-1.03) <0.001 
pre-test 0.02 (0.00) 1.02 (1.01-1.02) <0.001 
NF: no fidaxomicin treatment, F: Fidaxomicin treatment 
a potential carrier patients b CDI case patients  
 
Gamma distribution was confirmed to be more appropriate family for the model 
when assessing modified Park test (Table 6.12). Normality and 
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homoscedasticity of the residual were also confirmed through graphs of 
goodness of model fit (Figure 6.3 and 6.4). 
 
Table 6.12 Modified Park test to assess choice 
of family for GLM model of cohort phase II 
 Chi2 p 
Gaussian 105.45 <0.001 
Poisson 33.34 <0.001 
Gamma 1.64 0.201 
Inverse Gaussian 10.34 0.001 
 
 
Figure 6.3 Plot of probability of standard deviance residual 
distribution against costs of cohort phase II model 
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Figure 6.4 Plot of square root of standard deviance residual 
against linear prediction of cohort phase II model 
 
 
6.4.3 Phase I cohort and audit patients  
6.4.3.1 Patient characteristics  
As only cases patients were included in the cohort group, this analysis 
included 633 case patients and 132 control patients with available 
hospitalisation costs (Table 6.13). Case patients were older than controls [74 
(95% CI: 73-75) vs 65 (95% CI: 62-68) years, p<0.001) and they stayed 
hospitalised more time during index hospitalisation [LoS 39.1 (95% CI: 36.0-
42.8) vs 21.2 days (95% CI: 17.7-26.1), p<0.001; disease period 23.5 (95% 
CI: 21.5-26.4) vs 12.5 days (95% CI: 10.2-16.8), p<0.001; pre-test period 15.6 
(95% CI: 14.0-17.6) vs 8.6 days (95% CI: 6.6-12.4), p<0.001); and within 6 
months before it 13.1 (95% CI: 11.5-15.4) vs 6.4 (95% CI: 4.5-9.8) days, 
p=0.003]. Mortality rates were higher in case patients in all scenarios: during 
hospitalisation [29% (n=181) vs 4% (n=5), p<0.001]; within 4 weeks [24% 
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(n=155) vs 5% (n=6), p<0.001]; and within 1 year [53% (n=334) vs 17% (n=23), 
p<0.001]. Unadjusted costs of case patients included in the model and 
excluding outliers were more expensive than controls [£6,462 (95% CI: 6,128-
6,883) vs £4,419 (95% CI: 3,900-5,250), p<0.001]. Cost of hospitalisation 
within 6 months prior index hospitalisation were also higher in CDI cases 
[£3,810 (95% CI: 3,300-4,525)] than control patients [£2,532 (95% CI: 1,828-
3,618), p=0.032], but costs of hospitalisation within 6 months post index 
hospitalisation were higher in control patients [£3,487 (95% CI: 2,321-6,440) 
vs £2,027 (95% CI: 1,720-2,494), p=0.010]. 
 
6.4.3.2 Multivariable analysis 
Initially, the model included CDI status, age, gender, mode of acquisition, 
disease and pre-test periods, hospitalisation within 6 months prior to index 
hospitalisation, mortality during hospitalisation and recruitment as covariates 
after univariate analysis (Table 6.14). Recruitment variable was included in the 
initial model as a potential confounder. The process to choose the covariates 
is shown on Table 6.15 and all variables included in the initial model remained 
in the final model. 
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Table 6.13 Patients characteristics of cohort and audit phase I patients 
 control (n=132) case (n=633) 
 
n 
M (95% CI) 
F (P) 
n 
M (95% CI) 
F (P) 
p 
Demographics 
Age (years) 132 65 (62-68) 633 74 (73-75) <0.001 
gender (female, %) 132 77 (58.3) 633 367 (58.0) 0.940 
IMD (score) 129 
39.7 
(35.9-43.6) 
619 
40.8 
(39.1-42.4) 
0.599 
Recruitment (recruits, %) 132 132 (100) 633 217 (34.3) <0.001 
Clinical 
mode of acquisition  
(HCAI, %) 
132 80.0 (60.6) 633 434.0 0.077 
Hospitalisation 
LoS (days)a 132 21.2 (17.7-26.1) 633 39.1 (36.0-42.8) <0.001 
disease (days)a 132 12.5 (10.2-16.8) 633 23.5 (21.5-26.4) <0.001 
pre-test (days)a 132 8.6 (6.6-12.4) 633 15.6 (14.0-17.6) <0.001 
LoS before (days)a 132 6.4 (4.5-9.8) 633 13.1 (11.5-15.4) 0.003 
LoS after (days)a 132 12.9 (7.8-29.9) 633 7.6 (6.2-9.2) 0.212 
   Time to death (days) 23 137 (96-187) 334 72 (62-81) 0.001 
Mortality hospitalisation (%) 132 5 (3.8) 633 181 (28.6) <0.001 
4 weeks (%) 132 6 (4.6) 633 155 (24.5) <0.001 
1 year (%) 132 23 (17.4) 633 334 (52.8) <0.001 
Costs index (£)a 132 
£4,726 
(4,045-5,588) 
633 
£7,710 
(7,141-8,467) 
<0.001 
   model (£)a 128 
£4,419 
(3,9001-5,250) 
599 
£6,462 
(6,128-6,883) 
<0.001 
   before (£)a 132 
£2,532 
(1,828-3,618) 
633 
£3,810 
(3,300-4,525) 
0.032 
   after (£)a 132 
£3,487 
(2,321-6,440) 
633 
£2,027 
(1,720-2,494) 
0.010 
IMD score: index of multiple deprivation score. HCAI: healthcare-associated infection. LoS: length of 
stay, LoS before: number of hospitalised days 6 months prior to index hospitalisation, LoS after: number 
of hospitalised days 6 months post to index hospitalisation, Costs index: costs of index hospitalisation, 
Costs model: hospitalisation costs excluding outliers (5%), Costs before: costs of hospitalisation 6 
months prior to index hospitalisation, Costs after: costs of hospitalisation 6 months post to index 
hospitalisation. 
a bias corrected and accelerated confidence intervals 
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Table 6.14 Univariate analysis of cohort and audit phase I patients 
 
n β (SE) expβ (95% CI) p 
recruitment 776 -0.13 (0.08) 0.87 (0.74-1.02) 0.094 
CDI status 765 0.49 (0.10) 1.63 (1.63-1.64) <0.001 
age 776 -0.01 (0.00) 0.99 (0.99-1.00) 0.004 
gender 776 -0.12 (0.08) 0.88 (0.75-1.04) 0.129 
IMD score 757 0.00 (0.00) 1.00 (1.00-1.00) 0.934 
mode of acquisition 776 0.76(0.08) 2.15 (1.83-2.52) <0.001 
disease 776 0.02 (0.00) 1.02 (1.01-1.02) <0.001 
pre-test 776 0.02 (0.00) 1.02 (1.02-1.02) <0.001 
LoS before 776 0.00 (0.00) 1.00 (1.00-1.00) 0.984 
Mortality hospitalisation 776 -0.65 (0.28) 0.52 (0.30-0.90) 0.021 
4 weeks 776 -0.32 (0.10) 0.72 (0.60-0.87) 0.001 
1 year 776 -0.05 (0.08) 0.95 (0.81-1.11) 0.529 
IMD: index of multiple deprivation score, LoS before: number of hospitalised days 
within 6 months prior to index hospitalisation. 
 
GLM result of model with poisson distribution and link log is shown on Table 
6.16. Presence of toxin (expβ=1.22, 95% CI: 1.21-1.22), recruited patients 
(expβ=1.07 (1.06-1.07), male patients (expβ=0.94, 95% CI: 0.94-0.95), health-
care associated infection (expβ=1.17, 95% CI: 1.16-1.17), increased disease 
(expβ=1.02, 95% CI: 1.02-1.02) and increased pre-test (expβ=1.02, 95% CI: 
1.02-1.02) periods and mortality during hospitalisation (expβ=1.06, 95%: 1.05-
1.06) were associated with higher hospitalisation costs. Between 2008 and 
2012, adjusted costs of diarrhoea control patients were on average 
£5,151±3,353 and cost of CDI cases were on average £6,272±4,082 when 
considering cohort and audit patients. 
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Table 6.15 Stepwise process to choose the best model of cohot and audit phase 
I patients 
Initial CDI status, recruitment, age, gender, mode of acquisition, disease, pre-
test, LoS before, mortality hospitalisation  
Final CDI status, recruitment, age, gender, mode of acquisition, disease, pre-
test, LoS before, mortality hospitalisation    
Step Residual df AIC BIC p 
1 Initial  716 997.47 712932.90  
 
 
Table 6.16 GLM with family poisson and link log model of cohort and audit 
phase I 
 β (SE) expβ (95% CI) p 
CDI status 0.20 (0.00) 1.22 (1.21-1.22) <0.001 
recruitment 0.06 (0.00) 1.07 (1.06-1.07) <0.001 
age 0.00 (0.00) 1.00 (1.00-1.00) <0.001 
gender -0.06 (0.00) 0.94 (0.94-0.95) <0.001 
IMD 0.00 (0.00) 1.00 (1.00-1.00) <0.001 
mode of acquisition 0.15 (0.00) 1.17 (1.16-1.17) <0.001 
disease 0.02 (0.00) 1.02 (1.02-1.02) <0.001 
pre-test 0.02 (0.00) 1.02 (1.02-1.02) <0.001 
LoS before 0.00 (0.00) 1.00 (1.00-1.00) <0.001 
Mortality hospitalisation 0.05 (0.00) 1.06 (1.05-1.06) <0.001 
IMD: index of multiple deprivation, LoS before: number of hospitalised days 
within 6 months prior to index hospitalisation.  
 
Table 6.17 Modified Park test to assess choice of 
family for GLM model of cohort and audit phase I 
 Chi2 p 
Gaussian 17.24 <0.001 
Poisson 0.431 0.512 
Gamma 29.86 <0.001 
Inverse Gaussian 105.53 <0.001 
 
Modified Park test (Table 6.17) showed poisson distribution as the 
recommended family for GLM. Poisson distribution shows a variance 
proportional to mean. Both graphs to assess goodness of model fit (Figure 6.5 
and 6.6) confirmed the normality and homoscedasticity of residuals. 
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Figure 6.5 Plot of probability of standard deviance residual 
distribution against costs of cohort and audit phase I model 
 
 
Figure 6.6 Plot of square root of standard deviance residual 
against linear prediction of cohort and audit phase I model 
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6.4.4 Phase II cohort and audit patients  
6.4.4.1 Patient characteristics  
As cohort and audit patients without hospitalisation data during the index 
episode were not considered, 204 case patients, 383 carrier patients and 
3,703 control patients were included in this analysis. Case group was older 
than carrier and control groups [70 (95% CI: 68-73) vs 66 (95% CI: 64-67) vs 
64 years (95% CI: 64-65), p<0.001) and most of the patients were female. 
Case and carrier patients stayed hospitalised similar time considering the 
whole hospitalisation and the period post C. difficile test but more time 
comparing to control patients [LoS 27.8 (95% CI: 24.1-32.8) vs 29.1 (95% CI: 
25.6-33.9) vs 18.3 days (95% CI: 17.6-19.2), p<0.001; disease period was 
17.1 (95% CI: 14.6-20.2) vs 15.8 (95% CI: 14.0-18.8) vs 11.4 days (95% 
CI:11.0-12.0), p<0.001]. Considering the hospitalised time before toxin test 
and hospitalised period within 6 months prior to index hospitalisation carriers 
stayed more days in hospital than CDI cases and control patients [pre-test 
13.3 (95% CI: 10.9-16.8) vs 10.8 (95% CI: 8.6-14.2) vs 6.9 days (95% CI: 6.5-
7.5), p<0.001); Los before 12.7 (95% CI: 10.3-15.7) vs 11.4 (95% CI: 9.0-14.5) 
vs 5.0 days (95% CI: 4.6-5.4), p<0.001], but hospitalisation period post index 
hospitalisation was higher in potential carrier patients and similar comparing 
control patients and CDI cases [Los after 13.9 (95% CI: 11.0-19.7) vs 7.0 (95% 
CI: 6.4-7.7) vs 6.2 95% CI: 4.2-10.7), p<0.011]. Mortality rate was higher in 
case groups in all scenarios, during hospitalisation [20% (n=40) vs 13% (n=51) 
vs 9% (n=332), p<0.001]; within 4 weeks [20% (n=41) vs 15% (n=59) vs 11% 
(n=399), p<0.001]; and within 1 year [53% (n=107) vs 40% (n=153) vs 28% 
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Table 6.18 Patients characteristics of cohort and audit phase II 
 control (n=3,703) carrier (n=383) case (n=204) 
 
n M (95% CI) / F (P) n M (95% CI) / F (P) n M (95% CI) / F (P) p 
Demographics 
Age (years) 3,703 64 (64-65) 383 66 (64-67) 204 70 (68-73) <0.001 
gender (female, %) 3,703 1,896 (51.2) 383 215 (56.1) 204 115 (56.4) 0.078 
IMD (score) 3,604 40.1 (39.4-40.8) 375 40.6 (38.6-42.8) 195 40.3 (37.1-43.4) 0.928 
Clinical 
mode of acquisition (HCAI, %) 3,703 1,735 (46.8) 383 211.0 (55.1) 204 103.0 (50.5) 0.006 
Hospitalisation 
LoS (days)a 3,703 18.3 (17.6-19.2) 383 29.1 (25.6-33.8) 204 27.8 (24.1-32.8) <0.001 
disease (days)a 3,703 11.4 (11.0-12.0) 383 15.8 (14.0-18.8) 204 17.1 (14.6-20.2) <0.001 
pre-test (days)a 3,703 6.9 (6.5-7.5) 383 13.3 (10.9-16.8) 204 10.8 (8.6-14.2) <0.001 
LoS before (days)a 3,703 5.0 (4.6-5.4) 383 12.7 (10-15) 204 11.4 (9.0-14.5) <0.001 
LoS after (days)a 3,703 7.0 (6.4-7.7) 383 13.9 (11.0-19.7) 204 6.2 (4.2-10.7) <0.001 
Time to death (days) 1,039 92 (86-98) 153 87 (75-102) 107 88 (71-108) 0.760 
Mortality hospitalisation (%) 3,703 332 (9.0) 383 51 (13.3) 204 40 (19.6) <0.001 
4 weeks (%) 3,703 399 (10.8) 383 59 (15.4) 204 41 (20.1) <0.001 
1 year (%) 3,703 1039 (28.1) 383 153 (40.0) 204 107 (52.5) <0.001 
Costs index (£)a 3,703 £6,332 (6,039-6,442) 383 £8,091 (7,120-9,228) 204 £7,130 (6,338-8,301) <0.001 
model (£)a 3,396 £4,128 (4,023-4,246) 349 £5,471 (5,075-5,980) 190 £6,015 (5,544-6,592) <0.001 
before (£)a 3,703 £2,261 (2,108-2,428) 383 £4,865 (4,001-6,014) 204 £4,017 (3,275-5,324) <0.001 
after (£)a 3,703 £2,413 (2,248-2,614) 383 £4,041 (3,209-5,324) 204 £2,248 (1,694-3,187) 0.004 
Medicines         
   Fidaxomicin 3,703 0 383 128 (33.4) 204 130 (63.7) <0.001 
IMD score: index of multiple deprivation score, HCAI: healthcare-associated infection, LoS: length of stay, LoS before: number of hospitalised days 
6 months prior to index hospitalisation, LoS after: number of hospitalised days 6 months post to index hospitalisation, Costs index: costs of index 
hospitalisation, Costs model: hospitalisation costs excluding outliers (5%), Costs before: costs of hospitalisation 6 months prior to index 
hospitalisation, Costs after: costs of hospitalisation 6 months post to index hospitalisation. a bias corrected and accelerated confidence intervals. 
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(n=1,039), p<0.001]. Unadjusted hospitalisation costs omitting outliers, were 
more expensive in case group compared to potential carrier patients and 
diarrhoea controls [£6,015 (95% CI: 5,544-6,592) vs £5,471 (5,075-5,980) vs 
£4,128 (95% CI: 4,023-4,246), p<0.001]. Cost of hospitalisation 6 months prior 
index episode were higher for carrier patients [£4,865 (95% CI: 4,001-6,014)] 
compared to CDI cases [£4,017 (95% CI: 3,275-5,324)] and controls [£2,261 
(95% CI: 2,108-2,428), p<0.001] and costs of hospitalisation 6 months post 
index episode were similar in CDI cases [£2,248 (95% CI: 1,694-3,187)] and 
diarrhoea controls [£2,413 (95% CI: 2,248-2,614)] but higher for potential 
carrier group [£4,041 (95% CI: 3,209-5,324), p=0.004]. All characteristics are 
shown on Table 6.18. 
 
6.4.4.2 Multivariable analysis 
The initial model included CDI status, disease and pre-test periods, 
hospitalisation time prior to index hospitalisation, age, gender, mortality during 
hospitalisation, IMD score, mode of acquisition and recruitment variables. 
Univariate analysis was performed to help this choice (Table 6.19). Only 
recruitment variable was dropped from the initial model (Table 6.20). 
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Table 6.19 Univarite analysis of cohort and audit phase II patients 
 n β (SE) expβ (95% CI) p 
recruitment 4,358 0.09 (0.10) 1.09 (0.90-1.33) 0.387 
CDI status 4,290 0.12 (0.05) 1.13 (1.03-1.23) 0.010 
age 4,358 -0.01 (0.00) 0.99 (0.99-1.00) <0.001 
gender 4,358 -0.18 (0.04) 0.84 (0.77-0.91) <0.001 
IMD score 4,240 -0.01 (0.00) 0.99 (0.99-0.99) <0.001 
mode of acquisition 4,344 1.00 (0.04) 2.73 (2.55-2.93) <0.001 
disease 4,344 0.03 (0.00) 1.03 (1.02-1.03) <0.001 
pre-test 4,344 0.03 (0.00) 1.04 (1.03-1.04) <0.001 
LoS before 4,358 0.00 (0.00) 1.00 (1.00-1.00) 0.920 
mortality hospitalisation 4,358 -0.50 (0.20) 0.61 (0.41-0.90) 0.014 
4 weeks 4,358 -0.23 (0.07) 0.79 (0.69-0.91) 0.001 
1 year 4,358 0.00 (0.05) 1.00 (0.91-1.10) 0.975 
Fidaxomicin 4,358 0.26 (0.09) 1.30 (1.08-1.56) 0.006 
IMD score: index of multiple deprivation score, LoS before: number of hospitalised days 
within 6 months prior to index hospitalisation.  
 
Table 6.20 Stepwise process to choose the best model of cohot and audit phase II 
patients 
Initial CDI status, recruitment, age, gender, IMD, mode of acquisition, 
disease, pre-test, LoS before, mortality hospitalisation  
Final CDI status, age, gender, IMD, mode of acquisition, disease, pre-test, 
LoS before, mortality hospitalisation   
Step Residual df AIC BIC p 
1 Initial  3,923 952.19 3675241  
2 recruitment 3,924 952.19 3675235 0.171 
 
 
According to the best model chosen (Table 6.21) with poisson distribution and 
link log, male patients (expβ=0.96, 95% CI: 0.96-0.96), healthcare-associated 
infection (expβ=1.10, 95% CI: 1.10-1.10), increased disease (expβ=1.02, 95% 
CI: 1.02-1.02) and pre-test (expβ=1.02, 95% CI: 1.02-1.02) periods and 
mortality during hospitalisation (expβ=1.10, 95% CI: 1.10-1.10) were 
associated with hospitalisation costs of cohort and audit phase II patients. 
Also, potential carrier patients (expβ=0.98, 95% CI: 0.97-0.98) and CDI cases 
(expβ=0.95, 95% CI: 0.94-0.95) not treated with FDX were negatively 
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associated with costs and potential carrier (expβ=1.28, 95% CI: 1.28-1.28) and 
cases (expβ=1.34, 95% CI: 1.34-1.34) who received FDX had a positive 
association. 
 
Table 6.21 GLM with family poisson and link log model of cohort and audit 
phase II 
 β (SE) expβ (95% CI) p 
    NF - GDH+/TOX-a -0.02 (0.00) 0.98 (0.97-0.98) <0.001 
    F - GDH+/TOX-a 0.25 (0.00) 1.28 (1.28-1.28) <0.001 
NF - GDH+/TOX+b -0.05 (0.00) 0.95 (0.94-0.95) <0.001 
F - GDH+/TOX+b 0.29 (0.00) 1.34 (1.34-1.34) <0.001 
age 0.00 (0.00) 1.00 (1.00-1.00) <0.001 
gender -0.04 (0.00) 0.96 (0.96-0.96) <0.001 
IMD score -0.00 (0.00) 1.00 (1.00-1.00) <0.001 
mode of acquisition 0.16 (0.00) 1.17 (1.17-1.17) <0.001 
disease 0.02 (0.00) 1.02 (1.02-1.02) <0.001 
pre-test 0.02 (0.00) 1.02 (1.02-1.02) <0.001 
LoS before -0.00 (0.00) 1.00 (1.00-.100) <0.001 
Mortality hospitalisation 0.09 (0.00) 1.10 (1.10-1.10) <0.001 
NF: no fidaxomicin treatment, F: Fidaxomicin treatment, IMD: index of multiple 
deprivation score, LoS before: number of hospitalised days within 6 months prior 
to index hospitalisation.  
a carrier patients b CDI case patients 
  
Adding audit patients to the analysis, diarrhoea control patients had adjusted 
hospitalisation costs on average of £4,251±2,880, potential carrier patients not 
treated with FDX of £4,145±2,808, potential carrier patients treated with FDX 
of £5,448±3,692, CDI cases that did not received FDX treatment of 
£4,027±2,728 and CDI who received FDX of £5,694±3,859 between 2012 and 
2016. Chi-square of modified Park test (Table 6.22) showed poisson 
distribution as the best choice. Although there are still some outliers in the 
model, both graphs to assess goodness of model fit (Figure 6.7 and 6.8) 
confirmed the normality and homoscedasticity of the residuals. We chose not 
to remove more outliers as high cost patients are common and should be 
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considered in the model. Table 6.23 summarises all hospitalisation costs found 
in all 4 models. 
 
Table 6.22 Modified Park test to assess choice of 
family for GLM model of cohort and audit phase II 
 Chi2 p 
Gaussian 172.30 <0.001 
Poisson 8.88 0.003 
Gamma 51.37 <0.001 
Inverse Gaussian 172.30 <0.001 
 
Table 6.23 Summary of mean adjusted costs for model performed 
Model Patients 
CDI 
cases 
Potential 
carriers 
Controls Addition
al costs 
1 Cohort phase I £5,761 . £4,924 £837 
2 
Cohort phase II 
(no fidaxomicin) 
£5,011 £4,504 £4,227 £784 
3 
Cohort phase II 
(fidaxomicin) 
£6,355 £5,746 £4,227 £2,128 
3 Cohort and audit phase I  £6,272 . £5,151 £1,121 
4 
Cohort and audit phase II  
(no fidaxomicin) 
£4,027 £4,145 £4,251 -£224 
4 
Cohort and audit phase II 
(fidaxomicin) 
£5,694 £5,448 £4,251 £1,443 
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Figure 6.7 Plot of probability of standard deviance residual 
distribution against costs of cohort and audit phase II model 
 
 
Figure 6.8 Plot of square root of standard deviance residual 
against linear prediction of cohort and audit phase II model 
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6.4.5 Costs per year 
Using additional costs of CDI cases from the last two models, considering FDX 
as first-line treatment and data from PHE (PHE, 2017), we could estimate that 
between April 2007 and March 2016 RLBUHT spent additional £1.6 million, 
Merseyside hospitals £6 million and UK hospitals £124 million to treat 1,423, 
5,182 and 106,098 CDI patients (Table 6.24). 
 
Table 6.24 Number of CDI cases and additional costs of CDI at RLBUHT, 
Merseyside hospitals and England hospitals between 2007 and 2016. 
 
RLBUHT Merseyside England 
Year n costs n costs n Costs 
2007 512 £573,952 1,628 £1,824,988 33,434 £37,479,514 
2008 347 £388,987 1,185 £1,328,385 19,927 £22,338,167 
2009 220 £246,620 688 £771,248 13,220 £14,819,620 
2010 105 £117,705 457 £512,297 10,417 £11,677,457 
2011 64 £71,744 308 £345,268 7,689 £8,619,369 
2012 53 £59,413 224 £251,104 5,980 £6,703,580 
2013 50 £72,150 234 £337,662 5,034 £7,264,062 
2014 43 £62,049 231 £333,333 5,233 £7,551,219 
2015 29 £41,847 227 £327,561 5,164 £7,451,652 
Total 1,423 £1,634,467 5,182 £6,031,846 106,098 £123,904,640 
RLBUHT: Royal Liverpool and Broadgreen University Hospitals Trust  
 
6.5 Discussion 
We estimated costs of cohort and audit patients tested positive or negative for 
C. difficile toxin during 2008-2012 and cohort and audit CDI case patients, 
patients tested positive for GDH but negative for C. difficile toxin and control 
patients during 2012 and 2016. During the first phase, CDI cases mean 
unadjusted costs were £6,246 and control patients mean costs were £4,419, 
in the second phase, hospitalisation costs of CDI cases were £6,015, carrier 
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patients £5,741 and control patients £4,128. GLM models showed that during 
phase I, cases patients were between 17% (£5,761 vs £4,924 for cohort 
patients) and 22% (£6,272 vs £5,151 for audit and cohort patients) more 
expensive than controls. During phase II carrier patients that received 
standard treatment were 2% less expensive (£4,145 vs £4,251 for audit and 
cohort patients) to 7% more expensive (£4,504 vs £4,227 for cohort patients) 
compared to controls, but potential carrier patients treated with FDX were 28% 
(£5,448 vs £4,251 for audit and cohort patients) to 36% (£5,746 vs £4,227 for 
cohort patients) more expensive than control patients. Case patients not 
treated with FDX were 5% less expensive (£4,027 vs £4,251 for cohort and 
audit patients) and 19% more expensive (£5,011 vs £4,227 for cohort patients) 
compared to diarrhoea controls. Lastly, patients with a positive toxin test and 
treated with FDX had costs 34% (£5,694 vs £4,251 for audit and cohort 
patients) and 51% (£6,355 vs £4,227 for cohort patients) higher than control 
patients. Although CDI cases patients have incurred higher costs compared to 
other patients, it was not possible to find a trend when considering different 
recruitment groups (cohort or audit) and different phases (I and II). However, 
when audit patients were included, additional costs were higher than only 
cohort patients and during phase II costs of diarrhoea control patients were on 
average £800 lower compared to phase I. 
Total costs of CDI treatment were previously assessed and were between 
$9,822 and $12,854 (equivalent to £5,756 and £7,532 in 2008) compared to 
$6,950 and $9,008 (equivalent to £4,073 and 5,279 in 2008) for controls in 13 
CDI economic studies considering the currency 2008 US dollars (Ghantoji et 
al., 2010). In 2014, another review (Gabriel and Beriot-Mathiot, 2014) was 
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published on hospitalisation stay and costs attributable to CDI where seven 
studies were identified and mean costs for healthcare associated infections 
were between $2,454 and $29,000 in 2013 US dollars (equivalent to £1,562 
to £18,469 in 2013). Also, a recent systematic review by Nanwa et al (Nanwa 
et al., 2015) has identified 45 cost of illness (COI) studies from seven different 
countries where mean attributable costs in 2014 US dollars per patient ranged 
from $8,911 to $30,049 (equivalent to £5,458 to £18,408 in 2014). The only 
UK study published and identified in all these three reviews was conducted in 
1996 including 50 CDI cases and 92 control patients and case patients were 
around £4,000 more expensive than controls (Wilcox et al., 1996). In 2017 
another study was published with a UK cohort and median costs for recurrence 
cases was £7,539 and for first cases was £6,294 in GBP 2014. Both UK 
studies did not use the same methodology to calculate costs as our study. The 
first study only considered the average difference between LoS to calculate 
costs, while the second study calculate costs based on hospital bed days, use 
of medicines, laboratory tests, procedures and intravenous support in 28 days 
of hospitalisation. 
Despite costs were statistically significant higher in case than control patients 
in our study and in the literature, studies have different methodologies to 
perform economic analyses, different currency and cost calculation and also 
different population and samples. Thus, the average costs are just applicable 
for the respective study and it is not possible to make meaningful comparisons 
between studies and countries (Gabriel and Beriot-Mathiot, 2014, Nanwa et 
al., 2015). For more reliability and reproducibility, Gabriel and Nanwa studies 
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(Nanwa et al., 2015, Gabriel and Beriot-Mathiot, 2014) suggest the 
development of guidelines and the use of standard COI methodology.  
LoS is also a common outcome variable in COI studies and usually strongly 
related to costs of hospitalisation. In our study, during phase I mean LoS of 
CDI cases was 39 days while mean LoS of control patients was 21 days 
(p<0.001). On phase II, mean LoS of CDI cases and control patients were 
lower compared to phase I and was around 28 days and 18 days, respectively. 
Potential carrier patients stayed hospitalised around 29 days. Similar time of 
hospitalisation were found by Ghantoji et al (Ghantoji et al., 2010) where mean 
LoS for cases was 24 days (10-46 days) and for controls was 11 days (4-25 
days). In the Gabriel et al review (Gabriel and Beriot-Mathiot, 2014) LoS were 
lower and ranged between 3 and 21 days for CDI cases. In the UK study, 
mean LoS was higher for both cases (46 days) and controls (25 days) in 
1994/1995 (Wilcox et al., 1996) and in 2013/2014 the median LoS was 21 days 
for recurrent cases and 16 days for first cases (Wilcox, 2017). The decrease 
in hospitalisation period showed in phase I groups compared to phase II 
groups could be related to the transition from an epidemic period to an 
endemic period, to successful prevention and controlling measures 
implemented by the hospital during the years, to the implementation of a new 
diagnostic algorithm in 2012 or to the use of FDX as CDI treatment since 2011. 
LoS is an important marker to be followed and assessed as it is not only a 
consequence of medical conditions but also a risk factor for the development 
of several diseases including CDI, as it will determine time of exposure to 
microorganisms (Cohen et al., 2010).  
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The cost of FDX treatment was added to the hospitalisation costs and showed 
an increase of 27 to 41% in CDI case costs and an increase of 28 to 31% in 
potential carrier group. Disease and pre-test periods and healthcare-
associated infection were predictors of costs in the models, for every 
hospitalised day during these periods the cost increased 2% and healthcare-
associated infections increased costs between 17 to 30% compared to 
community-acquired infection. When we included audit patients in the model 
more variables became predictors of costs, as gender, mortality during 
hospitalisation, age, hospitalisation within 6 months prior to index 
hospitalisation and IMD score. Male patients were between 4 to 6% more 
expensive than females, patients who died during hospitalisation were 6 to 
10% more expensive, age, IMD score and hospitalisation prior index 
hospitalisation changed an insignificant amount to the costs. 
C. difficile is still a problem for healthcare settings and systems because of its 
burden and the difficulty to treat (Trafford, 2017). Different studies found that 
annual costs of CDI cases in the US were around $1.1 billion (equivalent to 
£680 million) in 1999 (Kyne et al., 2002), $496 million (equivalent to £270 
million) (McGlone et al., 2012) and $4.8 billion (equivalent to £2.6 billion) in 
2008 (Dubberke and Wertheimer, 2009) and $6.3 billion (equivalent to £4.1 
billion) in 2015 (Zhang et al., 2016). Annual costs to Canadian Society in 2012 
was estimated in CAD$280 million (equivalent to £177 million) (Levy et al., 
2015). European Hospital and Healthcare Federation (HOPE, 2013) estimated 
a total cost of €3 billion (equivalent to £2 billion) in 2006 and around €3.7 billion 
(equivalent to £3.1 billion) in 2013 for the European Union. Estimated annual 
costs in the UK decreased from £210 million in 2007/2008 to £29 million in 
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2016/2017. Although the number of cases has been decreasing during the 
years and it may have reached a constant incidence in the UK and Merseyside 
hospitals in the last 3 years, RLBUHT on the other hand remains decreasing 
CDI cases and in 2016/2017 was considerably below target (29 of 44) 
confirming the effectiveness of intervention measures adopted by the site. 
This study has some limitations. Firstly, as with the majority of COI studies of 
CDI, our study does not calculate indirect costs. Most of the studies have 
considered only direct costs and include mainly medical costs, such as 
hospitalisation, health care professionals, procedures, laboratory test and 
medicines. On Nanwa review (Nanwa et al., 2015), only one identified study 
has calculated indirect costs and no indirect cost analysis was identified in 
Ghatoji review (Ghantoji et al., 2010).  
Also, it was not possible to collect patient-level information and costing system 
(PLICS) data as we could not have access to the database. Thus, we have 
used HRG codes and national tariff payment system that is not accurate as it 
does not represent a real cost of each patient during hospitalisation period, but 
it is an average cost of a code given to the patient according to all diagnostic 
and procedures performed in this period not considering the high cost of FDX, 
for example. Moreover, not all patients had available hospitalisation 
information and for this reason they were excluded from the analysis, however 
they might have not incurred costs for the setting during the episode as there 
are no register of their hospitalisations on the information department system.  
Finally, our findings are not applicable to other hospitals outside the UK, as 
costs of hospitalisation are entirely related to the healthcare system. Thus, a 
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standardised method should be developed and implemented to allow 
comparison of different studies in different hospitals and countries. 
In conclusion, hospitalisation costs were related to CDI status, patients 
positive for C. difficile toxin and patients positive for GDH but negative for C. 
difficile toxin were around 35% and 10% more expensive than control patients, 
respectively. Although we can find similar results in the literature, it is not 
possible to compare studies as the methodologies were different. Also, it is 
important to highlight that our study use hospitalisation costs obtained through 
codes of diagnostic and procedures performed and did not consider non-
medical and indirect costs. 
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Chapter 7 
Final discussion 
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CDI is still a challenge for healthcare settings and healthcare systems. 
Although the number of cases in the UK has been decreasing over the years 
since the well-publicised outbreaks, there is still a need to understand the 
disease. This thesis has considered different clinical and economic 
approaches to CDI, including clinical outcomes, diagnosis algorithms and 
contribution of patients with discordant test results, stratification of disease 
using a biomarker, cost-effectiveness of interventional measures and costs of 
hospitalisation.  
The outbreak caused by the RT027 strain put healthcare settings on alert. In 
2008, we started recruiting CDI case and diarrhoea control patients to better 
understand the disease (Chapter 2). The recruitment occurred during 
epidemic and endemic phases. This thesis has brought together information 
from a large number of patients, and supplemented this with a clinical audit to 
increase the number of patients studied and information available. The audit 
has confirmed that inclusion and exclusion criteria utilised for study recruitment 
produced a cohort which was not representative of overall patients tested for 
C. difficile in the setting. The most important aspect was that the patients in 
the audit were more debilitated and thus were not recruited largely because of 
refusal. Mortality was higher in non-recruited patients at all time points and 
reached more than 25% during hospitalisation and within 4 weeks and more 
than 50% within 1 year after CDI diagnosis. Thus, the inclusion of patients 
from the clinical audit could also increase the strength of the study by 
minimising the selection bias of the cohort recruitment. 
Diagnostic methods have been improving and becoming more specific and 
sensitive for identifying CDI cases. In this thesis, we have shown that the 
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introduction of a new assay was cost-saving considering the unnecessary use 
of FDX to treat non-toxigenic (PCR-) patients (Chapter 3). This is an important 
finding as there is a debate about the best method to diagnose CDI. Whist UK 
(PHE, 2013) and Europe (Crobach et al., 2016) recommend the use of a 2-
step algorithm, in the US NAAT has been commonly used as a single test 
(Fang et al., 2017). Both approaches have advantages and disadvantages and 
a consensus may be difficult to achieve, and choice is likely to be dominated 
by local expertise, availability of equipment and financial resources.  
Clinical outcomes of patients were assessed (Chapter 3); carrier patients 
(GDH+/TOX-/PCR+) and case patients had similar clinical outcomes, such as 
mortality rates, time to discharge and costs in the multivariable analysis 
considering only toxigenic strains. In these models, the presence of a toxin 
positive result was only significant for CDI severity. When considering all 
patients, carriers and cases had worse outcomes when compared to diarrhoea 
control patients.  
Currently, no prognostic test for the prediction of clinical outcomes in CDI 
patients is available. This is important mainly to avoid recurrence, as 
recurrence rate is about 25% after the first episode. Although some studies 
(Rao et al., 2013, Dazley et al., 2015) have been published showing a positive 
association between PCT levels and CDI severity, this is the first study, using 
a bigger sample size, to assess mortality rates, recurrence rates and time to 
discharge in CDI patients and diarrhoea control patients (Chapter 4). High 
levels of serum PCT were associated with CDI severity, long-term mortality 
and CDI diagnosis and were associated with increased risk of delayed 
discharge in some scenarios. However, a positive result for TOX was not a 
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predictor of any outcome when considering only PCT tests performed within 3 
days after toxin test.  
One of the main challenges is to control and prevent the transmission of 
bacteria. Interventional measures are mainly focused on reducing the spread 
of the bacteria and reducing the chance of developing the disease through the 
use of antibiotics. Nevertheless, the majority of studies included in the 
systematic review (Chapter 5) were based on treatment of disease and 
prevention of recurrences. Screening during admission, vaccination, treatment 
with FDX and FMT were interventions identified as cost-effective measures for 
CDI considering papers published until 2015.  
CDI poses a significant financial burden for healthcare systems worldwide. In 
our setting, costs of hospitalisation, as expected, were higher for CDI patients 
compared to diarrhoea control patients (Chapter 6). Recruitment status (cohort 
or audit) was indifferent but epidemic phase (phase I) had higher costs than 
endemic phase (phase II) patients, even with the addition of FDX costs for 
phase II patients treated with this antibiotic. Predictors of costs were duration 
of disease and pre-test periods and healthcare-associated infection. Gender, 
age, mortality during hospitalisation, time of hospitalisation within 6 months 
before index hospitalisation and IMD score were also significant predictors 
when including non-recruited patients. Last year around £86,000 was spent to 
treat 29 cases, a reduction of more than 95% compared with the peak of the 
outbreak. 
As national and international guidelines have been updated according to 
epidemiological circumstances and healthcare settings have subsequently 
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altered their policies based on these recommendations, some of these 
changes have affected the work described in the chapters, such as group 
categorisation based on diagnostic tests, and use and contribution of 
antibiotics to clinical outcomes. The real hospitalisation cost of each patient 
(PLICS) was not possible to obtain and costs of hospitalisation used for all 
analysis were based on HRG codes and national tariff. This value may not 
reflect a patient infected by C. difficile, as some interventions (antibiotics and 
isolation ward) are more expensive than for a standard patient or patients with 
diarrhoea. Also, 2016/2017 national tariff prices were based on costs from the 
2011/2012 reference costs (NHS England, 2016). These costs are collected 
every financial year and refer to the average unit cost of healthcare provided 
and are adjusted according to the resource allocations based on differences 
between geographical locations of healthcare providers to compose the 
national tariff (NHS England, 2016). Moreover, not all patients recruited as a 
CDI case had an International Classification of Diseases (ICD)-10 code for 
CDI, and costs were associated with the whole hospitalisation period and not 
only with the CDI episode.  
Studies conducted using the same phase I cohort found that low levels of 
serum mannose-binding lectin was associated with CDI recurrence (Swale et 
al., 2014a), but did not find a clinical association between levels of the 
biomarkers faecal calprotectin and lactoferrin and CDI severity (Swale et al., 
2014b) and between faecal interleukin 8 and CDI recurrence (Miyajima et al., 
2014). Moreover, when considering patients infected by RT027 strain between 
2008 and 2010, genome-based infection tracking was considered a relevant 
tool to monitor persistence and transmission of the bacteria (Kumar et al., 
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2016). This same tool was used in other hospitals and confirmed its relevance 
to infection control when assessing C. difficile transmission and new cases 
linked to previous ones (Eyre et al., 2017).  
A study published this year (Dingle et al., 2017) found that the antibiotic 
stewardship introduced to restrict the use of fluoroquinolones in 2007 was a 
central strategy to decrease the number of HCAI and CAI cases after the 
outbreak in England. This decrease was higher than 75% considering all 
cases, however the proportion of CAI cases has been increasing during the 
years (Gupta and Khanna, 2014) and became higher than HCAI in England 
(PHE, 2017). Moreover, genome-sequencing studies have shown that only a 
low rate of cases were associated with a previous case (Eyre et al., 2017, 
Kumar et al., 2016), indicating that the problem may be wider. Airborne 
transmission, water and food contamination and asymptomatic patients are 
described in the literature as potential sources of bacteria (Gupta and Khanna, 
2014). Thus, studies on interventions to control and prevent transmission 
through these sources should also be undertaken. Potential carriers and 
asymptomatic patients may also play an important role on the spread of 
bacteria and for this reason the identification of those patients may be 
considered. Indeed, a CEA included in the systematic review concluded that 
the screening of all patients during hospital admission was a cost-effective 
strategy (Bartsch et al., 2012a). 
The pattern of FDX use is variable and each hospital can adopt a different 
protocol for its use (Goldenberg et al., 2016). Its use as a first line treatment 
for all CDI cases was a response from RLBUHT to C. difficile targets and 
financial penalties implemented by the UK government as an alternative to 
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control CDI cases (Walker et al., 2008). Considering the recurrence rates and 
short-term mortality, FDX showed superior results when used as a first-line 
treatment compared to the use in selected episodes or recurrences 
(Goldenberg et al., 2016). Financially, it was a good choice as penalties could 
cost around £50,000 for every case exceeding targets, and this antibiotic is 
known to decrease recurrence rates, however, its use regardless of the CDI 
severity or presence of toxin positive result is not recommended by PHE (PHE, 
2013). Although CEA studies selected in the systematic review have not 
shown its cost-effectiveness as a first option (Wagner et al., 2014, Bartsch et 
al., 2013), some recent studies have shown positive results. For instance, it 
was cost-saving when considering 65 patients treated in a London hospital 
(Nesnas et al., 2014), and in a study comparing 49 patients treated with FDX 
with 46 patients treated with VAN in the US (Gallagher et al., 2015). 
Additionally, it has been shown to be cost-saving and cost-effective in patients 
with increased recurrence risk (Watt et al., 2016). 
New findings and advances to improve CDI and its implications have been 
published worldwide. Candidate vaccines have shown promising results in 
preventing CDI. Pfizer (PF-06425090) and Valneva (VLA84) are developing 
vaccines, both currently in phase 3 trials, with estimated study completion 
dates later than 2020 (Pfizer, 2017, Kociolek and Shulman, 2017), however, a 
clinical trial on toxoid vaccine H-030-012 (Cdiffense) from Sanofi Pasteur was 
stopped as an interim trial concluded that the probability for success would be 
low (FierceFarma, 2017). Although results and information are still not 
available, a simulation model found that vaccination was a cost-effective 
strategy to prevent recurrence when costs were below $800 and efficacy 
 
 
196 
 
above 50% (Lee et al., 2010). Other antibiotics and biologic therapies such as 
cadazolid, ridinilazole and bezloxumab are also being studied. Cadazolid is 
currently in phase 3 trial with estimated study completion in 2021 (Actelion, 
2017), patients treated with this antibiotic in phase 2 showed low baseline 
minimum inhibitory concentration (MIC) values compared to VAN and was 
similar compared to FDX regardless of the clinical outcomes or C. difficile 
strain (Gerding et al., 2016). Recently, Summit Therapeutics was awarded with 
$62 million to develop ridinilazole (SMT19969) (Alliance News, 2017), an 
antibiotic in phase 2 trials that has already been shown to be superior to VAN 
when considering clinical cure and recurrence within 30 days (Vickers et al., 
2017). Bezlotoxumab, a human monoclonal antibody, on the other hand, was 
approved and launched in 2017 to prevent CDI recurrence when used in 
combination with standard antibiotic treatment. NICE has already published 
an evidence summary of the medicine (NICE, 2017) and the average cost of 
a single intravenous dose is £2,470. Recent advances have also been made 
in CDI diagnosis (Pollock, 2016), ultrasensitive assays have shown promising 
results as they can diagnose CDI with high sensitivity and specificity and could 
also have prognostic value (Song et al., 2015, Chromy et al., 2017). A CEA 
study showed that it was more cost-effective to invest in prevention by isolating 
patients than to invest in a more expensive diagnostic method by exchanging 
a two-step algorithm by a PCR assay considered the gold standard in this 
study (Schechner et al., 2017). 
There is a need for more studies to confirm the results found in this thesis. 
PCT measures should be performed at different time points to better 
understand PCT kinetics in CDI and, in the future, implement it as a routine 
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test to early stratification and prognosis of the disease if found to be clinically 
effective. The use of PLICS data can provide a more accurate and reliable 
cost of hospitalisation for each patient and comparison between CDI cases 
and diarrhoea controls may become more meaningful. Indirect costs should 
also be part of the calculation. A comparison between costs obtained by HRG 
codes and PLICS data may be useful to validate our results and also to 
validate this first method called payment by results implemented in the last 
decade that uses HRG codes to pay NHS Trusts for each hospitalisation 
(Appleby et al., 2012). Economic evaluation studies on intervention measures, 
other than the use of antibiotics, should be conducted as prevention and 
control are still the main and more important strategy to avoid new cases. 
Moreover, a CEA could be conducted using cost and quality of life data 
obtained from phase II cohort patients to adapt models and results to the local 
reality. Recently, a health-related quality of life questionnaire (HROOL) 
specific for CDI (Cdiff32) was developed and validated (Garey et al., 2016) 
and its use can overcome the limitation of published papers that used utility 
information for non-infectious diarrhoea.  
Furthermore, patient care and quality of life should of course be a priority for 
the research being undertaken. A study (Madeo and Boyack, 2010) 
interviewed some patients to identify their experiences and perceptions, and 
found that the main points are negative physical effects including pain, loss of 
appetite and energy, inability to control the bowel function caused by 
diarrhoea, understanding of illness as levels of understanding varied among 
patients and some of them were concern about the disease, and social and 
mental consequences including anxiety, depression, mood changes and 
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issues with privacy and dignity. In addition, many patients are now sharing 
their experiences in online forums for this disease, it is possible to comprehend 
their frustrations and insecurities, as it is a debilitating disease, bringing a 
feeling of shame and embarrassment and having an impact on the physical, 
psychological, social and financial aspects of life. It is important to give patients 
all the information and support they need. Patient and public education is 
another strategy to be considered by healthcare settings and healthcare 
systems as a lack of knowledge and information could be a reason for 
transmission of not only C. difficile but also of other infectious disease. A 
recently published study concluded that there is a demand for videos about 
CDI, mainly on modes of transmission and prevention, also, governmental 
agencies should use social media to inform and access a higher percentage 
of the population (Basch et al., 2017). CDI is still considered a problem 
worldwide, and research on diagnosis, treatment and prevention is important 
to reduce the morbidity and mortality associated with the disease, and its 
associated costs. 
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3: Multivariable analysis of PCT (log10) tested within 2 
days after toxin test as covariate and CDI diagnosis as 
outcome 
<2 
variable Odds ratio 95% CI p 
PCT (log10) 1.63 1.04-2.58 0.035 
age 1.03 1.00-1.06 0.065 
  
4: Multivariable analysis of PCT (log10) tested within 3 days 
after toxin test as covariate and CDI diagnosis as outcome 
<3 
variable Odds ratio 95% CI p 
PCT (log10) 1.19 0.98-1.44 0.075 
age 1.03 1.01-1.05 <0.001 
WCC 1.03 1.00-1.07 0.050 
 
5: Multivariable analysis of PCT (log10) tested within 4 days 
after toxin test as covariate and CDI diagnosis as outcome 
<4 
variable Odds ratio 95% CI p 
PCT (log10) 1.13 0.97-1.32 0.110 
age 1.02 1.01-1.03 0.003 
CCI 1.18 1.01-1.37 0.033 
WCC 1.05 1.01-1.08 0.005 
 
6: Multivariable analysis of PCT (log10) tested within 5 days 
after toxin test as covariates and CDI diagnosis as outcome 
<5 
variable Odds ratio 95% CI p 
PCT (log10) 1.12 0.98-1.29 0.089 
age 1.02 1.01-1.03 0.004 
pre-test 1.01 1.00-1.03 0.047 
CCI 1.21 1.06-1.39 0.006 
WCC 1.06 1.02-1.09 0.001 
 
7: Multivariable analysis of PCT (log10) tested in all time points 
after toxin test as covariates and CDI diagnosis as outcome 
all 
time 
points 
variable Odds ratio 95% CI p 
PCT (log10) 1.12 0.99-1.27 0.075 
age 1.02 1.01-1.03 0.002 
pre-test 1.02 1.01-1.03 0.001 
CCI 1.19 1.05-1.35 0.006 
WCC 1.06 1.03-1.08 <0.001 
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8: Multivariable analysis of CRP (log10) tested on the same 
day or before toxin test as covariate and CDI diagnosis as 
outcome 
<0 
variable Odds ratio 95% CI p 
CRP (log10) 1.16 0.89-1.53 0.271 
pre-test 1.03 1.01-1.06 0.010 
 
9: Multivariable analysis of CRP (log10) tested before and 
within 1 day after toxin test as covariate and CDI diagnosis 
as outcome 
<1 
variable Odds ratio 95% CI p 
CRP (log10) 1.13 0.91-1.39 0.277 
pre-test 1.03 1.01-1.05 0.003 
WCC 1.06 1.02-1.10 0.004 
 
10: Multivariable analysis of CRP (log10) tested before and 
within 2 days after toxin test as covariate and CDI diagnosis 
as outcome 
<2 
variable Odds ratio 95% CI p 
CRP (log10) 1.18 0.98-1.42 0.072 
pre-test 1.02 1.01-1.03 0.005 
WCC 1.06 1.03-1.10 0.001 
 
11: Multivariable analysis of CRP (log10) tested before and 
within 3 days after toxin test as covariate and CDI diagnosis 
as outcome 
<3 
variable Odds ratio 95% CI p 
CRP (log10) 1.29 1.08-1.53 0.005 
pre-test 1.02 1.01-1.03 0.001 
WCC 1.05 1.01-1.08 0.005 
CCI 1.16 1.01-1.33 0.041 
 
12: Multivariable analysis of CRP (log10) tested before and 
within 4 days after toxin test as covariate and CDI diagnosis 
as outcome 
<4 
variable Odds ratio 95% CI p 
CRP (log10) 1.32 1.12-1.56 0.001 
pre-test 1.02 1.01-1.03 0.003 
WCC 1.04 1.01-1.07 0.008 
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13: Multivariable analysis of CRP (log10) tested before and 
within 5 days after toxin test as covariate and CDI diagnosis 
as outcome 
<5 
variable Odds ratio 95% CI p 
CRP (log10) 1.33 1.13-1.56 0.001 
pre-test 1.02 1.01-1.03 0.002 
WCC 1.04 1.01-1.07 0.004 
 
14: Multivariable analysis of CRP (log10) tested before and 
within 6 days after toxin test as covariate and CDI diagnosis 
as outcome 
<6 
variable Odds ratio 95% CI p 
CRP (log10) 1.35 1.14-1.58 <0.001 
pre-test 1.02 1.01-1.03 0.002 
WCC 1.04 1.01-1.07 0.004 
 
15: Multivariable analysis of CRP (log10) tested before and 
within 7 days after toxin test as covariate and CDI diagnosis 
as outcome 
<7 
variable Odds ratio 95% CI p 
CRP (log10) 1.35 1.15-1.59 <0.001 
pre-test 1.02 1.01-1.03 0.002 
WCC 1.04 1.01-1.07 0.005 
 
16: Multivariable analysis of CRP (log10) tested before and 
within 8 days after toxin test as covariate and CDI diagnosis 
as outcome 
<8 
variable Odds ratio 95% CI p 
CRP (log10) 1.34 1.14-1.58 <0.001 
pre-test 1.02 1.01-1.03 0.002 
WCC 1.04 1.02-1.08 0.003 
 
17: Multivariable analysis of CRP (log10) tested in all time 
points as covariate and CDI diagnosis as outcome 
all 
time 
points 
variable Odds ratio 95% CI p 
CRP (log10) 1.35 1.16-1.57 <0.001 
pre-test 1.02 1.01-1.03 0.001 
WCC 1.04 1.01-1.07 0.004 
age 1.02 1.01-1.03 0.002 
CCI 1.18 1.04-1.34 0.010 
 
 
 
229 
 
18: Cox proportional hazards of multivariable analysis for time to 
discharge and PCT (log10) tested within 2 days after toxin test  
<2 
variable Haz ratio 95% CI p 
PCT (log10) 1.07 0.88-1.31 0.480 
mode of acquisition 0.20 0.11-0.37 <0.001 
 
19: Cox proportional hazards of multivariable analysis for time to 
discharge and PCT (log10) tested within 3 days after toxin test 
<3 
variable Haz ratio 95% CI p 
PCT (log10) 0.87 0.80-0.95 0.002 
mode of acquisition 0.33 0.25-0.44 <0.001 
age 0.99 0.98-1.00 0.001 
 
20: Cox proportional hazards of multivariable analysis for time to 
discharge and PCT (log10) tested within 4 days after toxin test 
<4 
variable Haz ratio 95% CI p 
PCT (log10) 0.93 0.87-1.00 0.061 
mode of acquisition 0.33 0.26-0.42 <0.001 
age 0.99 0.98-1.00 0.003 
toxin 0.72 0.57-0.90 0.004 
 
21: Cox proportional hazards of multivariable analysis for time to 
discharge and PCT (log10) tested within 5 days after toxin test 
<5 
variable Haz ratio 95% CI p 
PCT (log10) 0.93 0.87-0.99 0.028 
mode of acquisition 0.35 0.29-0.44 <0.001 
age 0.99 0.99-1.00 0.035 
toxin 0.71 0.58-0.87 0.001 
albumin 1.01 1.00-1.02 0.031 
 
22: Cox proportional hazards of multivariable analysis for time to 
discharge and PCT (log10) tested in all time points after toxin test 
all 
time 
points 
variable Haz ratio 95% CI p 
PCT (log10) 0.93 0.88-0.99 0.029 
mode of acquisition 0.32 0.26-0.39 <0.001 
toxin 0.65 0.54-0.77 <0.001 
albumin 1.01 1.00-1.02 0.003 
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23: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested on the same day or before 
toxin test 
<0 
variable Haz ratio 95% CI p 
CRP (log10) 0.93 0.81-1.07 0.307 
toxin 0.60 0.44-0.84 0.002 
mode of acquisition 0.33 0.23-0.48 <0.001 
 
24: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested before and within 1 day after 
toxin test  
<1 
variable Haz ratio 95% CI p 
CRP (log10) 0.98 0.89-1.09 0.746 
toxin 0.65 0.51-0.84 0.001 
mode of acquisition 0.34 0.26-0.44 <0.001 
albumin 1.01 1.00-1.02 0.040 
 
25: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested before and within 2 days after 
toxin test  
<2 
variable Haz ratio 95% CI p 
CRP (log10) 0.98 0.90-1.07 0.627 
toxin 0.67 0.54-0.84 0.001 
mode of acquisition 0.32 0.25-0.40 <0.001 
albumin 1.01 1.00-1.02 0.007 
 
26: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested before and within 3 days after 
toxin test 
<3 
variable Haz ratio 95% CI p 
CRP (log10) 0.94 0.87-1.02 0.152 
toxin 0.67 0.54-0.83 <0.001 
mode of acquisition 0.29 0.24-0.36 <0.001 
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27: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested before and within 4 days after 
toxin test 
<4 
variable Haz ratio 95% CI p 
CRP (log10) 0.96 0.88-1.04 0.275 
toxin 0.66 0.53-0.80 <0.001 
mode of acquisition 0.31 0.25-0.38 <0.001 
albumin 1.01 1.00-1.02 0.013 
 
28: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested before and within 5 days after 
toxin test 
<5 
variable Haz ratio 95% CI p 
CRP (log10) 0.93 0.86-1.01 0.071 
toxin 0.64 0.53-0.78 <0.001 
mode of acquisition 0.32 0.26-0.40 <0.001 
albumin 1.01 1.00-1.02 0.017 
 
29: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested before and within 6 days after 
toxin test 
<6 
variable Haz ratio 95% CI p 
CRP (log10) 0.93 0.86-1.01 0.096 
toxin 0.65 0.54-0.79 <0.001 
mode of acquisition 0.33 0.27-0.40 <0.001 
albumin 1.01 1.00-1.02 0.018 
 
30: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested before and within 7 days after 
toxin test  
<7 
variable Haz ratio 95% CI p 
CRP (log10) 0.94 0.86-1.01 0.100 
toxin 0.65 0.53-0.79 <0.001 
mode of acquisition 0.33 0.27-0.40 <0.001 
albumin 1.01 1.00-1.02 0.021 
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31: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested before and within 8 days after 
toxin test 
<8 
variable Haz ratio 95% CI p 
CRP (log10) 0.94 0.86-1.01 0.098 
toxin 0.65 0.53-0.79 <0.001 
mode of acquisition 0.33 0.27-0.40 <0.001 
albumin 1.01 1.00-1.02 0.021 
 
32: Cox proportional hazards of multivariable analysis for time to 
discharge and CRP (log10) tested in all time points  
all 
time 
points 
variable Haz ratio 95% CI p 
CRP (log10) 0.94 0.86-1.01 0.098 
toxin 0.65 0.53-0.79 <0.001 
mode of acquisition 0.33 0.27-0.40 <0.001 
albumin 1.01 1.00-1.02 0.021 
 
33: Multivariable analysis of PCT (log10) tested within 2 
days after toxin test as covariate and short-term mortality 
as outcome 
<2 
variable Odds ratio 95% CI p 
PCT (log10) 1.69 0.64-4.48 0.291 
CCI 2.09 1.08-4.05 0.029 
 
34: Multivariable analysis of PCT (log10) tested within 3 
days after toxin test as covariate and short-term mortality 
as outcome 
<3 
variable Odds ratio 95% CI p 
PCT (log10) 1.32 0.96-1.81 0.086 
CCI 1.34 1.00-1.80 0.050 
 
35: Multivariable analysis of PCT (log10) tested within 4 
days after toxin test as covariate and short-term mortality 
as outcome 
<4 
variable Odds ratio 95% CI p 
PCT (log10) 1.33 1.00-1.76 0.048 
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36: Multivariable analysis of PCT (log10) tested within 5 
days after toxin test as covariate and short-term mortality 
as outcome 
<5 
variable Odds ratio 95% CI p 
PCT (log10) 1.30 1.02-1.66 0.033 
CCI 1.35 1.08-1.68 0.008 
 
37: Multivariable analysis of PCT (log10) tested in all time points after 
toxin test as covariate and short-term mortality as outcome 
all 
time 
points 
variable Odds ratio 95% CI p 
PCT (log10) 1.28 1.01-1.62 0.038 
CCI 1.06 1.62-2.54 0.011 
mode of acquisition 1.03 7.78-2.02 0.044 
 
38: Multivariable analysis of CRP (log10) tested on the same 
day of before toxin test as covariate and short-term 
mortality as outcome 
<0 
variable Odds ratio 95% CI p 
CRP (log10) 3.03 1.09-8.44 0.034 
 
39: Multivariable analysis of CRP (log10) tested before and 
within 1 day after toxin test as covariate and short-term 
mortality as outcome  
<1 
variable Odds ratio 95% CI p 
CRP (log10) 1.85 0.95-3.62 0.073 
 
40: Multivariable analysis of CRP (log10) tested before and within 2 
days after toxin test as covariate and short-term mortality as 
outcome 
<2 
variable Odds ratio 95% CI p 
CRP (log10) 1.66 0.91-3.02 0.097 
mode of acquisition 8.02 1.03-62.64 0.047 
 
41: Multivariable analysis of CRP (log10) tested before and within 3 
days after toxin test as covariate and short-term mortality as 
outcome 
<3 
variable Odds ratio 95% CI p 
CRP (log10) 1.42 0.90-2.24 0.128 
mode of acquisition 5.22 1.18-23.06 0.029 
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42: Multivariable analysis of CRP (log10) tested before and within 4 
days after toxin test as covariate and short-term mortality as 
outcome 
<4 
variable Odds ratio 95% CI p 
CRP (log10) 1.40 0.92-2.12 0.116 
CCI 1.27 1.02-1.58 0.036 
mode of acquisition 3.64 1.05-12.66 0.042 
 
43: Multivariable analysis of CRP (log10) tested before and within 5 
days after toxin test as covariate and short-term mortality as 
outcome 
<5 
variable Odds ratio 95% CI p 
CRP (log10) 1.35 0.91-2.01 0.136 
CCI 1.27 1.02-1.58 0.031 
mode of acquisition 3.90 1.13-13.49 0.031 
 
44: Multivariable analysis of CRP (log10) tested before and within 6 
days after toxin test as covariate and short-term mortality as 
outcome 
<6 
variable Odds ratio 95% CI p 
CRP (log10) 1.35 0.91-2.01 0.137 
CCI 1.27 1.02-1.58 0.031 
mode of acquisition 3.98 1.15-13.76 0.029 
 
45: Multivariable analysis of CRP (log10) tested before and within 7 
days after toxin test as covariate and short-term mortality as 
outcome 
<7 
variable Odds ratio 95% CI p 
CRP (log10) 1.35 0.91-2.00 0.139 
CCI 1.27 1.02-1.58 0.031 
mode of acquisition 3.97 1.15-13.70 0.029 
 
46: Multivariable analysis of CRP (log10) tested before and within 8 
days after toxin test as covariate and short-term mortality as 
outcome 
<8 
variable Odds ratio 95% CI p 
CRP (log10) 1.35 0.91-2.01 0.136 
CCI 1.27 1.02-1.58 0.031 
mode of acquisition 3.95 1.14-13.66 0.030 
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47: Multivariable analysis of CRP (log10) tested in all time points as 
covariate and short-term mortality as outcome 
all 
time 
points 
variable Odds ratio 95% CI p 
CRP (log10) 1.42 0.96-2.10 0.079 
CCI 1.25 1.01-1.55 0.039 
mode of acquisition 3.39 1.13-10.19 0.030 
 
48: Multivariable analysis of PCT (log10) tested within 2 
days after toxin test as covariate and long-term mortality as 
outcome 
<2 
variable Odds ratio 95% CI p 
PCT (log10) 1.40 0.85-2.29 0.188 
CCI 1.80 1.14-2.83 0.011 
 
49: Multivariable analysis of PCT (log10) tested within 3 
days after toxin test as covariate and long-term mortality as 
outcome 
<3 
variable Odds ratio 95% CI p 
PCT (log10) 1.43 1.15-1.77 0.001 
CCI 1.52 1.22-1.89 <0.001 
albumin 0.97 0.95-1.00 0.025 
 
50: Multivariable analysis of PCT (log10) tested within 4 days after 
toxin test as covariate and long-term mortality as outcome 
<4 
variable Odds ratio 95% CI p 
PCT (log10) 1.33 1.12-1.58 0.001 
CCI 1.36 1.15-1.60 <0.001 
age 1.02 1.00-1.04 0.045 
mode of acquisition 2.07 1.16-3.71 0.014 
 
51: Multivariable analysis of PCT (log10) tested within 5 days after 
toxin test as covariate and long-term mortality as outcome 
<5 
variable Odds ratio 95% CI p 
PCT (log10) 1.28 1.10-1.48 0.002 
CCI 1.45 1.25-1.68 <0.001 
age 1.02 1.01-1.04 0.008 
mode of acquisition 2.15 1.29-3.59 0.003 
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52: Multivariable analysis of PCT (log10) tested in all time points after 
toxin test as covariate and long-term mortality as outcome 
all 
time 
points 
variable Odds ratio 95% CI p 
PCT (log10) 1.22 1.06-1.40 0.005 
CCI 1.42 1.24-1.61 <0.001 
age 1.03 1.01-1.04 0.001 
mode of acquisition 1.58 1.02-2.44 0.041 
 
53: Multivariable analysis of CRP (log10) tested on the same 
day or before toxin test as covariate and long-term mortality 
as outcome 
<0 
variable Odds ratio 95% CI p 
CRP (log10) 1.32 0.92-1.90 0.136 
age 1.04 1.01-1.07 0.010 
CCI 1.42 1.09-1.84 0.009 
 
54: Multivariable analysis of CRP (log10) tested before and 
within 1 day after toxin test as covariate and long-term 
mortality as outcome  
<1 
variable Odds ratio 95% CI p 
CRP (log10) 1.33 1.01-1.75 0.040 
age 1.04 1.01-1.06 0.002 
CCI 1.40 1.16-1.71 0.001 
 
55: Multivariable analysis of CRP (log10) tested before and 
within 2 days after toxin test as covariate and long-term 
mortality as outcome 
<2 
variable Odds ratio 95% CI p 
CRP (log10) 1.41 1.11-1.80 0.005 
age 1.03 1.01-1.05 0.007 
CCI 1.50 1.26-1.79 <0.001 
 
56: Multivariable analysis of CRP (log10) tested before and within 3 
days after toxin test as covariate and long-term mortality as 
outcome 
<3 
variable Odds ratio 95% CI p 
CRP (log10) 1.27 1.03-1.56 0.026 
age 1.02 1.01-1.04 0.007 
CCI 1.40 1.21-1.63 <0.001 
mode of acquisition 1.89 1.11-3.21 0.018 
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57: Multivariable analysis of CRP (log10) tested before and within 4 
days after toxin test as covariate and long-term mortality as 
outcome 
<4 
variable Odds ratio 95% CI p 
CRP (log10) 1.22 1.00-1.48 0.055 
age 1.02 1.01-1.04 0.007 
CCI 1.44 1.25-1.66 <0.001 
mode of acquisition 1.68 1.02-2.78 0.042 
 
58: Multivariable analysis of CRP (log10) tested before and within 5 
days after toxin test as covariate and long-term mortality as 
outcome 
<5 
variable Odds ratio 95% CI p 
CRP (log10) 1.15 0.95-1.39 0.141 
age 1.02 1.00-1.03 0.017 
CCI 1.43 1.24-1.65 <0.001 
mode of acquisition 1.66 1.03-2.68 0.038 
 
59: Multivariable analysis of CRP (log10) tested before and within 6 
days after toxin test as covariate and long-term mortality as 
outcome 
<6 
variable Odds ratio 95% CI p 
CRP (log10) 1.17 0.97-1.41 0.094 
age 1.02 1.00-1.03 0.016 
CCI 1.44 1.25-1.65 <0.001 
mode of acquisition 1.61 1.01-2.58 0.047 
 
60: Multivariable analysis of CRP (log10) tested before and within 7 
days after toxin test as covariate and long-term mortality as 
outcome 
<7 
variable Odds ratio 95% CI p 
CRP (log10) 1.17 0.97-1.41 0.097 
age 1.02 1.00-1.03 0.016 
CCI 1.44 1.25-1.65 <0.001 
mode of acquisition 1.60 1.00-2.57 0.049 
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61: Multivariable analysis of CRP (log10) tested before and within 8 
days after toxin test as covariate and long-term mortality as 
outcome 
<8 
variable Odds ratio 95% CI p 
CRP (log10) 1.16 0.97-1.40 0.110 
age 1.02 1.00-1.03 0.017 
CCI 1.44 1.25-1.66 <0.001 
mode of acquisition 1.63 1.02-2.61 0.042 
 
62: Multivariable analysis of CRP (log10) tested in all time points as 
covariate and long-term mortality as outcome 
all 
time 
points 
variable Odds ratio 95% CI p 
CRP (log10) 1.18 0.99-1.40 0.066 
age 1.02 1.01-1.04 0.002 
CCI 1.43 1.26-1.64 <0.001 
 
63: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and PCT (log10) tested within 
2 days after toxin test 
<2 
variable Haz ratio 95% CI p 
PCT (log10) 1.26 0.82-1.94 0.295 
 
64: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and PCT (log10) tested within 3 
days after toxin test 
<3 
variable Haz ratio 95% CI p 
PCT (log10) 1.14 0.98-1.32 0.083 
CCI 1.19 1.04-1.38 0.014 
 
65: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and PCT (log10) tested within 
4 days after toxin test 
<4 
variable Haz ratio 95% CI p 
PCT (log10) 1.14 1.00-1.30 0.056 
CCI 1.16 1.02-1.31 0.023 
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66: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and PCT (log10) tested within 
5 days after toxin test 
<5 
variable Haz ratio 95% CI p 
PCT (log10) 1.11 0.99-1.25 0.068 
CCI 1.17 1.06-1.29 0.002 
study phase 1.61 1.03-2.51 0.037 
 
67: Cox proportional hazards of multivariable analysis for time 
to death within 1 year and PCT (log10) tested in all time points 
after toxin test 
all 
time 
points 
variable Haz ratio 95% CI p 
PCT (log10) 1.09 0.98-1.21 0.126 
CCI 1.15 1.05-1.26 0.003 
study phase 1.66 1.14-2.41 0.008 
 
68: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and CRP (log10) tested on 
the same day or before toxin test 
<0 
variable Haz ratio 95% CI p 
CRP (log10) 1.37 0.98-1.92 0.064 
 
69: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and CRP (log10) tested 
before and within 1 day after toxin test 
<1 
variable Haz ratio 95% CI p 
CRP (log10) 1.29 1.01-1.64 0.040 
 
70: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and CRP (log10) tested 
before and within 2 days after toxin test 
<2 
variable Haz ratio 95% CI p 
CRP (log10) 1.34 1.09-1.65 0.005 
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71: Cox proportional hazards of multivariable analysis for time to 
death within 1 year and CRP (log10) tested before and within 3 
days after toxin test 
<3 
variable Haz ratio 95% CI p 
CRP (log10) 1.26 1.05-1.50 0.011 
study phase 1.92 1.22-3.03 0.005 
mode of acquisition 1.87 1.17-3.00 0.009 
 
72: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and CRP (log10) tested before 
and within 4 days after toxin test 
<4 
variable Haz ratio 95% CI p 
CRP (log10) 1.26 1.06-1.49 0.009 
CCI 1.14 1.04-1.26 0.007 
 
73: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and CRP (log10) tested before 
and within 5 days after toxin test 
<5 
variable Haz ratio 95% CI p 
CRP (log10) 1.22 1.04-1.44 0.014 
CCI 1.14 1.03-1.26 0.010 
study phase 1.74 1.14-2.65 0.010 
 
74: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and CRP (log10) tested before 
and within 6 days after toxin test 
<6 
variable Haz ratio 95% CI p 
CRP (log10) 1.23 1.05-1.44 0.011 
CCI 1.14 1.04-1.26 0.007 
study phase 1.77 1.17-2.68 0.007 
 
75: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and CRP (log10) tested before 
and within 7 days after toxin test 
<7 
variable Haz ratio 95% CI p 
CRP (log10) 1.23 1.05-1.44 0.011 
CCI 1.14 1.04-1.26 0.007 
study phase 1.77 1.17-2.68 0.007 
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76: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and CRP (log10) tested before 
and within 2 days after toxin test 
<8 
variable Haz ratio 95% CI p 
CRP (log10) 1.23 1.05-1.44 0.012 
CCI 1.14 1.04-1.26 0.007 
study phase 1.80 1.19-2.71 0.005 
 
77: Cox proportional hazards of multivariable analysis for 
time to death within 1 year and CRP (log10) tested in all time 
points 
all 
time 
points 
variable Haz ratio 95% CI p 
CRP (log10) 1.20 1.03-1.40 0.018 
CCI 1.13 1.03-1.24 0.009 
study phase 1.80 1.21-2.67 0.004 
 
78: Multivariable analysis of PCT (log10) tested within 2 
days after toxin test as covariate and CDI severity as 
outcome 
<2 
variable Odds ratio 95% CI p 
PCT (log10) 1.57 0.86-2.87 0.143 
 
79: Multivariable analysis of PCT (log10) tested within 3 
days after toxin test as covariate and CDI severity as 
outcome 
<3 
variable Odds ratio 95% CI p 
PCT (log10) 1.56 1.18-2.07 0.002 
 
80: Multivariable analysis of PCT (log10) tested within 4 
days after toxin test as covariate and CDI severity as 
outcome 
<4 
variable Odds ratio 95% CI p 
PCT (log10) 1.33 1.09-1.63 0.006 
 
81: Multivariable analysis of PCT (log10) tested within 5 
days after toxin test as covariate and CDI severity as 
outcome 
<5 
variable Odds ratio 95% CI p 
PCT (log10) 1.22 1.03-1.45 0.020 
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82: Multivariable analysis of PCT (log10) tested in all time 
points after toxin test as covariate and CDI severity as 
outcome 
all 
time 
points 
variable Odds ratio 95% CI p-value 
PCT (log10) 1.30 1.11-1.52 0.001 
 
83: Multivariable analysis of CRP (log10) tested on the same 
day or before toxin test as covariate and CDI severity as 
outcome 
<0 
variable Odds ratio 95% CI p 
CRP (log10) 1.29 0.84-1.98 0.245 
 
84: Multivariable analysis of CRP (log10) tested before or 
within 1 day after toxin test as covariate and CDI severity 
as outcome 
<1 
variable Odds ratio 95% CI p 
CRP (log10) 1.44 1.07-1.93 0.017 
 
85: Multivariable analysis of CRP (log10) tested before or 
within 2 days after toxin test as covariate and CDI severity 
as outcome 
<2 
variable Odds ratio 95% CI p 
CRP (log10) 1.53 1.17-1.99 0.002 
 
86: Multivariable analysis of CRP (log10) tested before or 
within 3 days after toxin test as covariate and CDI severity 
as outcome 
<3 
variable Odds ratio 95% CI p 
CRP (log10) 1.59 1.23-2.05 <0.001 
 
87: Multivariable analysis of CRP (log10) tested before or 
within 4 days after toxin test as covariate and CDI severity 
as outcome 
<4 
variable Odds ratio 95% CI p 
CRP (log10) 1.54 1.21-1.96 <0.001 
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88: Multivariable analysis of CRP (log10) tested before or 
within 5 days after toxin test as covariate and CDI severity 
as outcome 
<5 
variable Odds ratio 95% CI p 
CRP (log10) 1.54 1.22-1.94 <0.001 
 
89: Multivariable analysis of CRP (log10) tested before or 
within 6 days after toxin test as covariate and CDI severity 
as outcome 
<6 
variable Odds ratio 95% CI p 
CRP (log10) 1.54 1.22-1.94 <0.001 
 
90: Multivariable analysis of CRP (log10) tested before or 
within 7 days after toxin test as covariate and CDI severity 
as outcome 
<7 
variable Odds ratio 95% CI p 
CRP (log10) 1.54 1.22-1.94 <0.001 
 
91: Multivariable analysis of CRP (log10) tested before or 
within 8 days after toxin test as covariate and CDI severity 
as outcome 
<8 
variable Odds ratio 95% CI p 
CRP (log10) 1.52 1.21-1.92 <0.001 
 
92: Multivariable analysis of CRP (log10) tested in all time 
points as covariate and CDI severity as outcome 
all 
time 
points 
variable Odds ratio 95% CI p 
CRP (log10) 1.40 1.13-1.73 0.002 
 
93: Multivariable analysis of PCT (log10) tested within 2 
days after toxin test as covariate and CDI recurrence as 
outcome 
<2 
variable Odds ratio 95% CI p 
PCT (log10) 0.80 0.33-1.94 0.620 
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94: Multivariable analysis of PCT (log10) tested within 3 
days after toxin test as covariate and CDI recurrence as 
outcome 
<3 
variable Odds ratio 95% CI p 
PCT (log10) 0.94 0.55-1.59 0.806 
age 1.09 1.01-1.18 0.033 
 
95: Multivariable analysis of PCT (log10) tested within 4 
days after toxin test as covariate and CDI recurrence as 
outcome 
<4 
variable Odds ratio 95% CI p 
PCT (log10) 1.21 0.89-1.66 0.225 
age 1.06 1.01-1.10 0.010 
 
96: Multivariable analysis of PCT (log10) tested within 5 
days after toxin test as covariate and CDI recurrence as 
outcome 
<5 
variable Odds ratio 95% CI p 
PCT (log10) 1.06 0.81-1.39 0.647 
age 1.05 1.02-1.09 0.002 
 
97: Multivariable analysis of PCT (log10) tested in all time 
points after toxin test as covariate and CDI recurrence as 
outcome 
all 
time 
points 
variable Odds ratio 95% CI p 
PCT (log10) 1.01 0.81-1.26 0.960 
age 1.05 1.02-1.07 0.001 
 
98: Multivariable analysis of CRP (log10) tested on the same 
day or before toxin test as covariate and CDI recurrence as 
outcome 
<0 
variable Odds ratio 95% CI p 
CRP (log10) 1.47 0.65-3.32 0.360 
age 1.06 1.00-1.12 0.050 
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99: Multivariable analysis of CRP (log10) tested before or 
within 1 day after toxin test as covariate and CDI recurrence 
as outcome 
<1 
variable Odds ratio 95% CI p 
CRP (log10) 1.13 0.73-1.75 0.596 
age 1.04 1.01-1.08 0.017 
 
100: Multivariable analysis of CRP (log10) tested before or 
within 2 days after toxin test as covariate and CDI 
recurrence as outcome 
<2 
variable Odds ratio 95% CI p 
CRP (log10) 1.20 0.83-1.72 0.333 
age 1.03 1.01-1.06 0.014 
 
101: Multivariable analysis of CRP (log10) tested before or 
within 3 days after toxin test as covariate and CDI 
recurrence as outcome 
<3 
variable Odds ratio 95% CI p 
CRP (log10) 1.30 0.91-1.86 0.145 
age 1.04 1.01-1.07 0.006 
 
102: Multivariable analysis of CRP (log10) tested before or 
within 4 days after toxin test as covariate and CDI 
recurrence as outcome 
<4 
variable Odds ratio 95% CI p 
CRP (log10) 1.28 0.91-1.80 0.153 
age 1.04 1.01-1.06 0.007 
 
103: Multivariable analysis of CRP (log10) tested before or 
within 5 days after toxin test as covariate and CDI 
recurrence as outcome 
<5 
variable Odds ratio 95% CI p 
CRP (log10) 1.22 0.88-1.69 0.229 
age 1.04 1.02-1.07 0.002 
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104: Multivariable analysis of CRP (log10) tested before or 
within 6 days after toxin test as covariate and CDI 
recurrence as outcome 
<6 
variable Odds ratio 95% CI p 
CRP (log10) 1.24 0.90-1.72 0.185 
age 1.04 1.02-1.07 0.001 
 
105: Multivariable analysis of CRP (log10) tested before or 
within 7 days after toxin test as covariate and CDI 
recurrence as outcome 
<7 
variable Odds ratio 95% CI p 
CRP (log10) 1.24 0.90-1.72 0.185 
age 1.04 1.02-1.07 0.001 
 
106: Multivariable analysis of CRP (log10) tested before or 
within 8 days after toxin test as covariate and CDI 
recurrence as outcome 
<8 
variable Odds ratio 95% CI p 
CRP (log10) 1.25 0.90-1.73 0.180 
age 1.04 1.02-1.07 0.001 
 
107: Multivariable analysis of CRP (log10) tested in all time 
points as covariate and CDI recurrence as outcome 
all 
time 
points 
variable Odds ratio 95% CI p 
CRP (log10) 1.10 0.82-1.48 0.505 
age 1.05 1.02-1.07 0.001 
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108: Full search strategies  
 
(A) Embase and MEDLINE via Ovid 
 
1 exp Clostridium difficile/  
2 exp Clostridium Infections/  
3 Clostridium difficile.mp.  
4 Cdifficile.mp. 
5 (C adj difficile).mp.  
6 difficile clostridium.mp. 
7 Cdiff.mp. 
8 (C adj diff).mp. 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10 exp Economics/ 
11 quality of life/  
12 value of life/  
13 Quality-adjusted life years/  
14 models, economic/  
15 markov chains/  
16 monte carlo method/  
17 decision tree/  
18 ec.fs.  
19 economic$.tw.  
20 (cost or costing or costly or costed).tw.  
21 (price or pricing).tw.  
22 (pharmacoeconomic or (pharmaco adj economic)).tw. (3242) 
23 budget$.tw.  
24 expenditure$.tw.  
25 (value adj1 (money or monetary)).tw.  
26 (fee or fees).tw.  
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27 "quality of life".tw. 
28 qol$.tw. 
29 hrqol$.tw.  
30 "Quality adjusted life year$".tw.  
31 qaly$.tw.  
32 cba.tw.  
33 cea.tw.  
34 cua.tw.  
35 utilit$.tw.  
36 markov$.tw.  
37 monte carlo.tw.  
38 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 
23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 
or 37 (1406281) 
39 9 and 38  
40 humans/ not animals/  
41 39 and 40  
42 limit 41 to article 
 
(B) EconLit (via EBSCO) and Database of Abstracts of Reviews of Effects, 
NHS Economic Evaluation database and Health Technology Assessment 
database (via CRD). 
 
1 Clostridium difficile 
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